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Abstract 
 
Fibroblast growth factors (FGFs) and their receptors (FGFRs) are 
essential for controlling cell growth and proliferation, angiogenesis, 
wound healing and tumourigenesis. In mammals, there are twenty-three 
FGFs and five FGFRs, with each FGFR having different ligand binding 
specificities. FGFs are thought to act in a paracrine manner, in which they 
are secreted by one cell and activate FGFRs on another cell type, and such 
interaction helps to establish the fundamental crosstalk between 
epithelium and mesenchyme during development, homeostasis and 
tumourigenesis.  
 
This thesis aims to investigate the requirement of FGFR2-isoform IIIb 
(Fgfr2b) and one of its ligands, Fgf10, in gastrointestinal (GI) 
development, homeostasis and injury, using loss-of-function animal 
models. Fgfr2b
-/-
 and Fgf10
-/-
 exhibit similar multi-organ defects, 
including intestinal atresia. While caecal and colonic atresia have been 
previously described, the mechanism of duodenal atresia and the role of 
Fgf signalling in duodenal development have not been fully established. 
We demonstrate that absence of Fgfr2b or Fgf10 leads to decreased tissue 
proliferation and increased apoptosis in the duodenum, contributing to 
duodenal atresia. These mutants also develop gastric heterotopia in the 
rostral duodenum due to loss of gastric-intestinal boundary specification. 
In addition, we demonstrate reduced expression of Wnt targets Tcf1 and 
Tcf4 in the small intestine, with corresponding downregulation of Lgr5, an 
intestinal stem cell marker, and Cdx1, a homeobox gene involved in 
anterior-posterior patterning. We show by in vitro that Fgf10-Fgfr2b 
signalling is able to regulate Tcf4 expression via the Grb2/Sos/Ras/MAPK 
pathway. 
 
In order to study the requirement of Fgfr2b in intestinal homeostasis and 
injury, we crossed a transgenic line bearing a progesterone antagonist 
(RU486)-dependent Cre recombinase (A33-CrePR) expressed under the 
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control of the intestinal-specific A33 antigen promoter, with an existing 
conditional Fgfr2b line. Following RU486 administration with/without 
administration of dextran sodium sulphate (DSS) thereafter to induce 
ulcerative colitis (UC), the A33-CrePR
+
/Fgfr2b
flox/flox
 targeted Fgfr2b 
ablation with high efficiency across the small and large intestine. We 
demonstrate that significant downregulation of Fgfr2b does not affect 
intestinal homeostasis, but significantly increases the susceptibility of 
colonic epithelium to UC and delays wound healing, contributed by 
reduced epithelial proliferation.  
 
In order to study the requirement of Fgfr2b in gastric homeostasis, we 
characterised two stomach-specific minimal promoters for trefoil factor 1 
(Tff1) and H
+
K
+
-ATPase (Atp4b) to generate two inducible Cre 
recombinase (CreER
T2
) lines. Gastric surface mucous cells and acid-
producing parietal cells express Tff1 and Atp4b respectively, as well as 
Fgfr2b. We demonstrate by in vitro that Atp4b nucleotide -1,035bp to +24 
bp and Tff1 nucleotide -641 bp to +28 bp are optimal for driving Cre 
expression in the mouse stomach.  
 
Thus, our novel data provides evidence that Fgfr2b and Fgf10 are required 
for normal duodenal morphogenesis and differentiation, and Fgfr2b 
confers protection against DSS-induced colonic injury and promotes 
wound repair. 
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Chapter 1: Introduction 
 
1.1 Fibroblast Growth Factors and their Receptors 
 
1.1.1 Overview 
 
Fibroblast growth factors (FGFs) are a large family of multi-functional 
intercellular signalling molecules found in organisms across the 
evolutionary spectrum ranging from nematodes to humans (Ornitz and 
Itoh, 2001). These molecules play different roles depending on the cell 
type and context, including controlling cell proliferation and 
differentiation, angiogenesis, wound healing and tumourigenesis (Grose 
and Dickson, 2005, Itoh and Ornitz, 2004, Ornitz and Itoh, 2001, Thisse 
and Thisse, 2005). In the mouse and human, twenty-three FGFs have been 
identified, designated as FGF1-23 (with FGF15 as the mouse orthologue 
of human FGF19), sharing a 13-70% homology over a 120 amino acid 
central core region, with 28 highly conserved and six invariant amino 
acids (Ornitz and Itoh, 2001). In non-mammals, two additional FGFs, 
FGF24 and FGF25, were discovered in zebrafish, with FGF25 being an 
orthologue of FGF10 (Katoh and Katoh, 2005, Draper et al., 2003). 
Structural studies on FGF1 and FGF2 showed that these proteins adopt a 
!-trefoil structure, containing twelve !-strands arranged in a triangular 
array (Zhu et al., 1991, Faham et al., 1998). The molecular weights of 
mammalian FGFs can range from 17 kDa to 34 kDa (Ornitz and Itoh, 
2001). 
 
FGFs exert their activities by binding to and activating fibroblast growth 
factor receptors (FGFRs), which are a family of receptor tyrosine kinases. 
Each FGFR is made up of an extracellular ligand-binding domain 
containing three immunoglobulin (Ig)-like loops, a single transmembrane 
helix, and a cytoplasmic domain comprising of a split tyrosine kinase 
 21 
domain (Keegan et al., 1991, Lee et al., 1989) (Figure 1.1). In mammals, 
there are four FGF transmembrane receptors, designated FGFR1-4, and 
one soluble receptor known as FGFR5 (also known as FGFRL1) that 
lacks a tyrosine kinase domain (Wiedemann and Trueb, 2001). Alternative 
splicing of a single exon encoding the second-half of the third Ig-like loop 
in FGFR1-3 results in each receptor having two isoforms (‘IIIb’ and 
‘IIIc’), whilst FGFR4 only exists as the ‘IIIc’ isoform (Avivi et al., 1993, 
Chan et al., 1994, Johnson et al., 1991). These isoforms have distinct 
ligand binding specificities (Figure 1.2). As an example, FGF1, FGF3, 
FGF7 and FGF10 bind to FGFR2-isoform IIIb (FGFR2b) with high 
affinity, while FGF2 binds poorly to FGFR2b. Conversely, FGF1 and 
FGF2 bind with high affinity to FGFR2-isoform IIIc (FGFR2c), whereas 
FGF7 does not bind to FGFR2c (Miki et al., 1992, Yayon et al., 1992, 
Dell and Williams, 1992). These isoforms also display cell-type specific 
expression; the ‘IIIb’ isoforms are typically expressed in the epithelium, 
and the ‘IIIc’ isoforms are typically expressed in the mesenchyme (Ornitz 
and Itoh, 2001). As an example, FGFR2b is expressed in intestinal 
epithelium and can be bound and activated by the mesenchymally 
expressed FGF1, 3, 7, 10 and 22 (Zhang et al., 2006). These differential 
expression patterns help to establish the fundamental crosstalk between 
the epithelium and mesenchyme, allowing FGFs and FGFRs to perform 
their functions during development, homeostasis, injury and 
tumourigenesis. 
 
 
 
Figure 1.1 Schematic diagram of FGFR (modified from (Mohammadi 
et al., 2005)). 
The heparin binding site (HBS) is coloured orange, and is required for 
interaction with heparin and heparin sulphate proteoglycan (HSPG) for 
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FGFR activation (Schlessinger et al., 2000). ‘AB’ stands for acid box, 
which is required for interactions with neural cell adhesion molecule 
(NCAM) and N-cadherin (Sanchez-Heras et al., 2006), but not for FGF 
interaction and function (Shimizu et al., 2001). The single exon that 
determines the splice variant of FGFR is coloured blue. The N- and C-
termini are labelled ‘N’ and ‘C’ respectively. The split tyrosine kinase 
domains are labelled ‘TK-I’ and ‘TK-II’. 
 
 
 
Figure 1.2 Diagram showing binding specificity of FGFRs to FGFs, 
grouped by FGF subfamilies (modified from (Zhang et al., 2006)). 
The recent FGFR5 is added to the list, and marked with asterisk. FGF11-
14 are also known as FGF homologous factor (FHF) 1-4 due to their 
substantial sequence homology to FGFs and can bind to heparin, but fail 
to activate any of the seven principal FGFRs (Schoorlemmer and 
Goldfarb, 2001, Olsen et al., 2003). 
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1.1.2 Activation of FGFRs 
 
Unlike other growth factors, such as platelet-derived growth factor 
(PDGF), that are dimeric, FGFs are monomeric and are unable to activate 
FGFRs by themselves (Ornitz et al., 1992). FGFs require the presence of 
heparin or heparan sulphate proteoglycan (HSPG) to promote FGFR 
dimerisation, activation and induction of biological responses (Spivak-
Kroizman et al., 1994, Ornitz et al., 1992, Schlessinger et al., 1995). 
Interestingly, different FGF/FGFR interactions display different affinities 
for various lengths and sulphation patterns of the HSPG (Luo et al., 2006), 
implying that HSPG may contribute to the regulation of FGF activity and 
specificity. Structural studies have proposed two models for the 
FGFR:FGF:HSPG interaction complex. The ‘Pellegrini’ model proposed 
two FGFR:FGF complexes dimerised by a single HSPG chain connecting 
the two FGF molecules in a 2:2:1 FGFR:FGF:HSPG fashion (Pellegrini et 
al., 2000), while the ‘Schlessinger-Mohammadi’ model proposed two 
FGFR-FGF-HSPG complexes dimerised via the two FGFR molecules in a 
2:2:2 FGFR:FGF:HSPG fashion (Mohammadi et al., 2005) (Figure 1.3). 
In contrast to the canonical FGF/FGFR interactions, FGF19, FGF21 and 
FGF23 display low binding affinity to heparin and HSPG, and instead 
they require Klotho proteins as co-receptors to bind to FGFRs (Kurosu 
and Kuro, 2009, Kuro-o, 2008). The requirement of HSPG and Klotho in 
FGF/FGFR interactions demonstrates the complex mechanism by which 
FGF and FGFR activities are tightly regulated. 
 
Following FGFR dimerisation and activation, the tyrosine kinase domains 
are autophosphorylated (Dibb et al., 2004), and become a binding site for 
phospholipase C! (PLC-!), leading to the formation of two messengers, 
diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3) (Schlessinger, 
2004) (Figure 1.4). IP3 releases Ca
2+
 from the endoplasmic reticulum, 
then acts with DAG to translocate protein kinase C (PKC) to the cell 
membrane and stimulate its enzymatic activity, regulating the activity of 
other proteins (Schlessinger, 2004). Additionally, the docking proteins 
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FGFR substrate 2 (FRS2)-! and FRS2-", which contain phosphotyrosine 
binding domains, bind to the activated FGFR tyrosine kinase domains and 
function as a docking site for multiple Grb2/Sos complexes (Hadari et al., 
2001).  
 
Alternatively, activated FRS2 can phosphorylate Shp2 to form Grb2/Sos 
complexes (Hadari et al., 1998). Sos allows the exchange of GDP to GTP 
on Ras, leading to the subsequent activation of a cytosolic MAPK 
cascade. Phosphorylated ERK1 and ERK2 (MAPK) translocate to the 
nucleus where they phosphorylate transcription factors and other kinases 
to alter gene transcription (Schlessinger, 2004). Grb2 also recruits a 
docking protein Gab1, and following tyrosine phosphorylation by FGFRs, 
leads to recruitment and activation of the PI3K-Akt cell survival pathway 
(Ong et al., 2001). 
 
 
 
Figure 1.3 Dimerisation of FGFRs by FGFs and HSPGs (modified 
from (Harmer, 2006)). 
Cartoon models depicting the (A) ‘Pellegrini’ model of 2:2:1 
FGFR:FGF:HSPG, and (B) ‘Schlessinger-Mohammadi’ model of 2:2:2 
FGFR:FGF:HSPG for FGFR activation. FGFR is shown as black cartoon, 
FGF is shown as light grey cartoon, and HSPG is shown as an atom 
model.  
 
FGFR 
HSPG 
FGF 
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Figure 1.4 Schematic of FGFR signalling (Schlessinger, 2004). 
Activation of FGFR leads to direct PLC-!/PKC and Shc/Grb2/MAPK 
signalling pathways, or indirect Grb2/Sos/Ras/MAPK and 
Grb2/Gab1/PI3K/Akt pathways via the FRS2 docking protein. 
 
 
1.1.3 FGFs and FGFRs during development 
 
Various loss-of-function models in mouse, Xenopus and zebrafish have 
been generated to study the role of FGFs and FGFRs in vertebrate 
development. Since the work carried out in this thesis was performed 
mainly in mouse models, Table 1.1 summarises the phenotypes observed 
in Fgf and Fgfr knockout mice. From this table, Fgf4, 8, 9, 10, 15, 18 and 
Fgfr1, 2 are required for postnatal viability while loss of other Fgfs and 
Fgfrs leads to postnatal defects, implying that FGFs and FGFRs regulate 
multiple aspects of processes from embryonic to postnatal development. 
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Table 1.1 Summary of phenotypes in Fgf and Fgfr knockout mice. 
 
Gene Phenotype Reference
Fgf1 Viable; largely normal Miller et. al. (2000)
Fgf2 Viable; defects in neuronal and 
cardiovascular development
Dono et. al. (1998),        
Ortega et. al. (1998)
Fgf3 Most die at or soon after birth; 
defects in tail and inner ear 
development
Mansour et. al. (1994)
Fgf4 Embryonic lethal, E4-5; defects in 
trophectoderm and primitive 
endoderm
Feldman et. al. (1995), 
Goldin et. al. (2003)
Fgf5 Viable; defects in hair growth Hebert et. al. (1994)
Fgf6 Viable; defects in muscle Floss et. al. (1997)
Fgf7 Viable; largely normal Guo et. al. (1996)
Fgf8 Embryonic lethal, E9.5; defects in 
mesoderm and endoderm migration 
and cell fate determination
Sun et. al. (1999),          
Meyers et. al. (1998)
Fgf9 Die at birth; defects in lung and gut 
development 
Colvin et. al. (2001),         
Geske et. al. (2008)
Fgf10 Die at birth; defects in skeletal, gut 
and lung development
Sekine et. al. (1999),         
Min et. al. (1998)
Fgf12 Viable; defects in neuromuscular 
function
Goldfarb et. al. (2007)
Fgf14 Viable; defects in neurological 
functions
Wang et. al. (2002),         
Laezza et. al. (2007)
Fgf15 Embryonic lethal, E13.5-P21; defects 
in heart development and bile acid 
metabolism
Vincentz et. al. (2005), 
Inagaki et. al. (2005)
Fgf16 Viable; defects in heart development Itoh et. al. (2007)
Fgf17 Viable; defects in brain development Xu et. al. (2000)
Fgf18 Die at birth; defects in skeletal and 
lung development
Ohbayashi et. al. (2002),       
Liu et. al. (2002),                
Usui et. al. (2004)
Fgf21 Viable; largely normal Itoh et. al. (2007)
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Red and blue boxes indicate Fgf genes that are required for viability of 
mice. The two genes that were investigated further in this thesis are 
marked by blue boxes. 
  
1.2 Mouse gastrointestinal development 
 
As this thesis investigated the role of Fgf10 and Fgfr2b in GI 
development, homeostasis and injury, the following sections will provide 
information on the anatomy of developing and adult mouse gut, and 
discuss mouse models of ulcerative colitis.  
 
1.2.1 Stomach development 
 
In the mouse, gastrointestinal (GI) development occurs in several 
sequential steps: differentiation of definitive endoderm, formation and 
regional specialisation of the primitive gut tube, followed by 
morphogenesis and differentiation of component cell lineages (Figure 1.5) 
Fgf22 Viable; largely normal Umemori, personal 
communication
Fgfr1 Embryonic lethal, E7.5-9.5; defects in 
mesoderm and endoderm migration 
and cell fate determination
Deng et. al. (1994), 
Yamaguchi et. al. (1994), 
Ciruna et. al. (2001)
Fgfr2 Embryonic lethal; E6-8; defects in 
inner cell mass, and no visceral 
endoderm formed
Arman et. al. (1998)
Fgfr2b Die at birth; defects in skeletal, gut 
and lung development
DeMoerlooze et. al. 
(2000)
Fgfr3 Viable; defects in skeletal formation, 
inner ear development and abnormal 
intestinal crypt proliferation
Colvin et. al. (1996),       
Vildrich et. al. (2009)
Fgfr4 Viable; defects in cholesterol 
metabolism and bile acid synthesis
Yu et. al. (2000)
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(Grapin-Botton and Melton, 2000). At around embryonic (E) day 10.0, the 
stomach emerges as a bulge from the primitive gut tube (Aubin et al., 
2002). At E11.5, stomach epithelial cells proliferate rapidly and the 
epithelium is pseudo-stratified with little difference between the 
presumptive forestomach and presumptive glandular stomach (Fukamachi 
et al., 1979). The epithelium then begins to stratify and form 
intraepithelial vacuoles from E13.5 onwards. Mesenchymal cells then 
invade the epithelium and the stratified epithelium becomes a simple 
columnar structure by E15.5. From E15.5 to E18.5, the epithelial cells 
differentiate into an epithelial monolayer with numerous invaginations 
that have morphological features of mucus-producing pit and neck cells, 
acid-producing parietal cells and hormone-producing enteroendocrine 
cells observed in adult gastric units (Karam et al., 1997). 
Cytodifferentiation proceeds postnatally with expansion of these gastric 
lineages until P28, where distinct pit, isthmus, neck and base 
compartments are formed (Karam et al., 1997) (see Section 1.3.1 for adult 
stomach lineages). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Stages in gut tube formation and specification (modified 
from (Grapin-Botton and Melton, 2000)). 
 29 
Following gastrulation (A), where all three distinct germ layers 
(endoderm, mesoderm and ectoderm) are present, the anterior tip of the 
endoderm forms a fold (anterior intestinal portal, AIP) that travels 
posteriorly (indicated by the green arrow) to form the initial part of the 
primitive gut tube (B). This is later followed by the formation of a second 
fold at the posterior tip of the endoderm (caudal intestinal portal, CIP) that 
travels anteriorly (indicated by the green arrow) and finally fuses with the 
AIP at the yolk stalk, which connects the embryo to the yolk sac (C). 
Fusing of the two folds is also facilitated by ‘turning’ of the embryo, as 
indicated by the purple arrows in (C). The gut tube (D) then undergoes 
regionalisation characterised by swelling and budding of different organs: 
foregut (gives rise to oesophagus, stomach, first part of duodenum until 
the hepatic duct, pancreas, lungs and liver), midgut (gives rise to small 
intestine) and hindgut (gives rise to large intestine) (E) (Wells and Melton, 
2000). From this point onwards, the different segments of the gut undergo 
morphogenesis and differentiation. 
 
 
1.2.2 Intestinal development 
 
The development of the small and large intestines (caecum and colon) is, 
to some extent, similar to that of the stomach. Intestinal epithelium 
proliferates rapidly and becomes stratified at E11.5 (Fukamachi et al., 
1979). Also at this stage, the caecum develops as a bud that propagates off 
the main gut tube (hindgut region) at around E11.5. Numerous 
intraepithelial vacuoles form and fuse with the luminal surface at E13.5. 
Mesenchymal cells invade the epithelium and the stratified epithelium 
becomes a simple columnar structure by E15.5. From E15.5 to E18.5, the 
epithelial cells differentiate into a monolayer of numerous invaginations 
that have intestinal absorptive cells and mucin-producing goblet cells. In 
the small intestine, these invaginations lead to the formation of primitive 
villi. Crypts develop postnatally from P1 to P5 at the base of the 
invaginations, and cytodifferentiation continues postnatally until twenty 
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days post weaning (Subramanian et al., 1998). Throughout E12.5 to 
E18.5, the intestine undergoes a series of rotational events, resulting in the 
proper positioning of the gut within the abdominal cavity (Takahashi et 
al., 1998). 
 
 
1.3 Adult mouse gastrointestinal tract 
 
1.3.1 Anatomy of the stomach 
 
Following ingestion of food by the oral cavity and subsequent transfer 
into the stomach via the oesophagus, digestion is initiated by mixing the 
food with gastric juice containing acids and enzymes. During digestion, 
the food is converted into a mixture called chyme, which is then passed on 
to the small intestine through a valve known as pyloric sphincter. The 
adult stomach consists of two distinct parts: forestomach and glandular 
stomach. The forestomach consists only of stratified squamous 
epithelium, whereas the glandular stomach consists of gastric units and is 
further divided into corpus and pyloric antrum. In the corpus region, each 
gastric unit is composed of gastric precursors in the isthmus, mucus-
producing pit and neck cells, acid-producing parietal cells, hormone-
producing enteroendocrine cells, and zymogenic chief cells that produce 
intrinsic factor and pepsinogen (Figure 1.6) (Lorenz and Gordon, 1993).  
 
Using a combination of tritiated thymidine labelling, light microscopy and 
electron microscopy, the isthmal gastric precursors are thought to consist 
of undifferentiated granule-free stem cells and three committed daughter 
cells (granule-free pre-pit precursor cells, granule-free pre-neck cells, and 
pre-parietal cells) that give rise to the terminally differentiated gastric 
lineages (Figure 1.7) (Karam et al., 1997). In the pyloric antrum, however, 
each gastric unit is composed of gastric precursors in the isthmus, and 
mucus-producing pit and gland cells  (Lee et al., 1982). These gastric 
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precursors are thought to be stem cells and two committed daughter cells 
(granule-free pit cells and granule-free gland cells) that give rise to pit and 
gland cells (Figure 1.7) (Karam et al., 2008). 
 
 
 
Figure 1.6 Representation of gastric units located in the corpus of a 
normal mouse stomach epithelium (Syder et al., 2003). 
The left image shows a haematoxylin and eosin (H&E)-stained section of 
the gastric epithelium. Pit cells are marked by filled arrows, parietal cells 
are marked by arrowheads, and chief cells are marked by open arrows. 
The middle image shows the four compartments of a gastric unit. The 
right image shows a multilabel histochemical staining for pit cells 
(purple), isthmal progenitor cells (green), neck cells (blue), and chief cells 
(red). 
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Figure 1.7 Schematic diagram showing the lineage relationships and 
differentiation programmes of the epithelial cells in the corpus and 
antrum of mouse stomach (modified from (Li et al., 1998) and 
(Karam et al., 2008)). 
The arrows indicate the direction of migration of various gastric lineages. 
In the corpus, the pre-parietal cells can derive from three types of granule-
free cells: undifferentiated granule-free cells, pre-pit precursor cells and 
pre-neck precursor cells. In contrast, the pit and zymogenic cell lineages 
are derived from single committed precursors, which are pre-pit precursor 
and pre-neck precursor cells respectively. Pre-parietal cells differentiate 
into parietal cells during bipolar migration, while pit and zymogenic cells 
arise during unipolar migration. In the pyloric antrum, the isthmal 
multipotent stem cells give rise to two committed precursors: pre-pit 
precursors that terminally differentiate into pit cells while migrating 
upwards, and pre-gland precursors that terminally differentiate into gland 
mucous cells while migrating downwards. 
 
 
1.3.2 Anatomy of the intestine 
 
The adult intestine is divided into small and large intestines. The small 
intestine is further divided into duodenum, jejunum and ileum, while the 
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large intestine is further divided into caecum, proximal and distal colon. 
The small intestine absorbs nutrients from the chyme via its surface 
epithelium. Following removal of nutrients, the chyme, mostly consists of 
water and indigestible waste, such as cellulose, is then passed through the 
ileocaecal valve by peristaltic movements into the large intestine. 
Movement of chyme along the large intestine is slower, and this favours 
the growth of bacteria that are essential for the health of the digestive 
tract. These bacteria feed on the chyme and produce essential vitamins, 
for example Vitamin K and some of the B-complex vitamins, and compete 
with pathogenic bacteria to colonise the intestinal environment. Caecum 
and colon mainly absorb water and sodium from the chyme and eliminate 
wastes, which are composed mainly of undigested or unabsorbed food and 
bile pigments. 
 
The wall of both the small and large intestines is made up of four layers 
(Figure 1.8): 
a) mucosa, which lines the digestive tract and consists of epithelial tissue, 
b) submucosa, which lies outside the mucosa and contains connective 
tissue rich in blood vessels, lymphatics, nerve vessels, and a thin 
superficial muscular layer (the muscularis mucosa), 
c) muscularis propria, which underlies the submucosa and consists of 
smooth muscle that induces peristalsis (a wave-like contraction that 
pushes food along the digestive tract), 
d) serosa (visceral peritoneum), which is the outermost coat of the 
digestive tract and consists of connective tissue.  
 
In the mucosa of the small intestine, there are numerous finger-like 
projections, called villi, which increase the surface area of the small 
intestine to absorb nutrients from food (Figure 1.9). The mucosa also has 
numerous invaginations known as crypts of Lieberkühn. Within each 
villus, there is a network of blood capillaries and a central lymph vessel. 
Nutrients absorbed by the villi are passed to the blood vessels (for amino 
acids and simple sugars) or the lymphatic system (for fatty acids). In 
contrast, the caecal and colonic epithelium lacks villi and consists mainly 
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of crypts. New crypts are thought to form from existing crypts by a 
process known as ‘crypt fission (Totafurno et al., 1987). The exact 
mechanism of this process is still under investigation. It is believed that a 
fissure occurs at the bottom of the crypts and extends across the 
longitudinal axis, resulting in the formation of two crypts (Figure 1.10) 
(Totafurno et al., 1987, Wasan et al., 1998). Crypt fission also initiates 
when the number of stem cells present in a crypt doubles (Loeffler et al., 
1993). 
 
There are four main types of cells that populate the intestinal epithelium 
(Figure 1.11): 
a) absorptive cells (also known as enterocytes in the small intestine, and 
colonocytes in the large intestine), which are the most abundant cell 
lineage in the small intestine. These are simple columnar epithelial cells 
that display microvilli on the apical surface in order to increase their 
absorptive capacity. Their main functions are to absorb nutrients from the 
chyme, and secrete enzymes for digestion in the lumen. 
b) goblet cells, which are mucin-producing cells. Their cytoplasm consists 
mainly of mucinogen granules, while the basal portion of these cells is 
occupied by the cell organelles. The number of goblet cell increases 
gradually from the duodenum to the distal colon. 
c) enteroendocrine cells, which are hormone-secreting cells. These cells 
control gut physiology by secreting serotonin, somatostatin, motilin and 
secretin.  
d) Paneth cells, which are secretory cells that produce many anti-
microbial agents to provide host defence against bacteria. One important 
agent is cryptidin (alpha-defensins) that preferentially binds to bacterial 
cells and results in cell lysis by disrupting membrane function (Ouellette 
and Bevins, 2001). Other anti-microbial agents include lysozyme and 
phospholipase A2. Paneth cells reside at the bottom of the crypts, in the 
same vicinity to that of the stem cells, suggesting a critical role of Paneth 
cells in defending epithelial cell renewal from microbial invasion 
(Ouellette and Bevins, 2001). Paneth cells are the only lineage absent 
from the colonic crypts, and the reason for this is currently unclear.  
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Figure 1.8 Schematic diagram of the layers in a small intestine 
(Solomon, 1992).  
The four layers of the intestine are the mucosa, submucosa, muscularis 
propria and the visceral peritoneum. In this diagram, the mucosa shows 
numerous finger-like projections called villi that are present in the small 
intestine, but the mucosa in the caecum and colon lacks villi and contains 
only crypts. 
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Figure 1.9 Schematic diagram of small intestinal villi (Solomon, 1992). 
Each villus has a network of blood capillaries and a central lymph vessel. 
The base of each intestinal gland contains crypts of Lieberkühn. 
 
 
 
Figure 1.10 Schematic diagram of crypt fission (Wasan et al., 1998). 
Each crypt in the small intestine, caecum and colon replicates by this 
process. As crypts elongate, they bifurcate (divide into two) starting from 
the bottom. 
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Figure 1.11 Schematic diagram of the four main types of cells in the 
intestine (Alberts et al., 2007). 
These cells represent the different lineages present in the small intestine. 
The Paneth cells, however, are absent in the caecum and colon. The 
yellow arrows indicate that three of these cell types are secretory and only 
one (the enterocyte) is absorptive. 
 
 
1.3.3 Life cycle of intestinal epithelial cells 
 
Given the highly toxic environment in the intestinal lumen, cells lining the 
intestinal epithelium are highly proliferative, with crypt turnover taking 
approximately three days in the mouse (Creamer et al., 1961). Epithelial 
cells in both small and large intestines are thought to arise from a small 
population of stem cells that reside at the bottom of the crypts. Intestinal 
stem cells are elusive in identity, and proposed stem cell markers have 
been highly debated. The number of stem cells is estimated to be between 
four and six per crypt (Bjerknes and Cheng, 1999). Long-term tritiated 
thymidine labelling studies have shown that stem cells are located at the 
+4 position above the Paneth cells (Figure 1.12) (Potten et al., 1997). An 
alternative intestinal stem cell hypothesis has suggested that crypt base 
columnar (CBC) cells interspersed between Paneth cells at the base of the 
crypts are the true stem cells, as they display longetivity and multipotency 
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characteristics of stem cell nature (Figure 1.12) (Cheng and Leblond, 
1974, Bjerknes and Cheng, 1981c, Stappenbeck et al., 2003), although 
they appear to cycle rapidly. 
 
However, both models agree that stem cells give rise to all other epithelial 
cell lineages through the proliferation of the transit amplifying (TA) cells. 
TA cells reside in the lower two thirds of the crypt in the TA 
compartment, and divide every 12-16 hours to generate approximately 
300 cells per crypt per day (Marshman et al., 2002). During their 
proliferative cycles, TA cells migrate upwards along the crypt-villus axis 
while terminally differentiating into absorptive, goblet and 
enteroendocrine cells. However, both models have disagreement on the 
migration pattern of the Paneth cells. In the ‘+4 position’ stem cell model, 
the Paneth cells are believed to escape the upward migration flow and 
instead migrate downwards during the differentiation process, before 
residing at the crypt base for 3-6 weeks (Ireland et al., 2005, Bjerknes and 
Cheng, 1981b, Bjerknes and Cheng, 1981a). In the ‘CBC-stem cell zone 
model’, the Paneth cells do not migrate during differentiation and stay 
interspersed between the CBC cells (Cheng and Leblond, 1974, Bjerknes 
and Cheng, 1981c, Stappenbeck et al., 2003). 
 
Proliferation of TA cells is balanced by apoptosis and shedding of cells 
that have reached the top of the villus (or the crypt in the colon) into the 
lumen. Therefore, the intestinal epithelium sheet can be thought of as 
being in a virtually constant upward movement, except for the Paneth 
cells in the ‘+4 position’ stem cell model that migrate downwards. In the 
small intestine, as many as 6-10 crypts can surround a villus, resulting in 
the villi being polyclonal entities due to the convergence of differentiated 
cells from multiple crypts (Cheng and Leblond, 1974). The mechanism of 
controlling the balance between intestinal proliferation and differentiation 
has been a subject of intense investigation, and an example of a signalling 
pathway essential in this process is the Wnt/!-catenin signalling pathway. 
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Figure 1.12 Schematic diagram of the location of stem cells in 
intestinal crypts (Barker et al., 2008). 
In the ‘+4 position’ model, the stem cells are located at the +4 position 
above the Paneth cells, whereas in the ‘CBC-stem cell zone’, the stem 
cells are interspersed between the Paneth cells at the base of the crypts. 
 
 
1.4 Wnt signalling pathway 
 
The Wnt genes encode a family of glycoprotein signalling molecules. The 
central effector of the pathway activated by these molecules is the !-
catenin protein. In the absence of Wnt signalling, !-catenin is 
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phosphorylated by two serine/threonine kinases: casein kinase 1-! 
(CPK1-!) and glycogen synthase kinase-3" (GSK-3") (Figure 1.13) 
(Hinoi et al., 2000, Liu et al., 2002). The interaction between these kinases 
and "-catenin is facilitated by a scaffolding complex, formed by the 
adenomatous polyposis coli (APC) protein and Axin (Behrens et al., 1998, 
Ikeda et al., 1998, Yamamoto et al., 1998, Kishida et al., 1998). Together, 
these proteins form a "-catenin degradation complex by targeting the 
phosphorylated "-catenin to the 26S proteosome for degradation through 
ubiquitination by the "-transducin repeat-containing protein ("-TRCP) 
(Aberle et al., 1997). 
 
Conversely, Wnt signalling is activated when extracellular Wnt ligands 
bind to one of the Frizzled transmembrane receptors and one of the LRP 
(low-density lipoprotein receptor-related protein) co-receptors (Fig. 1.13). 
Axin is then recruited to the membrane, where it interacts with the 
cytoplasmic domain of the LRP co-receptor. The relocation of Axin 
causes destabilisation of the "-catenin degradation complex (Mao et al., 
2001, Tamai et al., 2000, Pinson et al., 2000). At the same time, 
hyperphosphorylation of the dishevelled (Dsh) protein occurs, which 
results in phosphorylation and inactivation of GSK3-", further repressing 
"-catenin degradation (Yanagawa et al., 1995). The consequent 
accumulation of unphosphorylated "-catenin in the cytoplasm results in 
translocation of free "-catenin to the nucleus, where it recruits the 
Legless/BCL9 and Pygopus proteins, and interacts with members of the 
TCF/LEF (T-cell factor/lymphoid enhancer factor) family of transcription 
factors, activating transcription of a number of Wnt target genes, such as 
the leucine-rich-repeat-containing G-protein-coupled receptor 5 (Lgr5) 
that marks actively cycling intestinal stem cells (Tetsu and McCormick, 
1999, Kramps et al., 2002, Belenkaya et al., 2002, Van de Wetering et al., 
1996, Korinek et al., 1997, Barker et al., 2007).  
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Figure 1.13 Schematic diagram of the Wnt signalling cascade (Giles et 
al., 2003). 
In the absence of a Wnt signal, cytoplasmic !-catenin is bound to a 
degradation complex, and degraded in the proteosome. In the presence of 
a Wnt signal, the degradation complex destabilises, and accumulated !-
catenin translocates to the nucleus and activates the TCF/LEF 
transcription factors. 
 
1.5 Inflammatory bowel disease 
 
1.5.1 Overview 
 
Inflammatory bowel disease (IBD) consists primarily of two disorders: 
ulcerative colitis (UC) and Crohn’s disease (CD). The first feature of IBD 
is chronic and uncontrolled inflammation of the intestinal mucosa that can 
affect any part of the GI tract (Papadakis and Targan, 2000). Diagnosis is 
based on the presence of architectural distortion, such as transmural or 
superficial patchy granulomatous infiltration, and/or acute inflammatory 
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cells (Hanauer, 2006). The second feature of IBD is the inability to 
downregulate those responses (Hanauer, 2006). In healthy people, the 
intestine becomes inflamed in response to pathogen then returns to a state 
of tolerance once the pathogen is eliminated from the gut. However, in 
patients with IBD, this inflammation is not downregulated, and the 
mucosal immune system remains activated, resulting in the intestine being 
chronically inflamed.  
 
Although UC and CD are recognised as clinically distinct conditions with 
different anatomical and histological findings (Figure 1.14), accurate 
diagnosis remains challenging because patients can have a spectrum of 
conditions with UC and CD at opposite ends (Sands, 2004). In UC, the 
inflammation affects primarily the mucosal lining of the colon and 
rectum, whereas in the CD, the inflammation usually affects the whole 
intestinal wall and can extend to any part of the GI tract (Podolsky, 2002). 
10% of patients have indeterminate features between UC and CD that 
cannot be clearly categorised, and often these patients remain in this 
category until the diagnostic features of UC or CD become apparent later 
on (Podolsky, 2002). 
 
In the UK, UC is affecting 120,000 people (about 1:500) with 6,000 to 
12,000 new cases being diagnosed each year. In contrast, CD is affecting 
60,000 people (about 1:1000) with 3,000 to 6,000 new cases diagnosed 
each year (statistics from National Association for Colitis and Crohn’s 
Disease (NACC) at http://www.nacc.org.uk/content/ibd.asp). There is 
approximately 3.7% chance that a patient with UC can develop colorectal 
cancer (CRC) (Eaden et al., 2001).  
 
The great diversity of symptoms within UC and CD suggests a complex 
interplay of genetic, environmental and immunological factors in the 
aetiology of IBD, and these factors are currently being studied with 
numerous mouse models of IBD.  
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Figure 1.14 Histologic features of human CD and UC (Xavier and 
Podolsky, 2007). 
Key features of CD include formation of discrete granulomas composed 
of macrophages, and significant infiltration of lymphoid cells and other 
inflammatory cells surrounding the granuloma. Key features of UC 
include significant infiltration of neutrophils within the lamina propria, 
formation of crypt abscesses, and extensive surface mucosal ulceration. 
 
 
1.5.2 Mouse models of UC 
 
Animal models of UC are valuable tools for investigating the pathogenesis 
of UC and testing emerging therapeutic strategies in the pre-clinical 
phase. While there are many types of mouse models of chronic intestinal 
inflammation, this section will only discuss the use of chemically induced 
models, as these models are most commonly used to study UC, and they 
closely resemble some of the immunological and histopathological aspects 
of human UC (Wirtz and Neurath, 2000). The three most common 
chemically induced models are TNBS colitis, oxazolone colitis, and DSS 
colitis. 
 
In the TNBS model, colitis is induced by intrarectal instillation of 2,4,6-
trinitrobenzene sulfonic acid (TNBS) in 30-50% ethanol (Wirtz and 
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Neurath, 2000). Ethanol breaks the mucosal barrier, while TNBS 
haptenises colonic proteins to make them immunogenic to the host 
immune system. Chronic TNBS colitis in SJL/L mice has resulted in Th1-
mediated granulomatous inflammation with severe diarrhoea, weight loss, 
thickening of the colonic wall and elevated level of infiltrating 
lymphocytes, especially the CD4
+
 T-cells (Neurath et al., 1995, Neurath et 
al., 1996), implying that this model is useful for studying Th1-dependent 
immune responses. However, the inflammatory process in mice is highly 
dependent on the strain and the concentration of TNBS administered 
(Wirtz et al., 2007).  
 
In the oxazolone model, colitis is induced similarly as that of TNBS, and 
often leads to weight reduction, diarrhoea, significant loss of goblet cells, 
and high death rates (Ekstrom, 1998, Boirivant et al., 1998). This model is 
useful for studying the contribution of Th2-dependent immune response to 
intestinal inflammation, due to its elevated production of Th2 cytokines 
IL-4 and IL-5, which is similar to those characteristics observed in human 
UC (Boirivant et al., 1998). Like TNBS, oxazolone colitis is strain-
dependent and requires individual optimisation, as a low dose of 
oxazolone can induce a mixed Th1/Th2-dependent colitis (Iijima et al., 
2004). 
 
In the DSS model, colitis is induced by administration of dextran sodium 
sulphate (DSS) in drinking water for three to seven days, which can lead 
to bloody diarrhoea, ulcerations and infiltrations with granulocytes 
(Okayasu et al., 1990). DSS is toxic to gut epithelial cells of the basal 
crypts and affects the integrity of the mucosal barrier. Several studies have 
shown that the adaptive immune system does not play a major part in this 
model (Dieleman et al., 1994), hence DSS colitis is often used to study the 
contribution of innate immune response to intestinal inflammation. In 
susceptible strains, such as the C57BL/6 strain, administration of DSS for 
several cycles results in chronic colitis and when combined with a single 
initial dose of the genotoxic colon carcinogen azoxymethane (AOM), can 
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result in inflammation-associated CRC (Tanaka et al., 2003). Hence, DSS 
colitis is a useful model to study the interplay between colitis and CRC. 
 
1.6 Experimental hypotheses 
 
Given that FGFs and FGFRs are crucial in multiple processes from 
embryonic development to angiogenesis, wound healing and 
tumourigenesis (Section 1.1), and both Fgf10
-/-
 and Fgfr2b
-/-
 embryos 
have gut defects (Table 1.1), the following hypotheses have been 
addressed: 
 
i) Fgf10-Fgfr2b signalling is essential for normal small 
intestinal development. 
ii) Fgfr2b is required for maintaining intestinal homeostasis. 
iii) Fgfr2b plays a protective role in intestinal injury and is 
required for normal wound repair. 
iv) Fgfr2b is expressed only within specific adult gastric 
lineages in the adult mouse. 
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Chapter 2: Materials and methods 
 
2.1 Animal husbandry 
 
2.1.1 Animal ethics 
 
All procedures were approved by the Cancer Research UK and Imperial 
College School of Medicine Animal Ethics Committees, and covered by 
the appropriate licences under the Home Office Animal Procedures Act 
1986. All mice were culled according to Schedule I of the Animals 
Procedures Act 1986. 
 
2.1.2 Animal breeding 
 
Please see individual chapters for this, as different breeding strategies 
were adopted for different work. 
 
2.1.3 Genotyping by PCR 
 
Yolk sacs or adult ear-snips were incubated in 200 µl of DirectPCR Lysis 
reagent (401-E; Viagen Biotech) with 0.2 mg/ml Proteinase K (P-6556; 
Sigma-Aldrich) for 3 hrs at 55°C. Proteinase K was heat inactivated at 
85°C for 45 min. Cell debris was pelleted, and 2 µl of supernatant was 
used for PCR. PCR amplification was performed using a Taq DNA 
Polymerase kit (201203; Qiagen). Each 20 µl PCR reaction contained 1X 
PCR buffer, 0.2 mM of each dNTP, 1.5 mM MgCl2, 0.3 µM of each 
primer, 1X Q-solution, 2.5 U of Taq DNA polymerase, and 2 µl of DNA 
sample. PCR was performed using a thermal profile starting 2 min 
denaturation at 94°C, followed by 30 cycles consisting of denaturation at 
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94°C for 30 s, annealing at x°C for 1 min and extension at 72°C for 1 min, 
with a final extension at 72°C for 5 min. X refers to the appropriate 
annealing temperature for each primer set, which varies for different 
genes (Table 2.1). PCR products were analysed by agarose gel 
electrophoresis (Section 2.4.5). 
 
2.2 Preparation of chemicals 
 
2.2.1 RU486 
 
RU486 mix was prepared by dissolving 3 mg of Mifepristone (RU486; 
M8046; Sigma-Aldrich) per 250 µl of 0.25% (w/v) 
carboxymethylcellulose/0.5% (v/v) Tween-80 solution, giving a final 
concentration of 12 mg/ml. 
 
2.2.2 Tamoxifen 
 
Tamoxifen mix was prepared by first dissolving 10 mg of tamoxifen 
(T5648; Sigma-Aldrich) per 100 µl of 100% ethanol, then adding 900 µl 
of autoclaved sunflower oil (Tesco) and vortexing the mix until a 
homogenous suspension was obtained, giving a final concentration of       
10 mg/ml.  
 
2.3 In situ hybridisation 
 
2.3.1 Production of DIG-labelled probes 
 
pBluescript IISK+ plasmid carrying a mouse cDNA of the cytoplasmic 
tyrosine kinase (TK) domain of Fgfr2 (nucleotides 1726-2714) was 
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obtained from our laboratory and has been previously described (De 
Moerlooze et al., 2000). 50 ng of the plasmid was transformed into 
bacteria, grown as maxi-culture and purified (Section 2.11.7 for full 
details). 10 µg of purified plasmid was linearised with BamHI (for 
antisense) and HindIII (for sense) separately. 
 
In vitro transcription was conducted using a DIG RNA Labelling kit 
(11175025910; Roche) where a 20 µl reaction volume consisting of 1 µg 
of DNA template, 1X transcription buffer, 30 mM DTT, 1X nucleoside 
triphosphates mix (ATP, GTP, CTP, and DIG-UTP), 1 U/µl Protector 
RNase Inhibitor, and 2 U/reaction T7 (for antisense) or T3 polymerase 
(for sense) was incubated for 2 hrs at 37°C. The sample was treated with  
2 U of RNase-free rDNase I (AM1906; Ambion) for 30 min at 37°C to 
remove DNA template after transcription. rDNase was inactivated with a 
DNase inactivation reagent provided by the kit. RNA was precipitated in 5 
mM EDTA pH 8.0, 120 mM LiCl, and 75% cold ethanol for 2 hrs at            
-20°C. RNA was pelleted, rinsed with 70% ethanol, and re-suspended in 
50-100 µl EDTA 10 mM. Labelled antisense and sense Fgfr2-TK probes 
were visualised by agarose gel electrophoresis (Section 2.4.5), and extent 
of DIG-labelling was estimated using a dot blot described in the following 
section. 
 
2.3.2 Dot blot 
 
Labelled control RNA (from the DIG RNA Labelling kit; 11175025910; 
Roche) was used to prepare standards of 10 ng/µl, 5 ng/µl, 2 ng/µl, 1 
ng/µl, 0.5 ng/µl, 0.1 ng/µl using 10X SSC as the diluent. Unlabelled 
control RNA (from the DIG RNA Labelling kit; 11175025910; Roche) at 
10 ng/µl was also prepared with 10X SSC (consisted of 1.5 M NaCl and 
0.15 M sodium citrate). 1 µl of antisense and sense probes prepared 
previously were diluted 1:100 with 10X SSC. All samples were then spot 
onto an 8 cm x 5 cm nitrocellulose membrane 0.45 µm pore size 
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(RPN203D; GE Healthcare) and allowed to air-dry for 10 min at room 
temperature (RT). Membrane was UV cross-linked with 1.2 kJ/m
2
 with a 
UV Stratalinker 2400 (Stratagene), and incubated in a PBS solution 
containing 0.1% (v/v) Tween-20 (63158; Sigma-Aldrich) and 1% (v/v) 
Blocking buffer (1096176; Roche) for 20 min at RT. Membrane was 
incubated with sheep anti-DIG antibody conjugated with alkaline-
phosphatase (11093274910; Roche) at 1:5000 (diluted in 1X TBST buffer, 
0.1% Tween-20, and 1% Blocking buffer) for 30 min at RT. Membrane 
was washed in TBST buffer for 2 x 15 min, in NTMT buffer (containing 
100 mM NaCl, 100 mM Tris-Cl pH 9.5, 50 mM MgCl2, and 0.1% Triton 
X-100 (T9284; Sigma-Aldrich)) for 2 min, and incubated in a solution 
containing 4.5 µl/ml NBT (11383213001; Roche) and 3.5 µl BCIP 
(10760994001; Roche) (made with NTMT) in dark for 5 min. Membrane 
washed in TBST for 5 min, incubated in 10% neutral-buffered formalin 
(NBF) for 30 min, and air-dried. 
 
2.3.3 In situ hybridisation (ISH) with labelled probes 
 
Tissues were fixed in 10% NBF, processed and embedded in paraffin 
(Section 2.5.2), sectioned at 10 µM thickness using gloves and DEPC-
treated water, and dried in an oven at 37°C overnight wrapped with 
aluminium foils. Sections were dewaxed by a 5 min immersion in sulphur-
free xylene (BDH), re-hydrated by 5 min incubation in decreasing 
concentrations of ethanol (100%, 95%, 70%), water and PBS. Sections 
were treated with 10 µg/ml Proteinase K (P2308; Sigma-Aldrich) for 20 
min at 37°C, washed in 0.2% (w/v) glycine/PBS (glycine obtained from 
241261; Sigma-Aldrich) for 5 min, and incubated in 4% 
paraformaldehyde (PFA) for 10 min. Sections were then washed in PBS 
for 3 x 5 min, 4X SSC for 2 min, and incubated with hybridisation buffer 
containing 50% (v/v) deionised formamide (F7508; Sigma-Aldrich), 10% 
(v/v) dextran sulphate (31493; Sigma-Aldrich), 1X Denhardt’s solution 
(53754, Sigma-Aldrich), 10 mM Tris-Cl pH 7.5, 60 mM NaCl, 1mM 
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EDTA, 0.25% SDS and 1 mg/ml tRNA (R5636, Sigma-Aldrich) for 1 hr 
at 57°C.  
 
Labelled antisense and sense probes were diluted to 1:100 with the 
hybridisation buffer, incubated at 75°C for 15 min to denature RNA 
secondary structures, and cooled on ice for 15 min. Each probe mixture 
was added to the sections, layered with a parafilm, and placed in tightly 
sealed humidified chamber at 57°C for overnight. The next day, sections 
were washed in 5X SSC for 10 min at 60°C, 50% formamide/2X SSC for 
30 min at 60°C, 2X SSC for 30 min at 60°C, 0.2X SSC for 30 min at 
60°C, 1X maleic buffer for 5 min at RT, and 1X Blocking buffer 
(1096176; Roche) for 30 min at RT. Sections were incubated with sheep 
anti-DIG antibody conjugated with alkaline-phosphatase (11093274910; 
Roche) at 1:1000 (diluted with 1X Blocking buffer) for 2 hrs at 37°C. 
Sections were washed in 1X maleic buffer for 2 x 15 min at RT, and 
incubated a detection buffer containing 0.1 M NaCl, 0.04M MgCl2, 100 
mM Tris-HCl pH 9.5, and 2 mM levamisole for 5 min at RT. Antibody 
binding was developed with a solution containing 4.5 µl/ml NBT 
(11383213001; Roche) and 3.5 µl BCIP (10760994001; Roche) (made 
with the detection buffer) in dark at RT until the desired intensity of 
colorimetric reaction was achieved. Sections were then washed in the 
detection buffer for 15 min, in water for 15 min, counterstained in Nuclear 
Fast Red (Vector Laboratories) for 5 min, and mounted in Crystalmount 
aqueous mounting medium (C0612; Sigma-Aldrich). All buffers were 
made with DEPC-treated water. 
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2.4 Gene expression 
 
2.4.1 RNA extraction 
 
Tissues weighing not more than 30 mg were isolated and snap frozen in 
liquid nitrogen. RNA was extracted with an RNeasy Plus Mini kit (74134; 
Qiagen) according to the manufacturer’s instructions. Briefly, tissues were 
homogenised in Buffer RLT Plus, passed through a DNA-binding column, 
added 70% ethanol, and passed through an RNA-binding column. Column 
membranes were washed with Buffer RW1 and RPE. RNA was eluted 
with 30 µl RNase-free water. RNA was re-treated with 2 U of RNase-free 
rDNase I (AM1906; Ambion) for 30 min at 37°C according to the 
manufacturer’s instructions. rDNase was inactivated with a DNase 
inactivation reagent provided by the kit. The total RNA yield was 
measured with a NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies), and RNA integrity was analysed with a denaturing 2% 
formaldehyde-agarose gel stained with ethidium bromide as described in 
the following section. 
 
2.4.2 Denaturing formaldehyde-agarose gel 
electrophoresis 
 
1.5 g of agarose (A4718; Sigma-Aldrich) was dissolved in 150 ml of 1X 
NorthernMax Denaturing Gel Buffer (AM8676; Ambion), containing 
formaldehyde and MOPS buffer, by heating. Ethidium bromide (E7637; 
Sigma-Aldrich) was added to the melted agarose to a final concentration 
of 0.5 µg/ml. Agarose mix was then poured into a gel cassette and allowed 
to cool. 500 ng of RNA was mixed with 2X volumes of Formaldehyde 
Load Dye, heated at 65°C for 10 min to denature the RNA, and cooled on 
ice for 2 min. 2 µl of RNA Millennium Markers (AM7150; Ambion) was 
mixed with 6 µl of NorthernMax Formaldehyde Load Dye (AM8552; 
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Ambion), heated and cooled as previously. RNA samples, including the 
markers, were electrophoresed at 100 V constant in 1X NorthernMax 
Running Buffer (AM8671; Ambion) until the desired migration extent 
was achieved. Bands were visualised under UV light, and photographed 
using an EagleEye Still Video system (Stratagene). 
 
2.4.3 First strand cDNA synthesis 
 
cDNA synthesis from RNA template was performed with a Superscript III 
First Strand Synthesis kit (18080-051; Invitrogen) according to the 
manufacturer’s instructions. Briefly, a 10 µl reaction mix containing 1 µg 
of RNA, 5 ng/µl random hexamer, and 1 mM dNTP was incubated at 
65°C for 5 min, and cooled on ice for 2 min. A separate 10 µl reaction 
mix containing 2X RT buffer, 10 mM MgCl2, 20 mM DTT, 4 U/µl 
RNaseOUT, and 20 U/µl Superscript III was added to the initial reaction 
mix, giving a total reaction volume of 20 µl. The combined reaction mix 
was incubated for 10 min at 25°C, for 50 min at 50°C, for 5 min at 85°C, 
and cooled on ice for 2 min. RNA template was removed by adding 1 µl 
of RNase H to the reaction, and incubating the reaction mix for 20 min at 
37°C. After the reverse transcription, cDNA was purified with a QIAquick 
PCR purification kit (28104; Qiagen) according to the manufacturer’s 
instructions. Briefly, cDNA was mixed with a Binding buffer, bound to a 
DNA-binding column, washed with Buffer PE, and eluted with 30 µl 
RNase-free water. The total cDNA yield was measured with a NanoDrop 
ND-1000 spectrophotometer (NanoDrop technologies), and cDNA 
integrity was assessed by PCR for Gapdh as described in the following 
section. 
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2.4.4 Reverse-transcriptase PCR 
 
PCR amplification was performed on the cDNA with various kits due to 
varying efficiencies of different kits in amplifying the gene of interest (see 
Table 2.2): Taq DNA Polymerase kit (201203; Qiagen), PuReTaq Ready-
To-Go PCR beads (407512; GE Healthcare), and MegaMix~Blue 
(2MMB; Microzone Ltd.).  
 
For the Taq DNA Polymerase kit, a 20 µl PCR reaction contained 1X 
PCR buffer, 0.2 mM of each dNTP, 1.5 mM MgCl2, 0.3 µM of each 
primer, 2.5 U of Taq DNA polymerase, and 100 ng of cDNA. Some 
reactions required an addition of Q-solution, a proprietary mix provided 
by the kit to enhance efficiency of PCR reactions, to a final concentration 
of 1X. For the PureTaq Ready-To-Go PCR beads, a 25 µl PCR reaction 
contained 0.2 mM of each dNTP, 50 mM KCl, 1.5 mM MgCl2, 0.3 µM of 
each primer, and 100 ng of cDNA. For the MegaMix~Blue, a 25 µl PCR 
reaction contained 0.3 µM of each primer and 100 ng of cDNA, with the 
remaining volume being the MegaMix solution. This master mix already 
contained 1.5 mM MgCl2. In all cases, some reactions required additional 
MgCl2 to achieve a final concentration of 2.0 mM or 2.5 mM. 
 
PCR was performed using a thermal profile starting 2 min denaturation at 
94°C, followed by 35 cycles consisting of denaturation at 94°C for 30 s, 
annealing at x°C for 1 min and extension at 72°C for 1 min, with a final 
extension at 72°C for 5 min. PCR product was analysed by agarose gel 
electrophoresis (Section 2.4.5) to confirm the correct amplicon size. X 
refers to the appropriate annealing temperature for each primer set, which 
varies for different transcripts (Table 2.2). 
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2.4.5 Agarose gel electrophoresis 
 
1.5 g of agarose (A4718; Sigma-Aldrich) was dissolved in 150 ml of 1X 
TAE buffer pH 8.2, containing 4.84 g/L Tris-base, 1.09 g/L glacial acetic 
acid and 0.3 g/L EDTA, by heating. Ethidium bromide (E7637; Sigma-
Aldrich) was added to the melted agarose to a final concentration of 0.5 
µg/ml. Agarose mix was then poured into a gel cassette and allowed to 
cool. 0.1 volume of Orange G 10 mg/ml (prepared in glycerol) (O3756; 
Sigma-Aldrich) was added to each DNA sample, mixed and added to the 
sample lanes. 10 µl of appropriate DNA ladder (NEB, UK), pre-mixed 
with 0.1 volume of Orange G 10 mg/ml, was also added to the sample 
lanes. All samples were electrophoresed at 100 V constant in 1X TAE 
buffer until the desired migration extent was achieved. Bands were 
visualised under UV light, and photographed using an EagleEye Still 
Video system (Stratagene). 
 
2.4.6 Taqman real-time PCR 
 
Taqman real-time primers were obtained from Applied Biosystems 
Inventory for the following murine genes: Fgf1 (Mm00438906_m1), Fgf3 
(Mm00433290_m1), Fgf7 (Mm00433291_m1), Fgf10 
(Mm00433275_m1), Fgf22 (Mm00445749_m1), Fgfr1b 
(Mm01215493_m1), Fgfr2b (Mm01275521_m1), and !-2 microglobulin 
(!2M; Mm00437762_m1). These primers have been carefully checked 
that they spanned across exon-exon boundary of a gene, and that they 
amplified the appropriate exon corresponding to the splice variants for 
Fgfr1 and Fgfr2. The reaction was set up using a Quantitect Probe PCR 
kit (204341; Qiagen). A 25µl reaction contained 1X PCR master mix and 
0.5X primers/probe mix. The master mix consisted HotStarTaq DNA 
polymerase, Tris-Cl pH 8.7, KCl, (NH4)2SO4, 8 mM MgCl2, dNTPs 
(including dUTP), and ROX fluorescent dye. The PCR was performed in 
an ABI 7900 Sequence Detector (Applied Biosystems) using a thermal 
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profile starting 95°C for 10 min, followed by 40 cycles consisting of 
denaturation at 95°C for 15 min, and combined annealing/extension at 
60°C for 1 min.  
  
2.4.7 SYBR Green PCR 
 
Primer sequences were obtained from various published sources (see 
Table 2.3). A 25 µl reaction contained 1X Platinum SYBR Green qPCR 
SuperMix-UDG w/ROX (11744500; Invitrogen), 0.2 mM of each primer, 
and 50 ng of cDNA. The PCR was performed in an ABI 7900 Sequence 
Detector (Applied Biosystems) using a thermal profile starting 50°C for 
20 min, 95°C for 10 min, followed by 40 cycles consisting of denaturation 
at 95°C for 15 s, and combined annealing/extension at 60°C for 1 min. A 
dissociation curve was run with each PCR (95°C for 15 s, followed by 
60°C for 15 s) to ensure no primer-dimer formation. 
 
2.4.8 Data analysis 
 
For each experiment, each cDNA sample was performed in triplicate for a 
chosen gene, and each plate also contained Gapdh or !2M as an internal 
control gene for the cDNA sample. The entire experiment was repeated 
three times. Average Ct value of the chosen gene for a cDNA sample was 
normalised to the average Ct value of !2M giving a !Ct value. The 
difference between the !Ct value of a treated/tested population and that of 
a control population gave rise to a !!Ct value that was then converted 
into a ‘fold changes’ value.  
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2.5 Immunohistochemical staining 
 
2.5.1 Gut tissue harvesting 
 
Following gut dissection, the caecum was separated from the gut and 
placed on ice. The small and large intestines were flushed with cold PBS 
to remove contents. The small intestine was divided into three segments, 
and all segments including the large intestine were thread onto metal rods. 
These rods were immobilised on a fibre-free blotting paper (PBP140; 
Hollingsworth & Vose Co. Ltd.), and the segments were cut open with a 
sharp scalpel. The segments were then rolled out onto the blotting paper, 
causing the gut segments to lay flat on the blotting paper with their villi 
pointing upwards. The blotting paper with the gut segments was immersed 
in 10% NBF overnight, and rinsed with 70% ethanol the next day. Each 
gut segment was then rolled up, pinned and processed as described in the 
following section. For the caecum, the tissue was cut on the outer 
curvature, flushed with cold PBS, stretched, pinned on a soft board, 
immersed in 10% NBF overnight, and rinsed with 70% ethanol the next 
day. Two longitudinal strips were cut from the fixed and stretched tissue, 
and processed as described in the following section. For the stomach, the 
tissue was cut on the outer curvature, stretched, pinned, and fixed as 
previously described for caecum. 
 
2.5.2 Tissue fixation and processing 
 
Tissues were fixed in 10% NBF overnight, dehydrated in serial alcohols, 
xylene and finally infiltrated overnight with molten paraffin wax (Figure 
2.1 for the detailed steps). Tissues were embedded on a casette, sectioned 
at 4 µM thickness and dried in an oven at 37°C overnight.  For embryonic 
work, gut tissues were dissected out under a dissecting microscope, fixed 
in 4% PFA overnight, and embedded in a 2% agarose before being 
processed as previously.  
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2.5.3 Tissue dewaxing and blocking of endogenous 
peroxidases 
 
Sections were dewaxed by a 5 min immersion in sulphur-free xylene 
(BDH), re-hydrated by 3 min incubation in decreasing concentrations of 
ethanol (100%, 70%, 50% in distilled water) and finally in distilled water. 
Sections were then treated with 1.6% hydrogen peroxide (BDH) in PBS 
for 10 min to block endogenous peroxidases, rinsed in tap water, and 
washed in PBS. 
 
2.5.4 Immunohistochemical staining and antigen retrieval 
 
Antigen retrieval was performed dependent on the antibody requirement 
(Table 2.4), which included 0.01 M citrate buffer pH 6.0, 100 µM EDTA 
pH 8.0, 0.1% bovine trypsin pH 7.8 (in 0.1% CaCl2/TBS), and 1X Glyca 
Antigen Retrieval Solution (HK167-5K; Launch Diagnostics, UK). The 
citrate, EDTA and glyca solutions were pre-heated by a microwave for 10 
min at high power (800 W) before adding the sections and microwaving 
them for a further 10 to 20 min at high power. For the trypsin antigen 
retrieval, the solutions were preheated to 37°C in a water bath before 
incubating the sections for a further 10 min.  
 
Sections were then rinsed in tap water, washed in PBS, and pre-incubated 
in normal serum (DakoCytomation Ltd., UK) from the donor species of 
the secondary antibody for 30 min, diluted at 1:10 in 1% PBS/BSA. 
Excess serum was removed, and sections were incubated in primary 
antibody for 1 hour at RT or overnight at 4°C, followed by incubation in a 
species-specific biotinylated secondary antibody (Vector Laboratories) for 
45 min. Sections were then incubated in a tertiary layer of avidin-biotin-
peroxidase complex (Vector Laboratories) for 30 min, and antibody 
binding was developed with DAB (BioGenex) until the desired staining 
was achieved. Primary and secondary antibodies were diluted 
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appropriately with 1% PBS/BSA, and tissue sections were washed in PBS 
for 3 x 5 min between each layer. Sections were then washed in PBS for  
2 x 5 min, rinsed in tap water, and counterstained lightly with H&E as 
described in the following section. 
 
2.5.5 Counterstaining 
 
After immunohistochemical staining was completed, Harris’ 
haematoxylin and eosin counterstained was applied to sections by 
immersing sections in Harris’ haematoxylin (Pioneer Research 
Chemicals) for 10 min, followed by a thorough rinse in tap water and 
immersion in acid alcohol (1% v/v concentrated HCl in 70% ethanol) for 
approximately 10 s. Following a second rinse in tap water, sections were 
immersed in Scott’s tap water (30 mM NaHCO3, 160 mM MgSO4) for      
10 s, and rinsed in tap water briefly. Sections were then rapidly 
dehydrated through graded alcohols to xylene (BDH Laboratories 
Supplies Inc., UK) and mounted in DePeX (BDH)  
 
2.6 Histochemical staining 
 
2.6.1 Detection of diastase/alcian blue/periodic acid 
Schiff (D/AB/PAS) 
 
D/AB/PAS is used routinely to stain mucin-producing cells and to identify 
the nature of the mucin. Sections were dewaxed as previously described 
(Section 2.5.3), and incubated in 0.5 g/100 ml !-amylase (A6211; Sigma-
Aldrich) for 30 min at 37°C. Sections were rinsed in distilled water before 
being treated with 10 mg/ml alcian blue pH 2.5 (made in 3% acetic acid) 
for 5 min. Sections were washed in running tap water and rinsed with 
distilled water. Sections were then treated with 1% periodic acid for 5 
min, and washed in distilled water before being treated with Schiff’s 
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reagent (VWR International) for 15 min. Sections were washed in running 
tap water for 5 min, cleared with 1% acid alcohol (made with 
concentrated HCl and 70% ethanol), dehydrated through graded alcohols 
to xylene (BDH) and mounted in DePeX (BDH). 
2.6.2 Detection of intestinal alkaline phosphatase (IAP) 
 
Sections were dewaxed as previously described (Section 2.5.3), except the 
final re-hydration step was performed in TBS, instead of PBS. Sections 
were washed for 2 x 10 min in NTMT buffer containing 100 mM NaCl, 
100 mM Tris-Cl pH 9.5, 50 mM MgCl2, and 0.1% Triton X-100 (T9284; 
Sigma-Aldrich). Sections were then incubated with a solution containing 
4.5 µl/ml NBT (11383213001; Roche) and 3.5 µl BCIP (10760994001; 
Roche) (made with NTMT) in dark at RT until the desired intensity of 
colorimetric reaction was achieved. Sections were washed in TBST for 2 
x 10 min, counterstained in Nuclear Fast Red (Vector Laboratories) for 5 
min, and mounted in Crytalmount aqueous mounting medium (C0612; 
Sigma-Aldrich).  
 
2.6.3 Wholemount X-Gal staining 
 
Dissected tissues were rinsed with cold PBS and fixed in a solution 
containing 0.1 M phosphate buffer pH 7.3, 0.4% PFA and 5 µM EGTA 
pH 8.0 (E3889; Sigma-Aldrich), 2 mM MgCl2 for 1.5 hrs at RT. Tissues 
were rinsed 3 x15 min in a solution containing 50 mM phosphate buffer 
pH 7.5, 2 mM MgCl2, 0.01% sodium deoxycholate (30970; Sigma-
Aldrich) and 0.02% NP-40 (74385; Sigma-Aldrich). Finally, tissues were 
incubated in a solution containing 0.1 M phosphate buffer pH 7.3, 2 mM 
MgCl2, 0.01% sodium deoxycholate, 0.02% NP-40, 5 mM Fe3
+
, 5 mM 
Fe2
+
, 2% X-Gal (16664; Sigma-Aldrich) and 20 mM Tris-Cl pH 7.5 at 
37°C until the desired colour was achieved. 
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2.6.4 Wholemount propidium iodide staining 
 
Tissue was dissected and fixed in 4% PFA overnight at 4°C. Tissue was 
rinsed 2 x 2 min in 1% PBST, and incubated with 10 µg/ml ribonuclease 
A (RNase A, P6513; Sigma-Aldrich) for 2 hrs at 37°C to remove any 
RNA. Tissue was rinsed 3 x 5 min with PBS, and incubated in 2.4 µg/ml 
propidium iodide (P4170; Sigma-Aldrich) at 4°C overnight. Tissue was 
rinsed 3 x 10 min with PBS, and mounted on a slide in 1:1 PBS/glycerol. 
 
2.6.5 TUNEL staining 
 
TUNEL staining was performed with the DeadEnd Colorimetric TUNEL 
System (G7130; Promega) according to the manufacturer’s instructions. 
Briefly, sections were dewaxed as previously described (Section 2.5.3), 
except after the 50% ethanol step, sections were immersed in 0.85% (w/v) 
NaCl for 5 min, PBS for 5 min, 4% PFA for 15 min and washed 2 x 5 min 
in PBS. Sections were permeabilised with 20 µg/ml Proteinase K (P2308; 
Sigma-Aldrich) for 10 min at RT, washed once in PBS for 5 min, and re-
fixed in 4% PFA for 5 min. Sections were washed 2 x 5 min in PBS, 
incubated with 100 µl Equilibration Buffer for 10 min at RT, followed by 
100 µl of TdT reaction mix for 60 min at 37°C. Sections were washed 
with 2X SSC for 15 min, washed 3 x 5 min in PBS, blocked with 0.3% 
(v/v) hydrogen peroxide (BDH) for 5 min, washed 3 x 5 min in PBS, and 
incubated with 1:500 Streptavidin-HRP for 30 min at RT. Sections were 
washed 3 x 5 min in PBS, and developed with DAB (BioGenex) until the 
desired staining was achieved. Sections were then washed in PBS for 2 x 
5 min, rinsed in tap water, and mounted in Crytalmount aqueous mounting 
medium (C0612; Sigma-Aldrich).  
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2.7 Morphometry 
 
Morphometry on all immunohistochemically- and histochemically- 
stained sections, except endomucin staining, was performed by calculating 
the average percentage of cells that were positively stained for a specific 
marker from the total number of cells. Endomucin vessel density was 
scored using a Weibel-1 graticule (Figure 2.2) by calculating the average 
percentage of lines that intersected with stained vessels (ten random areas 
per sample). Parametric results are presented as group mean ± standard 
error of mean (SEM). The significance of differences between parameters 
was evaluated by a Student’s t-test. All statistics were performed with 
GraphPad Prism version 5.0 (GraphPad Software Inc.).  
 
2.8 Crypt micro-dissection 
 
2.8.1 Tissue harvesting and fixation 
 
Mice were injected intraperitoneally with vincristine sulphate 1 mg/kg 
(Mayne Pharma Plc.) 2 hrs before culling. Gut tissues were harvested as 
previously described (Section 2.5.11), except the blotting paper carrying 
the intestinal segments was immersed in Carnoy’s fixative (made with 
6:1:3 of ethanol, acetic acid, and chloroform) for 3 hrs, and stored at 70% 
ethanol until use. 
 
2.8.2 Assessment of proliferation, crypt fission and crypt 
area 
 
A small area on the tissue measuring 3 mm x 3 mm was excised with a 
scalpel, re-hydrated gradually from 70% ethanol to 50%, 25% ethanol and 
PBS. Tissue was hydrolysed in 1M HCl for 10 min at 60°C, and stained 
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with Schiff’s reagent (VWR International) for 45 min at 4°C. Tissue was 
then placed on a glass slide in 50% acetic acid, and individual crypts were 
dissected out using fine needles at x40 magnification. For measuring 
arrested metaphases as a determination of crypt proliferation, 20 well-
orientated crypts per sample were assessed. Using a x200 magnification 
and focussing up and down through the width of each crypt, a total mitotic 
count per crypt was obtained. Mitotic nuclei were observed as darkly 
stained bodies compared to non-mitotic nuclei. Utilising the same 
preparation, crypt fission was assessed by scanning 200 crypts randomly 
and counting the number of crypts that were in fission. Crypts were scored 
only once irrespective of the amount of branching displayed by a single 
crypt. Fission was recorded as being abnormal if it was asymmetrical or 
did not originate from the base of the crypts. Using the same preparation, 
crypt area was assessed by drawing outlines of 20 well-orientated crypts 
at x25 using a Leitz drawing tube attached to the microscope, cutting out 
the outlines, obtain an average paper weight of the crypt, and calculating 
the actual crypt area based on 1 g of paper weight equating to 0.0851 mm
2
 
(personal communication with Robert Goodlad, Cancer Research UK).  
 
2.9 Western blot 
 
2.9.1 Protein extraction and measurement 
 
Tissue was dissected and rinsed with cold PBS. Selected segments of the 
tissue measuring approximately 0.5 cm
3
 were isolated and snap frozen in 
liquid nitrogen and stored at -80°C until use. Tissues were homogenised in 
lysis buffer containing 50 mM HEPES, 150 mM NaCl, 1% glycerol 
(G5516; Sigma-Aldrich), 1% Triton X-100 (T9284; Sigma-Aldrich), 1.5 
mM MgCl2, 5 mM EGTA (E3889; Sigma-Aldrich) and 1X Complete, 
Mini, EDTA-free protease inhibitor cocktail (11836170001, Roche) for  
30 s. Lysates were cooled on ice for 15 min before being spun at 
maximum speed for 15 min at 4°C. Protein concentration was measured 
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with a BCA Protein Assay kit (2322; Thermo Scientific) according to the 
manufacturer’s instructions. Briefly, a 2 mg/ml BSA stock was used to 
prepare a series of protein standards ranging from 25 µg/ml to 2 mg/ml 
using lysis buffer as the diluent. Extracted lysates were diluted 1:100 with 
the same diluent. Each standard and sample was prepared in triplicates. 
Following incubation of the protein samples/BCA reagent mix at 37°C for 
30 min, absorbance of each sample was measured at A562. A standard 
curve of average blank-corrected A562 for the standards against its 
concentration was plotted, and protein concentration in the unknown 
samples was determined from the standard curve. 
 
2.9.2 SDS-PAGE electrophoresis and western transfer 
 
SDS-PAGE electrophoresis was performed with 4-12% Bis-Tris Novex 
gels (NO0321BOX; Invitrogen) according to manufacturer’s instructions. 
Briefly, 30 µl samples containing 25 mg of total protein, 1X NuPAGE 
LDS sample buffer (NP0008; Invitrogen), and with/without NuPAGE 
Reducing agent (NP0004; Invitrogen) were heated for 10 min at 70°C. 
Samples were then run on the gel with 1X MES Running buffer (NP0002; 
Invitrogen) with/without 2.5 µl/ml of NuPAGE antioxidant (NP0005; 
Invitrogen), alongside with 10 µl of Full-Range Rainbow Molecular 
Weight Markers (RPN800E; GE Healthcare), at 180V constant for 1 hr. 
Separated proteins were then transferred to a 0.2 µm pore size PVDF 
membrane (LC2002; Invitrogen) pre-wet with 100% methanol, in 1X 
Transfer buffer (NP0006; Invitrogen), for 1.5 hrs at 30V constant. 
2.9.3 Western analysis 
 
PVDF membrane (LC2005; Invitrogen) was initially rinsed with PBST, 
before being incubated in a 5% (w/v) dried milk blocking solution 
(Marvel) made with PBST for 1 hr at RT. Membrane was then incubated 
with a primary antibody (diluted in 5% blocking solution) for overnight at 
4°C, followed by incubation in a HRP-conjugated secondary antibody for 
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1 hr at RT. Antibody binding was detected by incubating the membrane in 
an ECL Plus enhanced chemiluminescence detection system (RON2132; 
GE Healthcare) for 5 min, removing excess solution, and exposing a 
chemiluminescence film (RPN3103K; GE Healthcare). Membrane was 
washed for 3 x 15 min in PBST between each step.  
 
2.10 Cloning 
 
2.10.1 DNA extraction 
 
To obtain a better quality of genomic DNA from mouse tissue, a different 
DNA extraction protocol was employed. Tissue measuring 0.5 cm
3
 was 
incubated in 400 µl lysis buffer containing 100 mM NaCl, 500 mM Tris-
Cl pH 8.0, 100 mM EDTA pH 8.0, 1% SDS, and 1.4 mg/ml Proteinase K 
(P-6556; Sigma-Aldrich) at 55°C overnight with agitation, pelleted by 
centrifugation, and supernatant was mixed with 400 µl of 
phenol:chloroform:isoamyl alcohol 24:25:1 (77617; Sigma-Aldrich). The 
mix was vortexed, spun, and the top aqueous layer was aspirated carefully 
into a new tube. An equal volume of phenol:chloroform:isoamyl alcohol 
was added, and the purification procedure was repeated as previously. 
Isopropanol (I9516; Sigma-Aldrich) was added to the new sample, and the 
mix was spun to pellet DNA. The pellet was rinsed with 70% ethanol, air-
dried, and re-suspended in 50-100 µl of TE buffer, containing 100 mM 
Tris-Cl pH 8.0 and 10 mM EDTA pH 8.0. 
 
2.10.2 DNA purification 
 
Two methods of DNA purification were employed. The first method 
purified DNA from a piece of agarose gel using the QIAEX II Gel 
Extraction kit (20021; Qiagen), and the second method purified DNA in a 
solution mix (QIAquick PCR Purification kit (28104; Qiagen)). In the first 
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gel-purification method, a specific DNA band from an agarose gel was 
excised with a sterile scalpel and weighed not more than 30 mg. Three 
volumes of Buffer QX1 and 10 µl of QIAEX II were added to the gel 
slice, mixed and incubated at 50°C for 10 min. Sample was centrifuged 
briefly, and DNA pellet was washed with Buffer QX1 and Buffer PE 
before being re-suspended in 30-50 µl of sterile water. In the second 
method, five volumes of Buffer PB was added to the DNA sample, mixed, 
and spun briefly to allow DNA to bind to the column. Column was 
washed with Buffer PE, and DNA was eluted with 30-50 µl of sterile 
water. 
 
2.10.3 Restriction digest 
 
A 50 µl reaction containing 1X restriction digest buffer (appropriate to the 
restriction enzyme used), 1 U of restriction enzyme per 1 µg of DNA, and 
0.1 mg/ml BSA (optional) was incubated at 37°C for 2 hrs. Restriction 
digest buffers, enzymes and BSA were obtained from NEB. In some 
cases, double digest with two restriction enzymes simultaneously was 
performed only when there was a suitable buffer for both restriction 
enzymes to work efficiently. In some cases where restriction enzymes 
could be heat inactivated, the reaction was incubated at 65°C for 20 min to 
inactivate the restriction enzyme. Digested products were confirmed by 
agarose gel electrophoresis (Section 2.4.5). 
 
2.10.4 Ligation 
 
A 20 µl reaction containing 1X Ligation buffer, 30 ng of digested DNA 
insert, 10 ng of vector, and 1 U of T4 DNA ligase (C1263; Promega) was 
incubated at 16°C overnight. Ligation buffer and enzyme were obtained 
from Promega.  
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2.10.5 Generation of Escherichia coli (E. coli) DH5!  
competent cells 
 
An aliquot of competent cells was spread onto a Luria-Bertani (LB) agar 
plate. The plate was incubated at 37°C overnight. The next day, a small 
culture of 5 ml LB broth was inoculated with a single colony and 
incubated at 37°C overnight at 200 rpm. 250 ml of LB broth was then 
inoculated with 2 ml of the mini-culture and incubated at 37°C, 200 rpm 
until the bacterial density reached OD600 of 0.6. Cells were then chilled, 
pelleted, washed twice with ice-cold distilled water, washed once with 
10% glycerol, and finally re-suspended in 10% glycerol. Competent cells 
were aliquoted and stored at -80°C until use.  
 
2.10.6 Bacterial transformation 
 
After thawing an aliquot of competent cells on ice, 1-4 µl of DNA 
(containing 10 pg to 100 ng of DNA) was added to the cells and mixed 
gently. Cells were incubated on ice for 30 min, at 42°C for 30 s exactly, 
and on ice for 2 min. 250 µl of pre-warmed S.O.C. medium was added to 
the cells, and the whole mix was incubated at 37°C, 200 rpm for 1 hr. 50-
100 µl of the mix was plated on an LB plate containing the appropriate 
antibiotic, and incubated at 37°C overnight. 
 
2.10.7 Plasmid extraction 
 
Plasmid extraction was carried out from either a mini-culture of ! 5 ml or 
a maxi-culture of 150 ml LB broth. For a mini-culture, 5 ml of LB broth 
containing an appropriate antibiotic was inoculated with a single colony, 
and incubated at 37°C, 200 rpm overnight. 1.5 ml of the culture was 
pelleted, and plasmid was extracted from these cells with a Plasmid Mini 
kit (12123; Qiagen) according to the manufacturer’s protocol. Briefly, the 
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cell pellet was re-suspended in Buffer P1, Buffer P2, and lysed in Buffer 
N3. Cell debris was pelleted. The supernatant was passed though a 
plasmid binding column, washed with Buffer PE, and plasmid was eluted 
with 30-50 ml of sterile water. For a maxi-culture, 250 ml of LB broth 
containing an appropriate antibiotic was inoculated with 2 ml of the mini-
culture, and incubated at 37°C, 200 rpm overnight. The entire volume of 
the culture was pelleted, and plasmid was extracted from these cells with a 
Plasmid Maxi kit (12162; Qiagen) according to the manufacturer’s 
protocol. Briefly, the pellet was re-suspended in Buffer P1, Buffer P2, and 
lysed in Buffer N3. Cell debris was pelleted. The supernatant was passed 
through a large plasmid-binding column, washed with Buffer QC, and 
plasmid was eluted with Buffer QC. The plasmid was mixed with 
isopropanol, pelleted, washed with 70% ethanol, re-pelleted, air-dried and 
re-suspended in 500 µl of sterile water. 
 
2.10.8 DNA sequencing 
 
To verify the accuracy of DNA bases, 20 µl reaction containing 150 ng of 
DNA, 3.2 pmol sequencing primer, and 1X Terminator Ready Reaction 
Mix (4337449; Applied Biosystems) was placed in a thermal cycler with 
the following thermal profile: 95°C for 5 min, 30 cycles of 95°C for 30 s, 
50 - 55°C (depending on template) for 10 s, 60°C for 4 min, and hold at 
4°C. Reaction was then cleaned-up with a DyeEx 2.0 Spin kit (63204; 
Qiagen) according to the manufacturer’s protocol. Briefly, the reaction 
volume was added into a bead column, spun, and dried in a vacuum 
centrifuge. The sample was then submitted to the Equipment Park, Cancer 
Research UK for DNA sequencing. 
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2.11 Cell culture 
 
2.11.1 Maintenance of cell lines 
 
Mouse gastric surface mucous GSM10 and mouse gastric parietal 
MGE507 cell lines were obtained from NIPPN, Japan. Both cell lines 
were cultured at 33°C, 5% CO2 in DMEM/F12 (1:1) medium (Cell 
Services, Cancer Research UK) containing 10% (v/v) foetal bovine serum 
(FBS, 16000-044; Invitrogen), 1% (v/v/) L-glutamine (G7513; Sigma-
Aldrich), 10 µg/ml insulin (I2643; Sigma-Aldrich), 5.5 µg/ml transferrin 
(T7559; Sigma-Aldrich), 2 µg/ml ethanolamine (E0135; Sigma-Aldrich), 
6.7 ng/ml selenite (70153; Sigma-Aldrich) and 10 ng/ml epidermal growth 
factor (EGF, E4127; Sigma-Aldrich). Embryonic Albino Swiss Mouse 
fibroblast 3T3 and mouse mammary epithelial cell line HC11 were 
obtained from Cell Services, Cancer Research UK. Both cell lines were 
cultured at 37°C, 5% CO2 in DMEM/L-glutamine medium (11966-025; 
Invitrogen) containing 10% FBS, 10 ng/ml EGF and 10 µg/ml insulin. 
Immortalised human keratinocytes nTERT cell line (a kind gift from Dr. 
Richard Grose, Centre for Tumour Biology, Barts and The London) was 
cultured at 37°C, 5% CO2 in DMEM/F12 (1:1) medium (Cell Services, 
Cancer Research UK) containing 10% FBS, 1% L-gutamine, 400 ng/ml 
hydrocortisone (H0888; Sigma-Aldrich), 5 µg/ml insulin, 8.4 ng/ml 
cholera toxin (C8052, Sigma-Aldrich), 10 ng/ml EGF and 5 µg/ml 
transferrin. Human colorectal cell line SW480 (Cell Services, Cancer 
Research UK) was cultured at 37°C, 5% CO2 in DMEM/L-glutamine 
medium containing 10% FBS.  
 
2.11.2 Passaging of cell lines 
 
Cell lines with 80-90% confluence were split for continuous seeding. 
Cells were washed twice with versene (Cell Services, Cancer Research 
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UK), and incubated with 1 ml of 1X trypsin/EDTA (252000-056; 
Invitrogen) at 37°C until cells were fully dislodged. 5 ml of appropriate 
medium was added to the cell suspension, and the mix was spun at 2,000 
rpm for 5 min. Supernatant was discarded, and cell pellet was re-
suspended in the appropriate growth medium before being split into 
several plates. 
 
2.11.3 Storage and recovery of cultured cell lines 
 
Cell lines with 80-90% confluence were trypsinised as previously (Section 
2.12.2), except after centrifugation, the cell pellet was re-suspended in a 
‘freezing’ medium containing 8 ml of the appropriate growth medium, 1 
ml of FBS, and 1 ml of dimethyl sulfoxide (DMSO, D2650; Sigma-
Aldrich) with 1 ml of ‘freezing’ medium per 60 cm
2
 plate. The cell 
suspension was aliquoted into freezing vials (Nunc, UK), placed in a Cryo 
Freezing Container (Nalgene, UK) filled with isopropanol to allow 
gradual freezing, and stored at -80°C overnight. Freezing vials were 
transferred to liquid nitrogen the next day for long-term storage. For cell 
recovery, frozen cells were rapidly thawed using a water bath at 37°C.         
5 ml of the appropriate medium was added to the aliquot, and spun at 
2,000 rpm for 5 min. Supernatant was discarded, and the cell pellet was 
re-suspended in the appropriate growth medium before being added onto a 
plate.  
 
2.11.4 Transient transfection 
 
Transient transfection with DNA plasmid, such as luciferase vector, was 
carried out when the cells 80-90% confluent. For transfection in a 60 cm
2
 
plate, a first mix containing 250 µl of Optimem and 30 µl of 
Lipofectamine 2000 (11668-027; Invitrogen), and a second mix 
containing 250 µl of Optimem, 10 µg of luciferase vector, and 1 µg of 
phRL-Renilla plasmid were prepared. Each mix was vortexed briefly and 
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left at RT for 5 min. Both solutions were mixed, vortexed briefly, and left 
at RT for another 20 min. During this time, the cells in a 60 cm
2
 plate was 
rinsed twice with PBS, and 2 ml of the appropriate medium without 10% 
FBS was added to the plate. 500 µl of the transfection mix was added to 
the plate, and incubated at 37°C, 5% CO2 overnight. As a control, a 
similar experiment was performed, except the transfection mix contained 
1 µg of CMV-GFP plasmid instead of luciferase and Renilla contructs. 
 
2.11.5 Luciferase assay 
 
Luciferase assay was conducted with a Dual-Luciferase Reporter Assay 
System (E1910; Promega) according to the manufacturer’s protocol. 
Briefly, cells on the 10 cm
2
 plate was rinsed twice with PBS, and lysed 
with 500 µl of 1X Passive Lysis Buffer at RT for 15 min. Cell debris was 
pelleted, and 20 µl of supernatant was aliquoted in triplicate in a 96-well 
plate (PMX-096-145M; Fischer Scientific). 100 µl of Luciferase Assay 
Buffer was added to each sample, mixed gently and the luciferase activity 
was measured by a luminometer. Following this, 100 µl of Stop & Glo 
Buffer was added to each sample, mixed gently and the renilla activity 
was measured as previously. Each luciferase reading was normalised to its 
individual Renilla reading to obtain a more accurate measurement. 
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Table 2.1 Sequences and annealing temperatures of the primers used 
for animal genotyping. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Schematic diagram showing the steps involved in tissue 
processing prior to embedding. 
 
 
 
 
Mouse          
line
Primer      
label
Sequence (5' to 3')
Annealing 
temp (x°C)
Amplicon        
size
SE-IIIa GGCAGTAAATACGGGCCTG
AS-loxP CGTAAACTCCTCTTCAGACC
SE-IIIb CTGCCTGGCTCACTGTCC
AS-TM CTCAACAGGCATGCAAATGCAAGGTC
SE-loxP CACCAAAGAACGGAGCCGGTT
AS-exon ACTCTTTGGCCTCTATCT
SE-cre GGACATGTTCAGGGATCGCCAGGCG
AS-cre GCA TAA CCA GTG AAA CAG CAT TGC TG
Rosa1 AAAGTCGCTCTGAGTTGTTAT
Rosa2 GCGAAGAGTTTGTCCTCAACC
Rosa3 GGAGCGGGAGAAATGGATATG
65 Wt (no band)               
Cre (269 bp)
ROSA26-lacZ-
loxP
55 Wt (500 bp)                  
Mutant (250 bp)
A33-CrePR
Fgfr2b
flox/flox
Fgfr2b
+/-
55 Wt (no band)               
loxP (1 kb)
Fgf10
+/-
55 Wt (no band)               
loxP (400bp)
55 loxP (410 bp)            
Wt (320 bp)               
70% ethanol for 30 min  
80% ethanol for 1 hr 
 2 x 95% ethanol for 1 hr 
3 x 100% ethanol for 1 hr 
All steps at 40°C 
Xylene for 60 min x 3, all at 40°C 
Paraffin wax for 60 min x 4, all at 60°C 
 72 
Table 2.2 Sequences and conditions of the primers used for reverse-transcriptase PCR. 
 
Gene
Primer      
label
Sequence (5' to 3')
Annealing 
temp (x°C)
MgCl2 conc 
(mM)
Kit type
Amplicon        
size (bp)
Positive control Reference
SE-gapdh TGATGACATCAAGAAGGTGGTGAAG
AS-gapdh GAGGCCATGTAGGCCATGCGGT
SE-fgf1  ACCGAGAGGTTCAACCTGCC  
AS-fgf1  GCCATAGTGAGTCCGAGGACC 
SE-fgf2  GCCAGCGGCATCACCTCGCT   
AS-fgf2  TATGGCCTTCTGTCCAGGTCCCGT 
SE-fgf3  GATGGGCCTGATCTGGCTTCTGCT 
AS-fgf3  CACCATCTCATGGTCCTTGTGGCC 
SE-fgf4 TACTGCAACGTGGGCATCGGA
AS-fgf4 GTGGGTTACCTTCATGGTAGG
SE-fgf5  CATCTTCTGCAGCCACCTGATCCA 
AS-fgf5  AAGTTCCGGTTGCTCGGACTGCTT 
SE-fgf6  CACGCTGCAGGCTCTCGTCTTCTT 
AS-fgf6  CAGTCATGATTGGGGACACCTTGC 
SE-fgf7  ATCCTGCCAACTCTGCTCTACAGA 
AS-fgf7  CTTCCCTTTGACAGGAATCCCCTT 
SE-fgf8  GTGGAGACCGATACTTTTGG 
AS-fgf8  GCCCAAGTCCTCTGGCTGCC 
Gapdh 62
Fgf1 55
Fgf4 60
Fgf2 65
Fgf3 60
Fgf5 65
Fgf6 60
Fgf7 55
Fgf8 55
Qiagen Taq
Ready-To-Go
Qiagen Taq
Megamix
Adult eye Ozawa et al., 
1997
Adult brain Post et al., 
1996
E14.5 embryo Kawauchi         
et al., 2005
E10.5 embryo Herbert et al., 
1990
Adult brain Ozawa et al., 
1997
Adult brain Ozawa et al., 
1997
Adult brain Ozawa et al., 
1997
Adult liver
Adult stomach Ozawa et al., 
1997
509
371
1.5
2.5
1.5
1.5
1.5
573
344
652
542
1.5
2.0
2.0
2.0
234
387
437
Qiagen Taq
Ready-To-Go
Megamix
Qiagen Taq
Ready-To-Go
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Gene
Primer      
label
Sequence (5' to 3')
Annealing 
temp (x°C)
MgCl2 conc 
(mM)
Kit type
Amplicon        
size (bp)
Positive control Reference
SE-fgf9  ATGGCTCCCTTAGGTGAAGTTGG 
AS-fgf9  GCCTCCGCCTGAGAATCCCCTTTAAATG 
SE-fgf10  CTCTTTTTGGTGTCTTCGTTCCC 
AS-fgf10  CGCTGACCTTGCCGTTCTTCTC 
SE-fgf11  GTCGCTTTAAGGAGTGCGTC  
AS-fgf11  CACTGTGGAGAGAAGGCTCC 
SE-fgf12  TGTATCGCCAACAGGAATCAGG 
AS-fgf12  GGAGAGGGAAGAACGGAAGAG 
SE-fgf13  CTATCGCCAGCTCGCTCATCC 
AS-fgf13  CACCAGAGACGCTTCTGCTC 
SE-fgf14  GGTGGATATCTTCTCTAAAGTG 
AS-fgf14  GGATGGTTCTCGGTACATGG 
SE-fgf15  GGAACAAAGGACAGCCTAGA 
AS-fgf15  CAGAACTGAGAGCCAGGAGC 
SE-fgf16  GAACGAGCGCCTGGGCCAGATCG 
AS-fgf16  GGACATGGAGGGCAACTTAGAAGG 
SE-fgf17  CACCCGTCTCCTAATTTTAACC 
AS-fgf17  CGAACTGCTTCTGCCTTTCAGC 
SE-fgf8  CACCACAGTCACCAAGCGATCC 
AS-fgf18  CTTTGGTTTCTCGCAGTTTCCTC 
Megamix
Qiagen Taq
Ready-To-Go
Qiagen Taq
Qiagen Taq
Megamix + Q-
solution
Megamix
Ready-To-Go
Qiagen Taq
Megamix
Hajihosseini et 
al., 2002
Hajihosseini et 
al., 2002
Hajihosseini et 
al., 2002
Hajihosseini et 
al., 2002
55
55
55
196
228
219
278
55
55
1.5
1.5
1.5
1.5
497
505
340
1.5
1.5
1.5
1.5
E14.5 embryo Hajihosseini et 
al., 2002
Hajihosseini et 
al., 2002
Hajihosseini et 
al., 2002
E14.5 embryo Hajihosseini et 
al., 2002
1.5
1.5Fgf18 55
Adult brain Hajihosseini et 
al., 2002
Adult brain
Hajihosseini et 
al., 2002
Adult brain
626
498
30765
Fgf16 65
Fgf17 65
Fgf11
Fgf12
Fgf9
Fgf15 Adult brain
Adult brain
Adult stomach
55
Fgf10
Adult brain
Fgf13
Fgf14
Adult brain
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Gene
Primer      
label
Sequence (5' to 3')
Annealing 
temp (x°C)
MgCl2 conc 
(mM)
Kit type
Amplicon        
size (bp)
Positive control Reference
SE-fgf20  ATGGCTCCCTTGACCGAAGTCGG 
AS-fgf20  GGCGGCGCAGGATGCCGTCAGG 
SE-fgf21  CTGGGGGTCTACCAAGCATA 
AS-fgf21  CACCCAGGATTTGAATGACC 
SE-fgf22  AATTGCTAGCATGCGCAGCCGCCTCTGGCTG 
AS-fgf22  AGGCCTCGAGAGACGAGACCAAGACTGGCA 
SE-fgfr1b  GCAGGGCTGCCTGCCAACGAGACAGTG 
AS-fgfr1b  GGTCTGGTGCAGTGAGCCACGCAGACTG 
SE-fgfr1c  GCAGGGCTGCCTGCCAACGAGACAGTG 
AS-fgfr1c  GAACGGTCAACCATGCAGAGTGATGG 
SE-fgfr2b  CCCATCCTCCAAGCTGGACTGCCT 
AS-fgfr2b  CTGTTTGGGCAGGACAGTGAGCCA 
SE-fgfr2c  CCCATCCTCCAAGCTGGACTGCCT 
AS-fgfr2c  CAGAACTGTCAACAATGCAGAGTG 
SE-fgfr3b  GACAGACACACGGATGTGCTGGA 
AS-fgfr3b   GTGAACACGCAGCAAAAGGCTTT                               
SE-fgfr3c  GACAGACACACGGATGTGCTGGA 
AS-fgfr3c  GCACCACCAGCCACGCAGAG 
SE-fgfr4c  TACAGCTATCTCCTGGATGTGCTG 
AS-fgfr4c  GAAATCGTGCGTGACATTAAGGAG 
Ready-To-Go
Ready-To-Go
Megamix
Megamix
Qiagen Taq
Ready-To-Go
Ready-To-Go
Megamix
Ready-To-Go
Megamix
Adult brain Hajihosseini et 
al., 2002
Adult brain Hajihosseini et 
al., 2002
Adult brain Hajihosseini et 
al., 2002
Adult brain Hajihosseini et 
al., 2002
E14.5 embryo Hajihosseini et 
al., 2002
Adult stomach Hajihosseini et 
al., 2002
Adult 
oesophagus
Zhang            
et al., 2006
Adult brain Hajihosseini et 
al., 2002
Adult liver Badman         
et al., 2007
Adult brain Hajihosseini et 
al., 2002
318
363
354
195
226
318
300
239
349
2001.5
1.5
1.5
1.5
1.5
1.5
1.5
Fgfr4c 60
1.5
Fgfr3b 60
Fgfr1b 60
Fgfr1c 55
Fgf21 60
1.5
Fgfr3c 60
Fgfr2b 55
Fgfr2c 60
Fgf22 60
Fgf20 65
1.5
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Table 2.3 Sequences of the primers used for SYBR Green PCR. 
 
 
 
 
 
Mouse          
line
Primer      
label
Sequence (5' to 3')
Amplicon        
size
SE-Shh AGCCTACAAGCAGTTTATTCCCAA
AS-Shh CAGCTTCACTCCAGGCCACT
SE-Tcf1 GCCAGCCTCCACATGGCGTC
AS-Tcf1 GCTGCCTGAGGTCAGAGAATAA
SE-Tcf4 GAGAGTGCAGCCATCAACCAG
AS-Tcf4 GTGATCGGAGGAAGCGAAAGG
SE-Cdx1 CTAGGACAAGTAGCTTGCCCTCTT
AS-Cdx1 TCCAACAGGCTCACCACACA
SE-Lef1 AGACACCCTCCAGCTCCTGA
AS-Lef1 CCTGAATCCACCCGTGATG
SE-Ax2 GGTTCCGGCTATGTCTTTGC
AS-Ax2 CAGTGCGTCGCTGGATAACTC
SE-Bcat TGCTGGTGACAGGGAAGACA 
AS-Bcat TGCCGGCTGGTCAGATG 
SE-Lgr5 TCACACACCCATCTCTGGTAG
AS-Lgr5 CTACTTTGCCCAGTTTCTGTTGAG
SE-GAP TGAAGCAGGCATCTGAGGG 
AS-GAP CGAAGGTGGAAGAGTGGGAG 
Tcf4 242 bp
Cdx1 65 bp
Shh 241 bp
Tcf1 161 bp
Gapdh 102 bp
66 bpBeta-catenin
Lgr5 76 bp
Axin2 66 bp
Lef1 123 bp
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Table 2.4 List of antibodies and conditions used for immunohistochemistry. 
 
 
Antigen
Antigen 
Retrieval
Primary antibody
Primary antibody dilution and 
incubation condition
Secondary antibody
BrdU Citrate buffer for 
15 min
Mouse monoclonal anti-BrdU (1585860; 
Roche, UK)
1:5 dilution for 1 hr at RT Biotinylated horse anti-mouse 
used at 1:400
Active (cleaved) 
Caspase 3
Citrate buffer for 
15 min
Rabbit polyclonal anti-Caspase 3 (AF835; 
R&D Systems, UK) 
1:500 dilution for 1 hr at RT Biotinylated goat anti-rabbit 
used at 1:250
Endomucin Not required Rat monoclonal anti-Endomucin (sc-65495; 
Santa Cruz Biotechnology)
1:600 dilution for 1hr at RT Biotinylated rabbit anti-rat 
used at 1:250
Citrate buffer for 
15 min Upstate)
1:100 dilution  for 1hr at RT Biotinylated horse anti-mouse 
used at 1:400
Tff2 Citrate buffer for 
10 min
Rabbit polyclonal anti-Tff2 (kind gift from 
Professor Blin, Tubingen, Germany)
1:500 for 1 hr at RT Biotinylated goat anti-rabbit 
used at 1:250
Sox2 Citrate buffer for 
20 min
Rabbit polyclonal anti-Sox2 (AB5603; 
Chemicon, UK)
1:1000 dilution at 4°C overnight Biotinylated goat anti-rabbit 
used at 1:250
Cdx2 Citrate buffer for 
20 min
Mouse monoclonal anti-Cdx2 (MU392-UC; 
BoGenex) 
 neat for 1hr at RT Biotinylated horse anti-mouse 
used at 1:400
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Antigen
Antigen 
Retrieval
Primary antibody
Primary antibody dilution and 
incubation condition
Secondary antibody
Atp4b Citrate buffer for 
10 min
Mouse monoclonal anti-Atp4b (A274; 
Sigma-Aldrich Co. Ltd.) 
1:1000 for 1 hr at RT Biotinylated horse anti-mouse 
used at 1:400
Tcf4 Citrate buffer for 
15 min
Mouse monoclonal anti-Tcf4 (05-511; 
Chemicon) 
1:500 at 4°C overnight Biotinylated horse anti-mouse 
used at 1:400
Muc2 Citrate buffer for 
15 min
Rabbit polyclonal anti-Muc2 (sc-15334; 
Santa Cruz) 
1:400 for 1 hr at RT Biotinylated goat anti-rabbit 
used at 1:250
Lysozyme Citrate buffer for 
10 min
Rabbit polyclonal anti-Lysozyme (A0099; 
DAKO) 
1:500 for 1 hr at RT Biotinylated goat anti-rabbit 
used at 1:250
Pep2 Citrate buffer for 
10 min
Sheep polyclonal anti-Pep2 (PC132; The 
Binding Site)
1:1000 for 1 hr at RT Biotinylated rabbit anti-sheep 
used at 1:250
Chromogranin 
A/B
Citrate buffer for 
10 min
Rabbit polyclonal anti-Chromogranin A/B 
(ab15160; Abcam) 
1:1250 for 1 hr at RT Biotinylated goat anti-rabbit 
used at 1:250
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Antigen
Antigen 
Retrieval
Primary antibody
Primary antibody dilution and 
incubation condition
Secondary antibody
Fgfr2b Citrate buffer for 
15 min
Rat monoclonal anti-Fgfr2b (MAB7161; 
R&D Systems) 
1:100 to 1:1000 at 4°C overnight Biotinylated goat anti-rat used 
at 1:250
Glyca buffer for 
15 min
EDTA buffer for 
15 min
Trypsin for 10 
min
Fgfr2b Citrate buffer for 
15 min
Rabbit polyclonal anti-Fgfr2b (from 
Ishiwata)
1:100 to 1:1000 at 4°C overnight Biotinylated goat anti-rabbit 
used at 1:250
EDTA buffer for 
15 min
Trypsin for          
10 min
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Figure 2.2 Weibel-1 graticule for quantifying endomucin-stained 
microvessel density. 
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Chapter 3: Fgf10-Fgfr2b signalling in 
intestinal development 
 
3.1 Introduction 
 
Several studies have demonstrated the requirement for Fgfr2b and Fgf10 
in GI development. Embryos null for either Fgf10 or Fgfr2b exhibit 
similar multi-organ defects (Ohuchi et al., 2000), including GI defects. In 
the stomach, loss of either Fgfr2b or Fgf10 leads to disproportionately 
smaller glandular stomach with disrupted mucosal architecture, absence of 
several early cytodifferentiation markers, including parietal cells, and 
abnormal expression of members of the Hedgehog family of signalling 
molecules (Spencer-Dene et al., 2006). In the developing intestine, 
absence of Fgfr2b or Fgf10 leads to duodenal, caecal (Burns et al., 2004, 
Fairbanks et al., 2004b) and colonic atresia (Fairbanks et al., 2005, 
Fairbanks et al., 2006, Sala et al., 2006). These studies demonstrated that 
elimination of either Fgfr2b or Fgf10 leads to decreased proliferation and 
increased apoptosis in intestinal epithelium and mesenchyme, resulting in 
atresia. Amongst the ligands for Fgfr2b, Fgf1
-/-
 (Miller et al., 2000), Fgf3
-
/-
 (Mansour, 1994), Fgf7
-/-
 (Guo et al., 1996) and Fgf22
-/-
  (personal 
communication with Dr. Hisashi Umemori, Department of Biological 
Chemistry, University of Michigan) mice have no overt GI defects. 
 
While duodenal atresia has been reported in both Fgfr2b
-/-
 and Fgf10
-/-
 
embryos (Fairbanks et al., 2004a, Kanard et al., 2005), the mechanism and 
the role of these genes in duodenal development has not been fully 
established. Duodenal obstruction occurs in 1 of 10000 live births in 
humans with mortality rate of 34%, and usually requires immediate 
significant surgical correction (Choudhry et al., 2009). Unlike caecal and 
colonic morphogenesis that begins with a ‘bud’ that proliferates and 
subsequently elongates as an embryo develops, the small intestine 
originally develops from a continuous gut tube. We therefore investigated 
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whether duodenal atresia in these knockout mutants is caused by an 
imbalance in cell proliferation and apoptosis at a focal point in the 
proximal duodenum, and whether loss of Fgfr2b or Fgf10 affects 
duodenal cytodifferentiation. This knowledge will help us to understand 
human congenital duodenal atresia and other pathological anomalies, such 
as gastric heterotopia and paraduodenal heterotopia in adults. 
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3.2 Materials and methods 
 
3.2.1 Animal breeding 
 
Fgfr2b
+/-
 and Fgf10
+/-
 lines have been previously described (De 
Moerlooze et al., 2000, Min et al., 1998). Fgfr2b
+/-
 and Fgf10
+/-
 lines were 
maintained as heterozygotes due to perinatal lethality of Fgfr2b
-/-
 and 
Fgf10
-/-
. Both Fgfr2b
+/-
 and Fgf10
+/-
 lines were crossed with themselves to 
generate Fgfr2b
-/-
 and Fgf10
-/-
 embryos at different embryonic stages. The 
morning of the vaginal plug appearance was considered as E0.5. Fgfr2b
-/-
 
and Fgf10
-/-
 embryos were identified by absence of limbs. Wildtype (wt) 
and heterozygous embryos were identified by genotyping yolk sacs for the 
presence of a loxP site in the heterozygotes (Section 2.1.3). 
 
3.2.2 Immunohistochemistry 
 
Time-mated mice were injected with 5-bromo-2’-deoxyuridine (BrdU, 
550891; BD Biosciences) solution at 50 mg/kg 1 hr before culling. Gut 
tissues were dissected in cold PBS, fixed, processed and embedded as 
previously described (Section 2.5.2). Immunohistochemistry was 
performed with anti-BrdU, anti-Caspase-3 (CSP-3), anti-endomucin, anti-
!-catenin, anti-TFF2, anti-SOX2, anti-CDX2, anti-ATP4b, anti-PEP2, 
anti-TCF4 and anti-chromogranin A/B as previously described (Section 
2.5). Morphometry was performed as previously described (Section 2.7). 
 
3.2.3 Histochemistry 
 
Diastase/alcian blue/periodic acid Schiff (D/AB/PAS) and intestinal 
alkaline phosphatase (IAP) staining was performed as previously 
described (Section 2.6.1 and 2.6.2). Wholemount propidium iodide 
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staining was performed as previously described (Section 2.6.4). TUNEL 
staining was performed as previously described (Section 2.6.5). 
 
3.2.4 RT-PCR 
 
RNA was extracted from small intestine of E18.5 Wt, Fgfr2b
-/-
 and  
Fgf10
-/-
 embryos, and cDNA synthesis was performed as previously 
described (Section 2.4). Reverse transcriptase PCR was performed for 
Fgfr2b and Fgf10 as previously described (Section 2.4.4). SYBR Green 
PCR was performed for Shh, Tcf1, Tcf4, Cdx1, Lef1, Axin2, !-catenin, 
Lgr5 and Gapdh as previously described (Section 2.4.7). 
 
3.2.5 TOPflash/FOPflash reporter assay 
 
SW480 cells (1.5 x 10
6
 cells per 60 cm
2
 area dish) were transfected with a 
combination of 9.5 µg of either TOP-luciferase or FOP-luciferase plasmid 
DNA (kind gift from Dr. Marc Rodriguesz, Cancer Research UK), and 0.5 
µg of phRL-Renilla as previously described (Section 2.11.4). SW480 cell 
line has been successfully used in this assay in other studies (Hecht et al., 
2000, Korinek et al., 1997). The TOP-luciferase construct contains two 
sets (with the second set in the reverse orientation) of three copies of the 
wildtype TCF binding site (AGATCAAAGG) upstream of the herpesvirus 
thymidine kinase minimal promoter and firefly luciferase open reading 
frame. The FOPflash construct is the same as the TOPflash, except for a 
double mutation in the TCF binding site (AGGCCAAAGG; mutation 
underlines). After overnight incubation, cells were split into 24-well plates 
(50,000 cells per well). Following overnight incubation, the cells were 
serum-starved for eight hours before being given a combination of 2.5 
µg/ml heparin (H2149; Sigma-Aldrich) and rhFGF10 (354-FG; R&D 
Systems) at 50, 100 and 200 ng/ml. Following 16 hrs of incubation, cells 
were harvested for luciferase assay as previously described (Section 
2.11.5). 
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In a separate experiment, similar setup was adopted, except following 
serum-starvation, the cells were given a combination of 2.5 µg/ml heparin, 
100 ng/ml rhFGF10, and one of the following drugs: a MAPK inhibitor 
U0126 (10 µM) (662005; Calbiochem), a PI3K inhibitor LY294002 (20 
µM) (440202; Calbiochem) or a PKC inhibitor bisindolylmaleimide I (5 
µM) (BIM-I, 203290; Calbiochem). These concentrations have been 
previously established to be optimal for SW480 cell lines (Graness et al., 
1998, Wang et al., 2004, Steinkamp et al., 2003). These inhibitors have 
also been validated in the human gastric adenocarcinoma AGS cell line to 
be functionally active. Following 16 hrs of incubation, cells were 
harvested for luciferase assay as previously described (Section 2.11.5). 
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3.3 Results 
 
3.3.1 Fgfr2b and Fgf10 are expressed along the GI tract 
during development 
 
Reverse-transcriptase PCR was used to determine the expression gradient 
of Fgfr2b and Fgf10 along the developing GI tract in E18.5 Wt embryos. 
Both Fgfr2b and Fgf10 are expressed with the highest intensity in the 
caecum and colon, followed by stomach and small intestine (Figure 3.1).  
 
 
 
Figure 3.1 Reverse-transcriptase PCR showing Fgfr2b and Fgf10 
expression level along the E18.5 mouse GI tract. 
This mRNA profile is a representation of the profile shown by three Wt 
E18.5 embryos. Fgfr2b and Fgf10 are expressed higher in the caecum and 
colon than in the small intestine. St: stomach, Si: small intestine, Ca: 
caecum, Co: colon, +ve: positive control, -ve: negative control. Positive 
control came from adult Wt stomach. The negative control for Fgfr2b and 
Fgf10 came from E18.5 Fgfr2b
-/-
 and Fgf10
-/-
 small intestine respectively, 
whereas the negative control for Gapdh was a no-template control. 
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3.3.2 Fgfr2b-/- and Fgf10-/- embryos have 
disproportionately short small intestine 
 
Small intestine of Wt, Fgfr2b
-/-
, Fgf10
-/-
 embryos at two time-points, 
E16.5 and E18.5, was examined. While the overall size as measured by 
crown-rump lengths of Fgfr2b
-/-
 and Fgf10
-/-
 embryos is reduced by 
approximately 20% of the Wt littermates at E18.5, these mutants also 
display disproportional reduction in the small intestinal length by 
approximately 30% of the Wt littermates (Figure 3.2). The mutants also 
have poorly developed caecum and colon as previously reported (Burns et 
al., 2004, Fairbanks et al., 2004b, Fairbanks et al., 2005, Fairbanks et al., 
2006, Sala et al., 2006). As in previous studies, Wt, Fgfr2b
+/-
 and Fgf10
+/-
 
embryos are indistinguishable, implying that no significant gene dosage 
effect has occurred (data not shown). Only data from the Wt group is 
presented in all cases. The proliferative capacity of the intervillous region, 
where epithelial progenitors reside, in the intestinal epithelium of these 
embryos was assessed by BrdU labelling and Ki-67 immunostaining, to 
determine whether the overall embryonic size reduction is contributed by 
a reduction in intestinal proliferative capacity. The mutants have 
significantly reduced epithelial proliferation compared to Wt at both 
E16.5 and E18.5 (Figure 3.3). Analysis of apoptosis by active caspase-3 
(CSP-3) immunostaining and TUNEL labelling show no significant 
difference in epithelial apoptosis in the mutants compared to Wt (data not 
shown). 
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Figure 3.2 Comparison of small intestinal length of Fgfr2b
-/-
 and 
Fgf10
-/-
 embryos to Wt littermates. 
(A) Wholemount photograph of dissected GI tract of E18.5 Wt and 
Fgfr2b
-/-
 embryos. The yellow arrows indicate the caecum. Fgfr2b
-/-
 and 
Fgf10
-/-
 small intestine is shorter than the Wt, but only representation of 
the Fgfr2b
-/-
 is shown. 
 (B) Quantification of the mean small intestinal length and crown-rump 
height (±SEM) of E16.5 and E18.5 Fgfr2b
-/-
 and Fgf10
-/-
 embryos 
normalised to Wt littermates (100%). Intestines were stretched out prior to 
measurement. Fgfr2b
-/-
 and Fgf10
-/-
 embryos have disproportionately short 
small intestine. Asterisks indicate that the difference in the means is 
A 
B 
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statistically significant (when compared with Wt littermates at the same 
time point) by a Student’s t-test; *** P<0.001; n = 5 embryos/group. 
 
 
 
 
 
Figure 3.3 Comparison of epithelial proliferation in the proximal 
small intestine of E16.5 and E18.5 Fgfr2b
-/-
 and Fgf10
-/-
 embryos to 
Wt littermates.  
(A) BrdU immunostaining of E18.5 Fgfr2b
-/-
 and Fgf10
-/-
 proximal small 
intestine. Scale bars: 100 µm. 
(B) Quantification of the mean percentage BrdU incorporation (±SEM) in 
the intervillous epithelium of E16.5 and E18.5 Wt, Fgfr2b
-/-
, and Fgf10
-/-
 
embryos. Fgfr2b
-/-
 and Fgf10
-/-
 have significantly reduced intervillous 
epithelial proliferation. ** P<0.01, *** P<0.001 by Student’s t-test; n = 6 
embryos/group.  
 
 
 
A 
B 
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3.3.3 Duodenal atresia in Fgf10-/- and Fgfr2b-/- is a defect 
occurring during intestinal morphogenesis 
 
Fgfr2b
-/-
 and Fgf10
-/-
 display duodenal atresia with variable penetrance: 
16% for Fgfr2b
-/-
 and 33% for Fgf10
-/-
. Most of the duodenal atresia is 
type III (complete separation) while type I (incomplete separation) 
examples are only occasionally seen. Dilation of the proximal duodenum, 
characteristic of obstruction, is evident in these cases. Most of the 
complex intestinal organogenesis occurs between stages E11.5 and E13.5 
in the mouse (Ramalho-Santos et al., 2000). The E14.5 stage was 
examined to determine whether duodenal atresia is the result of an 
intestinal organogenesis defect or late term regression of a normally 
developed structure. Duodenal atresia is clearly observed at this stage in 
both Fgfr2b
-/-
 and Fgf10
-/-
 embryos, with the duodenum ending in a blind 
pouch (Figure 3.4). Further examination of the duodenum at earlier time 
points of E11.5, E12.5 and E13.5 reveals that duodenal atresia can be 
observed as early as E12.5, with no obvious defect evident at E11.5 
(Figure 3.4). 
 
To determine the mechanism of duodenal atresia, gross morphology of 
E18.5 small intestine in the mutants was compared to their Wt littermates. 
The proximal small intestine, the area where duodenal atresia is observed, 
shows a similar rotation to that seen in Wt, indicating that these mutants 
display no overt gut malrotation that contributed to the atresia (Figure 
3.5). Duodenal stenosis (abnormal narrowing of the intestinal lumen) and 
overt gut malrotation have been linked to loss of Shh (Ramalho-Santos et 
al., 2000), and our expression data confirm normal Shh expression in the 
small intestine of Fgfr2b
-/-
 and Fgf10
-/-
 embryos (Figure 3.5). To 
determine whether duodenal atresia is a consequent of vasculature defects, 
vascular density in the proximal small intestine of E18.5 mutants was 
compared to their Wt littermates. Vascular density is unaffected (Figure 
3.6). 
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To establish whether duodenal atresia is caused by proliferative defects in 
duodenal epithelial and mesenchyme, BrdU labelling and active CSP-3 
immunostaining on serial cross-sections at E11.5, the stage before 
duodenal atresia is initially observed, show no significant decrease in 
proliferation nor increase in apoptosis at any focal point of the duodenum 
(data not shown). However, the mutants show a significant general 
reduction of epithelial proliferation, whilst no corresponding increase in 
apoptosis along the duodenal length is observed (Figure 3.7). 
Mesenchymal proliferation and apoptosis are unaffected at this stage. The 
same parameters were examined at E12.5 on non-atretic and atretic 
duodena from Fgfr2b
-/-
 embryos. A wholemount staining approach using 
propidium iodide to visualise mitotic and apoptotic cells via confocal 
microscopy was utilised (Foley and Bard, 2002). Both non-atretic and 
atretic duodenal tissues (epithelium and mesenchyme) in Fgfr2b
-/-
 
embryos show significantly reduced proliferation and increased apoptosis 
compared to Wt (Figure 3.8). However, in the mutants, the atretic ends 
show a significantly increase in the number of apoptotic cells than in the 
non-atretic duodenum, and an unexpectedly higher level of proliferation 
in the atretic ends than in the non-atretic duodenum (Figure 3.8).  
 
 
 
 91 
 
Figure 3.4 Duodenal phenotype of Fgfr2b
-/-
 and Fgf10
-/-
 embryos at 
E14.5, E13.5, and E12.5.  
Entire GI tract of the embryos was dissected to show type III duodenal 
atresia, which is characterised by a blind-ending pouch. Duodenal atresia 
can be detected as early as E12.5, indicating a defect occurring during 
intestinal morphogenesis. Oe: oesophagus, St: stomach, Du: duodenum, 
Si: small intestine, Ca: caecum, Co: colon. Scale bars: 1 mm. 
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Figure 3.5 Ventral views of E18.5 GI tract of Wt, Fgf10
-/- 
and Fgfr2b
-/-
 
embryos, and comparison of Shh expression level in the small 
intestine. 
Red dotted lines indicate the direction of the proximal small intestine 
rotation from the stomach. The proximal small intestine of Fgfr2b
-/-
 and 
Fgf10
-/-
 show similar rotation to the Wt, and has no aberrant expression of 
Shh. Duodenal stenosis and gut malrotation have been implicated in Shh
-/-
 
mutants (Ramalho-Santos et al., 2000). Scale: 1 mm. Shh expression data 
was normalised to the mean of Gapdh expression, and error bars (±SEM) 
came from three experiments; n = 4 embryos/group. 
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Figure 3.6 Comparison of vascular density in the proximal small 
intestine of Fgfr2b
-/- 
and Fgf10
-/-
 embryos to Wt littermates. 
(A) Endomucin stained longitudinal sections of Wt, Fgfr2b
-/-
, and Fgf10
-/-
 
E18.5 proximal small intestine. Red arrow shows the point of atresia. 
(B) Quantification of the mean vascular density (±SEM) in Wt, Fgfr2b
-/-
, 
and Fgf10
-/-
 E18.5 proximal small intestine using the Weibel-1 graticule. 
Fgfr2b
-/-
 and Fgf10
-/-
 show normal vascular density. n = 6 embryos/group.  
 
 
A 
B 
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Figure 3.7 Comparison of proliferation and apoptosis in proximal 
small intestine of E11.5 Fgfr2b
-/-
 and Fgf10
-/-
 embryos to Wt 
littermates. 
B 
A 
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(A) BrdU and active CSP-3 immunostained sections of Wt, Fgfr2b
-/-
, and 
Fgf10
-/-
 proximal small intestine. The black dotted lines indicate the 
boundary between the epithelium and mesenchyme. Scale bars: 50 µm. 
(B) Quantification of the mean percentage BrdU incorporation (±SEM) 
and mean active CSP-3 staining (±SEM) in the epithelium and 
mesenchyme of Wt, Fgfr2b
-/-
, and Fgf10
-/-
 proximal small intestine. 
Fgfr2b
-/-
 and Fgf10
-/-
 have reduced epithelial proliferation in the proximal 
small intestine. ** P<0.01, *** P<0.001 by Student’s t-test; n = 10 
embryos/group.  
 
 
 
Figure 3.8 Comparison of proliferation and apoptosis in proximal 
small intestine of E12.5 Fgfr2b
-/-
 embryos to Wt littermates. 
A 
B 
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(A) Wholemount propidium iodide staining of (a) duodenal atresia, (b) 
higher power view showing the epithelium and mesenchyme of an atretic 
end (marked by a yellow dotted box in (a)), (c) higher power view of 
mesenchyme of the atretic end (marked in (a)), and (d) the epithelium and 
mesenchyme of a corresponding Wt littermate. Yellow arrows show 
apoptotic nuclei that are smaller and more brightly stained than normal 
nuclei, and sometimes fragmented. White arrows show mitotic nuclei 
ranging from pro-metaphase to late anaphase. 
(B) Quantification of the mean percentage of mitotic and apoptotic cells 
(±SEM) in the Wt duodenum, Fgfr2b
-/-
 duodenum with no atresia, and the 
atretic duodenum of Fgfr2b
-/-
 mutants. Duodenal atresia is contributed by 
an increase in tissue apoptosis at a focal point on the duodenum. * P<0.05, 
** P<0.01, *** P<0.001 by Student’s t-test; n = 4 samples/group. 
 
 
3.3.4 Fgfr2b-/- and Fgf10-/- embryos develop gastric 
heterotopia in the GI tract 
 
To determine whether Fgfr2b and Fgf10 play a role in small intestinal 
differentiation during development, small intestine was examined by H&E 
staining and immunostained with markers for intestinal and gastric 
lineages. While enteroendocrine cells stained by chromogranin A/B 
appear normal in number and distribution in the mutants, the duodena of 
both Fgfr2b
-/-
 and Fgf10
-/- 
embryos show an approximately 30% reduction 
in the mean number of goblet cells in the proximal small intestine (Figure 
3.9). There are heterotopic areas of gastric epithelial cells in the rostral 
duodenum (Figure 3.10). These gastric cell patches express normal gastric 
surface mucin shown using combined D/AB/PAS staining. The remaining 
segments of the small intestine (middle and distal) have normal goblet cell 
numbers. Further immunohistochemical analysis on the rostral duodenum 
reveals absence of trefoil factor-2 (TFF2)-expressing Brunner’s glands, 
and partial loss of both intestinal-specific alkaline phosphatase (IAP) and 
the transcription factor CDX2 (Figure 3.10). Regions devoid of CDX2 
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abundantly express SOX2, a gastric-specific transcription factor, and 
H
+
,K
+
-ATPase !-subunit (ATP4b), a marker for hydrochloric acid-
producing parietal cells (Figure 3.10). This observation is also evident at 
E14.5, the stage prior to intestinal differentiation, with SOX2 expression 
extending into the rostral duodenum and interspersing within CDX2-
expressing cells (Figure 3.11). The remaining segments of the small 
intestine (middle and distal) in the E18.5 mutant foetuses also show 
normal CDX2 and IAP staining with no SOX2 and ATP4b expression 
(data not shown). Pepsinogen-secreting chief cells cannot be adequately 
assessed at these stages as pepsinogen is poorly expressed prior to birth 
(data not shown). 
 
 
 
Figure 3.9 Comparison of cytodifferentiation in the small intestine of 
E18.5 Fgfr2b
-/-
 and Fgf10
-/-
 embryos to Wt littermates. 
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Quantification of the mean number of goblet (immunostained by 
D/AB/PAS) and enteroendocrine cells (immunostained by chromogranin 
A/B) (±SEM) in the small intestine of Wt, Fgfr2b
-/-
, and Fgf10
-/-
. Fgfr2b
-/-
 
and Fgf10
-/-
 embryos have reduced number of goblet cells in the proximal 
small intestine. * P<0.05 by Student’s t-test; n = 6 embryos/group. 
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Figure 3.10 continue on next page 
 
 
* * 
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Figure 3.10 Gastric heterotopia of the rostral duodenum in E18.5  
Fgfr2b
-/-
 and Fgf10
-/-
 embryos. 
Immunostaining of markers for stomach and intestinal cell lineages, 
including TFF2, CDX2, ATP4b and SOX2, and histochemical staining 
using D/AB/PAS and IAP. D/AB/PAS staining shows gastric regions in 
the duodenum of Fgfr2b
-/-
 and Fgf10
-/-
 (red asterisks). The mutants also 
have loss of Brunner’s glands, and partial loss of IAP expression (blue 
arrows). Immunostaining images for the pairs CDX2/ATP4b and 
CDX2/SOX2 were taken from consecutive sections to show that regions 
devoid of CDX2 express ATP4b and SOX2 (red arrows). Scale bars: 50 
µm. 
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Figure 3.11 Gastric heterotopia of the rostral duodenum in E14.5  
Fgfr2b
-/-
 and Fgf10
-/-
 embryos. 
Immunostaining of SOX2 and CDX2 on consecutive sections of E14.5 Wt 
and Fgfr2b
-/-
 proximal small intestine. Right panels show the magnified 
version of the region marked by a red dotted box in the left. Red dotted 
lines show the gastric-intestinal boundary. Fgfr2b
-/-
 embryos show 
extended expression domain of SOX2 into the duodenum, which does not 
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occur in Wt. Fgf10
-/-
 embryos display similar phenotype, therefore only 
the images for Fgfr2b
-/-
 are shown.  
 
 
3.3.5 Fgf10-/- and Fgfr2b-/- small intestine has significant 
downregulation of Wnt signalling 
 
To determine whether Fgf10-Fgfr2b signalling may interact with the Wnt 
pathway, expression levels of major Wnt targets in the small intestine of 
Fgfr2b
-/-
 and Fgf10
-/-
 embryos were examined. RT-PCR results show 
significant downregulation of Tcf1, Tcf4, Cdx1, and Lgr5 in these mutants 
compared to Wt (Figure 3.12). On the other hand, Lef1, Axin2 and !-
catenin expression levels are unchanged. TCF4 immunostaining confirms 
the downregulation of this protein throughout the small intestine of the 
mutants, while !-catenin levels and distribution are normal (Figure 3.13).  
 
 
 
 104 
 
Figure 3.12 Comparison of gene expression in small intestine of 
Fgfr2b
-/-
 and Fgf10
-/-
 embryos to Wt littermates. 
Fgfr2b
-/-
 and Fgf10
-/-
 small intestine has reduced expression of Tcf1, Tcf4, 
Cdx1 and Lgr5. RNA was extracted from whole E18.5 small intestine of 
Wt, Fgfr2b
-/-
 and Fgf10
-/-
, and subjected to real-time PCR. All data was 
normalised to the mean of Gapdh expression, and error bars (±SEM) came 
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from three experiments; n = 4 embryos/group. * P<0.05, *** P<0.001 by 
Student’s t-test. 
 
 
 
Figure 3.13 Immunohistochemical staining of TCF4 and !-catenin in 
E18.5 Wt, Fgfr2b
-/-
 and Fgf10
-/-
. 
The mutants have reduced TCF4 in the small intestine, with no overt 
difference in !-catenin localisation and distribution. 
 
 
3.3.6 Fgfr2b-Fgf10 signalling pathway regulates Tcf4 via 
the MAPK pathway 
 
To determine the regulatory mechanism of Tcf4 expression by Fgf10-
Fgfr2b signalling, TOPflash/FOPflash reporter assay was initially used to 
determine the optimum concentration of rhFGF10 for stimulating Wnt 
activity in SW480 cells. Luciferase data show that Wnt activity increases 
with increasing concentration of rhFGF10, with 100 ng/ml being the 
optimal concentration since addition of 200 ng/ml does not significantly 
increase Wnt activity (Figure 3.14). RT-PCR for Tcf4 expression indicates 
a significant increase in Tcf4 mRNA level by approximately 3-fold at 50 
ng/ml rhFGF10, but not at 100 ng/ml and 200 ng/ml (Figure 3.14). 
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Following this, the TOPflash/FOPflash reporter assay was performed in 
combination with 100 ng/ml rhFGF10 and an inhibitor for MAPK 
(U0126), PI3K (LY294002) or PLC-! (BIM-1). Luciferase data shows 
that U0126 and LY294002 markedly downregulates Wnt activity, with 
highest level of downregulation observed with U0126 (Figure 3.15). RT-
PCR for Tcf4 expression further confirms the downregulation of Tcf4 
mRNA by approximately 75% by U0126, but not by LY294002 and BIM-
I (Figure 3.15). 
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Figure 3.14 Effect of rhFGF10 on Wnt activity and Tcf4 mRNA 
expression in SW480 cell line. 
(A) The graph shows the rhFGF10-dose response luciferase assay of 
SW480 cells transfected with the TOP-luciferase or the FOP-luciferase 
construct. Luciferase activity was measured and normalised to Renilla 
luciferase activity. Fold activation was calculated as normalised luciferase 
reading from TOP-/FOP-luciferase constructs. 50 ng/ml and 100 ng/ml 
rhFGF10 significantly stimulates Wnt activity in SW480 cells. The values 
(±SEM) indicated were the average of three independent experiments. n = 
3 samples/group. * P<0.05, ** P<0.01 by Student’s t-test. 
A 
B 
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(B) The graph shows a trend of increasing Tcf4 mRNA level with 
increasing concentration of rhFGF10. However, only the 50 ng/ml 
rhFGF10 shows statistically significant increase in Tcf4 expression. All 
data was normalised to the mean of Gapdh expression, and error bars 
(±SEM) came from three experiments; n = 3 samples/group. ** P<0.01 by 
Student’s t-test. 
 
 
 
 
 
Figure 3.15 Effect of inhibitors on Wnt activity and Tcf4 mRNA 
expression in SW480 cell line. 
(A) TOPflash/FOPflash reporter assay of SW480 cells treated with a 
combination of 100 ng/ml rhFGF10 and one of the following inhibitors: 
U0126 (10 µM), LY294002 (20 µM) or BIM-1 (5 µM). Addition of 
A 
B 
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U0126 and LY294002 significantly downregulates Wnt activity. 
Luciferase activity was measured and normalised to Renilla luciferase 
activity. Fold activation was calculated as normalised luciferase reading 
from TOP-/FOP-luciferase constructs. The values (±SEM) indicated were 
the average of three independent experiments. n = 3 samples/group * 
P<0.05, ** P<0.01 by Student’s t-test. 
(B) The graph shows a significant downregulation of Tcf4 mRNA level in 
cell treated with U0126, but not with LY294002 and BIM-I, as evidenced 
by RT-PCR. All data was normalised to the mean of Gapdh expression, 
and error bars (±SEM) came from three experiments; n = 3 
samples/group. *** P<0.001 by Student’s t-test. 
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3.4 DISCUSSION 
 
Loss of Fgfr2b or Fgf10 alone is sufficient to cause duodenal atresia with 
variable penetrance and severity. This variable penetrance may correlate 
with the expression level of Fgfr2b and Fgf10 along the developing GI 
tract, where different segments of the GI tract requires different levels of 
Fgf10 or Fgfr2b for normal development. We have established that 
Fgfr2b and Fgf10 are expressed in the small intestine during development, 
although at a lower level compared to the caecum and colon. Additionally, 
a previous study using an FGF10-LacZ reporter line demonstrated a high 
concentration of FGF10-expressing cells in the rostral duodenum of E18.5 
(Kanard et al., 2005), providing more evidence of the importance of this 
growth factor in normal duodenal development. Our findings also show a 
higher penetrance of duodenal atresia in Fgf10
-/-
 embryos, possibly 
because in the absence of FGFR2b, FGF10 can signal via the FGFR1-IIIb 
isoform (FGFR1b) (Zhang et al., 2006, Beer et al., 2000).  
 
One of the main aims of this study is to investigate the mechanism of 
duodenal atresia occurring in these mutants. Members of the Hedgehog 
family have been reported to play important roles during gut development, 
where Shh mutants showed duodenal stenosis and overt gut malrotation 
(Ramalho-Santos et al., 2000). Our results show normal Shh expression 
level in the small intestine, in contrast to the stomach (Spencer-Dene et 
al., 2006), and no overt gut malrotation in both Fgfr2b
-/-
 and Fgf10
-/-
 
embryos. A previous study also showed normal Shh level by ISH in E12.5 
Fgfr2b
-/-
 small intestine (Burns et al., 2004). More than a century ago, 
Tandler proposed that intestinal atresia results from a failure in the 
recanalisation of the solid cord stage of duodenal development in human 
(Tandler, 1900). Our data did not support Tandler’s theory because 
duodenal atresia cannot be detected at E11.5 and by this stage the 
duodenum has already developed an intestinal lumen (Figure 3.7).  
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Barnard and Louw (1955) alternatively proposed that intestinal atresia 
arises from an intrauterine mesenteric vascular accident of normally 
developed intestine late in gestation, resulting in necrosis and subsequent 
resorption (Barnard and Louw, 1956, Louw and Barnard, 1955). We find 
no necrosis and normal vascular density in the proximal small intestine of 
the mutants, including at the site of atresia, confirming that duodenal 
atresia is unlikely to be a consequence of defects in vasculature. Normal 
mesenteric vasculature in E11.5 to E13.5 Fgf10
-/-
 colon has been 
previously demonstrated (Fairbanks et al., 2005). However, our data does 
not preclude the possibility of minor functional differences, such as 
changes in morphology and location, of intestinal endothelial cells 
between Wt and mutants. 
 
Another aspect of our investigation concerned small intestinal epithelial 
and mesenchymal proliferation and apoptosis. Serial cross-sections of 
E11.5 (the stage before duodenal atresia is first observed) duodenum do 
not show a focal imbalance of cell proliferation and apoptosis, but instead 
show a significant reduction of epithelial proliferation along the small 
intestines of the mutants. This suggests that reduced epithelial 
proliferation could have contributed to duodenal atresia. This finding is 
confirmed by our further examination on E12.5 non-atretic and atretic 
duodena in the Fgfr2b
-/-
 embryos via wholemount staining with propidium 
iodide. Propidium iodide has been used and validated successfully to 
detect mitotic and apoptotic cells (Coles et al., 1993, Foley and Bard, 
2002). Both non-atretic and atretic duodena in the mutants have higher 
apoptotic activity than in the Wt. The significantly higher apoptotic 
activity in the atretic duodenum than in the non-atretic duodenum 
suggests that duodenal atresia is possibly a result of increased apoptosis at 
a particular focal point in the duodenum. The mechanism that specifies 
the focal point of atresia is currently unclear. Previous studies on caecal 
and colonic atresia in Fgfr2b
-/-
 and Fgf10
-/-
 embryos have also shown 
reduced epithelial proliferation and increased apoptosis, further 
confirming the requirement of Fgfr2b and Fgf10 in normal intestinal 
morphogenesis (Burns et al., 2004, Sala et al., 2006). The unexpectedly 
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higher tissue proliferation in the atretic ends compared to the non-atretic 
duodenum may indicate a response to tissue injury where increased tissue 
proliferation is required to repair the epithelium and mesenchyme at the 
atretic ends.  
 
Cytodifferentiation analysis on the small intestine of these mutants reveals 
a significant reduction of goblet cells in the proximal small intestine, most 
likely due to gastric heterotopia. This phenotype occurs with complete 
penetrance regardless of the presence of duodenal atresia. Mucin-
producing gastric epithelial cells are present partially in the rostral 
duodenum, accompanied by loss of Brunner’s glands and partial loss of 
IAP. On the other hand, regions of intestinal epithelium with goblet cells 
express IAP. Expression of gastric-specific markers, SOX2 and ATP4b, is 
normally restricted to the stomach epithelium with no transcript detected 
beyond the pyloric sphincter, which delineates the duodenal boundary, 
and CDX2 expression is normally restricted to the intestine. In E18.5 
Fgfr2b
-/-
 and Fgf10
-/-
 embryos, the duodenum partially expresses CDX2, 
and the regions devoid of CDX2 abundantly express SOX2 and ATP4b.  
 
Further examination on E14.5 mutants, the stage prior to intestinal 
differentiation, shows that the expression boundary between SOX2-
expressing gastric cells and CDX2-expressing intestinal cells in both 
mutants is poorly defined at the pyloric sphincter. We have previously 
shown that the development of the pyloric sphincter is normal in both 
mutants (Spencer-Dene et al., 2006). SOX2 expression extends into the 
rostral duodenum whereas CDX2 expression is limited to the small 
intestine. This suggests that Fgfr2b and Fgf10 regulate a signalling 
mechanism that restricts SOX2 expression into the intestinal region, and 
loss of Fgfr2b or Fgf10 causes the cells in the intestinal region to commit 
into gastric cells even before intestinal differentiation has started.  
 
Gastric heterotopia is a result of an anterior-posterior patterning defect in 
the small intestine, and canonical Wnt signalling has been implicated in 
specifying anterior-posterior axis of the GI tract (Theodosiou and Tabin, 
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2003, He, 2003, Mlodzik, 2002, Wodarz and Nusse, 1998, Yamaguchi, 
2001). Tcf4
-/-
/Tcf1
-/-
 double knockout embryos have been reported to 
display duodenal atresia with large areas of gastric heterotopia (Gregorieff 
et al., 2004). Our study also show that Fgfr2b
-/-
 and Fgf10
-/-
 embryos 
develop disproportionately short small intestines (when measured against 
the overall embryonic size) during late-stage embryogenesis mostly due to 
reduction in the number of proliferating cells in the intervillous region. A 
previous study has also shown the absence of intestinal proliferative cells 
in Tcf4
-/-
 embryos, implying a strong link between Wnt signalling and 
Fgf10-Fgfr2b signalling (Korinek et al., 1998).  
 
Expression studies on various Wnt targets in the small intestine of  
Fgfr2b
-/-
 and Fgf10
-/-
 embryos reveal significant downregulation of Tcf1, 
Tcf4, Cdx1 and Lgr5, with normal expression level of Lef1, !-catenin and 
Axin2. While the loss of Fgfr2b and Fgf10 does not fully eliminate Tcf4 
and Tcf1 expression, the significant reduction of both Wnt targets may be 
sufficient to generate the patterning defects in the stomach/duodenum 
region. However, the heterotopia in the Fgfr2b
-/-
 and Fgf10
-/-
 small 
intestine is less severe than that of the Tcf4
-/-
/Tcf1
-/-
 embryos. Our findings 
are also consistent with the hypothesis that gastric heterotopia only occurs 
when both Tcf4 and Tcf1 are downregulated, as loss of either Tcf4 or Tcf1 
alone is not sufficient (Roose et al., 1999, Korinek et al., 1998). 
Additionally, loss of Tcf4 leads to depletion of intestinal epithelial stem-
cell compartments, and our data suggests that downregulation of Tcf4 
could have contributed to the reduced proliferating capacity of intestinal 
progenitor cells in the intervillous region of the small intestine, leading to 
reduced epithelial proliferation observed earlier. This finding is also 
consistent with the significant downregulation of Lgr5, a stem cell marker 
and a downstream target of the Wnt signalling pathway (Jaks et al., 2008, 
Korinek et al., 1998). 
 
A previous study on Fgf10-Fgfr2b signalling in mouse mammary gland 
development showed that an ectopic source of recombinant FGF10 failed 
to induce Lef1 expression in the mammary epithelium, suggesting that 
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Lef1 expression is independent of Fgf10, consistent with our findings in 
the small intestine (Mailleux et al., 2002). Cdx1 expression requires Tcf4 
(Lickert et al., 2000), and the reduced Cdx1 expression level in these 
mutants reflects the downregulation of Tcf4.  
 
While Cdx1
-/-
 mice have no gut abnormality (Subramanian et al., 1995), 
Cdx2
-/-
 embryos die before gastrulation but heterozygous mice are viable 
(Chawengsaksophak et al., 1997). Several studies have shown that Cdx2
+/-
 
mice develop gastric heterotopia in paracaecal regions with the lesions 
expressing SOX2 (Beck et al., 1999, Stringer et al., 2008). Our Fgfr2b
+/-
 
and Fgf10
+/-
 adult mice show absence of gastric heterotopia in the ileum, 
caecum and proximal colon, with largely normal CDX2 expression (data 
not shown), indicating that the mechanism of gastric heterotopia in both 
cases may be different. 
 
FGF2 has been previously shown to reduce GSK3 activity and induce 
nuclear translocation of !-catenin via the FRS2-GRB2-GAB1-PI3K-AKT 
signalling cascade (Katoh and Katoh, 2006, Holnthoner et al., 2002). 
FGF10 hypomorphic (Fgf10
+/!
;Mlc1v-LacZ
+/!
) lungs have been 
previously shown to have reduced nuclear !-catenin activation 
(Ramasamy et al., 2007), implying a relationship between Fgfs and !-
catenin distribution. We did not, however, observe any noticeable change 
in !-catenin levels or nuclear/cytoplasmic distribution in the small 
intestine between null and Wt embryos. This suggests that Fgf10-Fgfr2b 
signalling may interact with the Wnt signalling pathway via an alternative 
signalling cascade to regulate the expression of Tcf1 and Tcf4 in the gut.  
 
Indeed, our in vitro studies using the human colorectal carcinoma SW480 
cell line show that Fgf10-Fgfr2b signalling is able to regulate Tcf4 
expression in the developing small intestine via the Grb2/Sos/Ras/MAPK 
pathway. Inhibition of the MAPK pathway by U0126, an inhibitor of this 
pathway, leads to significant downregulation of Tcf4 expression and Wnt 
activity. We also show that the MAPK pathway cannot be regulated via 
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the PKC pathway because inhibition of the PKC pathway by BIM-I does 
not affect Wnt activity and Tcf4 expression. The question as to whether 
the regulation of Tcf4 expression by Fgf10-Fgfr2b signalling is direct or 
indirect requires further investigation. In addition, inhibition of the PI3K 
pathway leads to downregulation of Wnt activity but not Tcf4 expression, 
suggesting that the PI3K pathway is regulating a different component of 
the Wnt pathway in our in vitro experiments.  
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3.5 Conclusion 
 
In conclusion, we have shown that Fgf10 and Fgfr2b are required for 
normal duodenal morphogenesis and establishment of the gastric-
duodenal differentiation boundary via the canonical Wnt signalling 
pathway. Loss of either Fgfr2b or Fgf10 leads to disproportionately short 
small intestine due to reduced proliferation in the intervillous epithelium, 
duodenal atresia contributed by reduced tissue proliferation and increased 
apoptosis at a focal point, and gastric heterotopia due to loss of gastric-
intestinal boundary specification. 
 
In addition, we have also shown that loss of either Fgf10 or Fgfr2b leads 
to significant downregulation of Wnt targets Tcf1 and Tcf4 in the small 
intestine, with corresponding downregulation of Lgr5, an intestinal stem 
cell marker, and Cdx1, a homeobox gene involved in anterior-posterior 
patterning. Using in vitro studies, we have shown that Fgf10-Fgfr2b 
signalling can regulate Tcf4 expression via the Grb2/Sos/Ras/MAPK 
pathway. This knowledge will enhance our understanding on human 
congenital duodenal atresia and other pathological anomalies, such as 
gastric heterotopia and paraduodenal heterotopia in adults. 
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Chapter 4: Fgfr2b in intestinal homeostasis 
 
4.1 Introduction  
 
While the previous chapter has demonstrated the requirement of Fgfr2b in 
GI development, the role of Fgfr2b in maintaining adult GI homeostasis is 
not well understood. Expression of Fgfr2b and Fgf7 has been detected 
throughout the adult rat GI tract from the oesophagus to colon, implying a 
possible role of Fgfr2b and Fgf7 in maintaining intestinal homeostasis 
(Housley et al., 1994). Additionally, systemic administration of rhFGF7 
rapidly induced the proliferation of epithelial cells in the foregut to the 
colon, and continued treatment led to the selective induction of mucin-
producing cells in a dose-dependent fashion, providing further evidence 
on the ability of Fgf7, which signals via Fgfr2b, to activate GI epithelial 
populations in vivo (Housley et al., 1994). Recent studies have also 
demonstrated the importance of Fgfr2b in maintaining other organ 
homeostasis. Ablation of Fgfr2b specifically in the skin resulted in 
epidermal hyperthickening that developed with age, and 10% of these 
mutants developed spontaneous papillomas, implying the role of Fgfr2b 
in postnatal skin development and in adult skin homeostasis (Grose et al., 
2007). Ubiquitous expression of soluble dominant negative Fgfr2b in 
postnatal mice for six weeks starting immediately after birth led to the 
formation of rudimentary mammary epithelial tree with completely absent 
terminal end buds compared to a well-branched structure observed in wild 
type, demonstrating the role of Fgfr2b in postnatal mammary 
development (Parsa et al., 2008). 
 
Since absence of Fgfr2b during early pre-implantation development leads 
to perinatal lethality (De Moerlooze et al., 2000), we utilise an inducible 
Cre recombinase-mediated excision, using the progesterone antagonist 
(RU486) to drive the intestinal-specific A33 antigen promoter. The A33 
antigen is expressed on the basolateral surface of intestinal epithelial
 
cells 
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of all lineages, independent of their position along the
 
rostrocaudal and 
crypt-villus axis (Johnstone et al., 2000, Johnstone et al., 2002). An 
alternative approach to this method is the use of Villin-CreER
T2
, however 
this line directs high Cre expression in the duodenum that gradually 
decreases along the intestine with the lowest Cre expression in the colon 
(el Marjou et al., 2004). In addition, the Cre expression directed by Villin-
CreER
T2 
tends to be mosaic (personal communication with Prof. Ian 
Tomlinson, Oxford University). Conversely, the A33-CrePR line directs 
high Cre expression in the colon that gradually decreases towards the 
proximal small intestine (Malaterre et al., 2007), making it an optimal 
model for this study as the large intestine expresses higher Fgfr2b mRNA 
than the small intestine (see below). Additionally, the A33-CrePR line has 
been used successfully in a previous study to knock out c-Myb in the 
colonic crypts (Malaterre et al., 2007). 
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4.2 Materials and Methods 
 
4.2.1 Animal breeding 
 
A33-CrePR line was a kind gift from Dr. Theo Mantamadiotis (in Prof. 
Joan Heath’s laboratory, Peter MacCallum Cancer Centre and Pathology 
Department, University of Melbourne, Australia) and has been previously 
described (Malaterre et al., 2007). A33-CrePR
+
 mice were initially 
crossed with Fgfr2b
flox/flox
 conditional mice to generate an A33-
CrePR
+
/Fgfr2b
flox/wt
 line, and this line was subsequently crossed with 
itself to generate A33-CrePR
+
/Fgfr2b
flox/flox
 and Fgfr2b
flox/flox
 lines.  
 
4.2.2 RU486 administration 
 
RU486 mix was prepared as previously described (Section 2.2.1). Twelve 
six-week-old males and females for both A33-CrePR
+
/Fgfr2b
flox/flox
 and 
Fgfr2b
flox/flox
 strains were given 250 µl of RU486 mix daily by gavage for 
up to 28 days. Following this, mice were wither culled the next day or left 
for another 28 days. 
 
4.2.3 Immunohistochemistry 
 
Mice were injected with BrdU solution (550891; BD Biosciences) at 50 
mg/kg 1 hr before culling. Gut tissues were dissected in cold PBS, fixed, 
processed and embedded as previously described (Section 2.5.2). 
Immunohistochemistry was performed with anti-BrdU, anti-CSP-3, anti-
FGFR2b, anti-MUC2, anti-chromogranin A/B, anti-lysozyme and anti-
TCF4 as previously described (Section 2.5). Morphometry was performed 
as previously described (Section 2.7). 
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4.2.4 Crypt microdissection 
 
Mice were injected intraperitoneally with vincristine sulphate 1 mg/kg 
(Mayne Pharma Plc.) 2 hrs before culling. Crypt microdissection was 
performed as previously described (Section 2.8). 
 
4.2.5 RT-PCR 
 
RNA was extracted from the different GI segments of C57/BL6, A33-
CrePR
+
/Fgfr2b
flox/flox
 and Fgfr2b
flox/flox
 mice, and cDNA synthesis was 
performed as previously described (Section 2.4). Reverse transcriptase 
PCR was performed for Fgfr2b as described in Section Section 2.4.4, 
while SYBR Green PCR was performed for Fgfr1b and Tcf4 as described 
in Section 2.4.7. 
 
4.2.6 Western blot 
 
Protein was extracted from the different GI segments of C57/BL6, A33-
CrePR
+
/Fgfr2b
flox/flox
 and Fgfr2b
flox/flox
 mice, and Western blot for Cre and 
FGFR2b was performed as previously described (Section 1.9). 
 
4.2.7 In situ hybridisation (ISH) 
 
Gut tissues from A33-CrePR
+
/Fgfr2b
flox/flox
 and Fgfr2b
flox/flox
 mice were 
dissected, fixed, processed and embedded as previously described 
(Section 2.5.2). ISH for Fgfr2b was performed as previously described 
(Section 2.3.3). 
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4.3 Results 
 
4.3.1 Fgfr2b is expressed in adult mouse GI tract 
 
Reverse transcriptase PCR and ISH were used to determine the expression 
gradient of Fgfr2b along the adult mouse GI tract. Fgfr2b is expressed 
highly in the stomach and distal part of the intestine (ileum, caecum and 
colon) compared to the proximal small intestine (duodenum and jejunum) 
(Figure 4.1). Fgfr2b mRNA is detected strongly at the crypt-villus 
junction and in the crypts of the small intestine, and at the bottom of 
caecal and colonic crypts (Figure 4.4). 
 
 
 
 
 
Figure 4.1 Reverse-transcriptase PCR showing Fgfr2b expression 
level in an adult mouse GI tract. 
This mRNA profile is a representation of the profile shown by three Wt 
C57/BL6. Fgfr2b is expressed higher in the distal region than the 
proximal region of the intestine. Fore: forestomach, Glan: glandular 
stomach, Duo: duodenum, Jej: jejunum, Ile: ileum, Cae: caecum, Pro: 
proximal colon, Dis: distal colon, +ve: positive control from adult lung 
mRNA. Negative control (omitted from the above figure) came from 
E18.5 Fgfr2b
-/-
 whole embryo mRNA and show absence of band (data not 
shown). 
 
 
 
 
 
Fgfr2b 
 
Gapdh 
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4.3.2 RU486 administration leads to reduced Fgfr2b 
mRNA in the GI tract of A33-CrePR+/Fgfr2bflox/flox 
 
Western blot was used to determine the expression gradient of Cre along 
the GI tract of A33-CrePR
+
/Fgfr2b
flox/flox
 and Fgfr2b
flox/flox
 mice. Cre is 
expressed highly in the caecum and colon, and this expression decreases 
towards the duodenum (Figure 4.2). RU486 administration on A33-
Cre
+
/Fgfr2b
floxflox
 mice for 14 days consecutively show a significant 
reduction of Fgfr2b mRNA by approximately 90% in the colon and 70% 
in the small intestine compared to the Fgfr2b
flox/flox
 mice (Figure 4.2). 
There is no significant difference in the level of Fgfr2b excision between 
the 14 days and 28 days of RU486 administration. The significant 
reduction of Fgfr2b mRNA is observed globally along the entire GI tract 
with little mosaicism, as evidenced by ISH (Figure 4.4). These results 
cannot be validated further by immunohistochemistry and Western blot, 
as published anti-FGFR2b antibodies are not specific for the mouse 
FGFR2b antigen despite testing various antigen retrieval conditions, 
antibody concentrations and on fresh-frozen tissues (Figure 4.3). 
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Figure 4.2 Comparison of Cre and Fgfr2b expression in the intestine 
of A33-CrePR
+
/Fgfr2b
flox/flox
 and Fgfr2b
flox/flox
. 
(A) Cre expression is detectable by immunoblotting in tissue lysates from 
the gut of A33-CrePR
+
/Fgfr2b
flox/flox
 mice, with higher expression in the 
distal intestine than the proximal intestine. GAPDH was used as a control 
for equal loading. This result is a representation of the profile shown by 
three mice. 1: duodenum, 2: jejunum, 3: ileum, 4: caecum, 5: proximal 
colon, 6: distal colon, 7: positive control from adult duodenum of Villin-
CreER
T2
 mouse, 8: negative control from lung tissue of A33-CrePR
 
mouse. 
(B) RU486 was administered on Fgfr2b
flox/flox
 (labelled as ‘2b
fl/fl
’) for four 
weeks, and A33-CrePR
+
/Fgfr2b
flox/flox
 (labelled as ‘Cre
+
/2b
fl/fl
’) for two 
and four weeks. Mice were culled one day after RU486 administration. 
The A33-CrePR system excises Fgfr2b alleles with higher efficiency in 
the distal intestine than in the proximal intestine. Data was normalised to 
the mean of Gapdh expression, and error bars (±SEM) came from three 
experiments; n = 4 animals/group. 
 
 
A 
B 
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Figure 4.3 Demonstration of anti-FGFR2b antibodies in Western blot 
and immunofluorescence staining. 
(A) Protein lysate was obtained from two whole E14.5 Wt (labelled as ‘1’ 
and ‘2’) and Fgfr2b
-/-
 (labelled as ‘3’ and ‘4’) embryos, and subjected to 
western transfer and probed with published anti-FGFR2b antibodies from 
Ishiwata (Ishiwata et al., 2002) and R&D Systems. GAPDH was used as a 
control for equal loading. Both antibodies detect FGFR2b expression in 
Wt and mutant tissues, implying that the antibodies are not specific for the 
mouse FGFR2b antigen. 
(B) Immunofluorescence was performed on E18.5 stomach and duodenal 
sections from Wt and Fgfr2b
-/-
 embryos using antibodies as described 
previously. The antibody from R&D Systems show absence of positive 
B 
A 
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staining even in Wt tissue, hence is omitted from the above figure. The 
antibody from Ishiwata show apparently positive staining in Fgfr2b
-/-
 
stomach and duodenum (yellow arrow), largely indistinguishable to that 
of the Wt.  
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Figure 4.4 Continue on next page 
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Figure 4.4 Comparison of Fgfr2b mRNA expression in the GI tract of 
A33-CrePR
+
/Fgfr2b
flox/flox
 and Fgfr2b
flox/flox
 following RU486 
administration for 28 days. 
ISH for Fgfr2b mRNA was performed with tissue sections from the 
different segments of the GI tract from both mice groups, however only 
results from jejunum and ileum are shown. Blue arrows indicate the 
location of Fgfr2b mRNA at the crypt-villus junction and the bottom of 
crypts. The A33-CrePR
+
/Fgfr2b
flox/flox
 mice show reduced Fgfr2b mRNA 
level. 
 
4.3.3 Reduced Fgfr2b does not lead to overt change in 
body weight 
 
To determine whether downregulation of Fgfr2b can affect body weight 
as a parameter for measuring intestinal homeostasis, mice were given four 
weeks of RU486 and left for another four weeks, with body weight 
measured every two days. The A33-Cre
+
/Fgfr2b
floxflox
 mice show a 
consistent trend of reduced body weight compared to the Fgfr2b
floxflox
 
mice regardless of the gender (Figure 4.5). However, both mice groups 
show no significant difference in their body weight when data at two 
separate time points were compared: the first time point was immediately 
after the four weeks of RU486 administration (28
th
 day), and the second 
time point was immediately after the entire experiment (56
th
 day) (Figure 
4.5). 
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Figure 4.5 (continue on next page) 
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Figure 4.5 Comparison of body weight between A33-
CrePR
+
/Fgfr2b
flox/flox
 and Fgfr2b
flox/flox
 mice following RU486 
administration. 
(A) Both mice groups were given RU486 for the first 28 days, and left for 
another 28 days. Body weight was measured every two days for eight 
weeks. The Fgfr2b
flox/flox
 mice consistently show a trend of reduced body 
weight compared to the controls. All data was presented as mean (±SEM) 
body weight; n = 6 animals/group/gender. 
(B) Average gain in body weight between both mice groups was 
calculated at the end of 28 and 56 days separately. Body weight between 
both groups was largely similar. All data was presented as mean (±SEM) 
body weight; n = 6 animals/group/gender.  
B 
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4.3.4 Reduced Fgfr2b does not lead to overt change in 
intestinal crypt proliferation, apoptosis and 
differentiation 
 
Various markers for proliferation, apoptosis and differentiation were used 
to determine the effect of reduced Fgfr2b mRNA on intestinal 
homeostasis. Both A33-CrePR
+
/Fgfr2b
flox/flox
 and Fgfr2b
flox/flox
 mice have 
largely similar degree of epithelial proliferation as measured by BrdU 
immunostaining and crypt microdissection (Figure 4.6 and 4.7). The crypt 
microdissection technique assessed number of cells in metaphase, number 
of crypts undergoing fission and crypt volume in a three-dimensional 
aspect. Both groups also have largely similar rate of apoptosis as 
measured by active CSP-3 immunostaining (Figure 4.6), and 
differentiated cells as evidenced by immunostaining for goblet cells 
(MUC2), enteroendocrine cells (chromogranin A/B) and Paneth cells 
(lysozyme) (Figure 4.8). To establish whether reduced Fgfr2b mRNA can 
affect the expression of intestinal transcription factors, expression level of 
Tcf4 was compared between A33-CrePR
+
/Fgfr2b
flox/flox
 and Fgfr2b
flox/flox
 
mice. Both mice groups show no significant difference in the Tcf4 mRNA 
and protein expression (Figure 4.9). The A33-CrePR
+
/Fgfr2b
flox/flox
 mice 
also show largely normal CDX2 immunostaining (Figure 4.9). 
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Figure 4.6 Continue on next page 
 
 
 
 
 
 
 
A 
B 
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Figure 4.6 Comparison of proliferation and apoptosis in the GI tract 
of Fgfr2b
wt/wt
, Fgfr2b
flox/flox
 and A33CrePR
+
/Fgfr2b
flox/flox
 following 
RU486 administration. 
(A) All three groups of mice were given RU486 for 28 days consecutively 
and culled after another 28 days. Representative images for BrdU and 
CSP-3 IHC came from distal colon. 
(B) Quantification of the mean number of cells positively stained cells in 
20 random fields of intestinal epithelium viewed at x40 magnification. All 
three groups show largely similar epithelial proliferation and apoptosis. 
All data was presented as mean (±SEM); n=12 animals/per group. Duo: 
duodenum, Jej: jejunum, Ile: ileum, Cae: caecum, Col: distal colon. 
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Figure 4.7 Comparison of proliferation by crypt microdissection in 
the GI tract of Fgfr2b
wt/wt
, Fgfr2b
flox/flox
 and A33CrePR
+
/Fgfr2b
flox/flox
 
following RU486 administration. 
All three groups of mice were given RU486 for 28 days. Quantification 
was performed as described in Section 2.8.2. All three groups show 
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largely similar crypt proliferation. All data was presented as mean 
(±SEM); n = 8 animals/per group. 
 
 
Figure 4.8 Continue on next page 
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Figure 4.8 Comparison of differentiation markers in the GI tract of 
Fgfr2b
wt/wt
, Fgfr2b
flox/flox
 and A33CrePR
+
/Fgfr2b
flox/flox
 following 
RU486 administration. 
(A) Representative images for MUC2 and chromogranin A/B IHC came 
from distal colon, whereas representative images for lysozyme came from 
jejunum as the colon does not have Paneth cells. 
(B) Quantification of the mean number of cells positively stained cells in 
20 random fields of intestinal epithelium viewed at x40 magnification. 
The A33CrePR
+
/Fgfr2b
flox/flox
 mice show largely normal 
cytodifferentiation. All data was presented as mean (±SEM); n=12 
animals/per group. Duo: duodenum, Jej: jejunum, Ile: ileum, Cae: 
caecum, Col: distal colon. 
B 
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Figure 4.9 Comparison of TCF4 and CDX2 expression in the GI tract 
of Fgfr2b
wt/wt
, Fgfr2b
flox/flox
 and A33CrePR
+
/Fgfr2b
flox/flox
 following 
RU486 administration. 
(A) Representative images for TCF4 and CDX2 IHC came from jejunum.  
(B) RNA was extracted from jejunum and distal colon, and subjected to 
SYBR Green RT-PCR for Tcf4. The A33CrePR
+
/Fgfr2b
flox/flox
 mice show 
largely normal Tcf4 expression. All data was normalised to the mean of 
B 
A 
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Gapdh expression, and error bars (±SEM) came from three experiments;        
n = 4 mice/group. 
 
 
4.3.5 Fgfr2b may be functionally redundant in 
maintaining adult intestinal homeostasis 
 
Reverse-transcriptase PCR was used to determine whether other Fgfs and 
Fgfrs are expressed in the adult GI tract. RT-PCR results show that the GI 
tract expresses various Fgfs and Fgfrs with different expression gradient 
along the GI tract (Figure 4.10). Of the Fgf receptors, all Fgfrs, except 
Fgfr2c, are expressed in the intestinal region. Fgfr1b expression level was 
compared between A33-CrePR
+
/Fgfr2b
flox/flox
 and Fgfr2b
flox/flox
 mice to 
determine whether Fgfr1b may compensate for the downregulation of 
Fgfr2b. RT-PCR data show largely normal Fgfr1b expression in both 
mice groups (Figure 4.11). 
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Figure 4.10 Reverse-transcriptase PCR showing expression of Fgfs 
and Fgfrs in adult mouse GI tract. 
This mRNA profile is a representation of the profile shown by three Wt 
C57/BL6 mice of approximately six weeks old. Fgf19 and Fgf23 could 
not be optimised. Fgfr2b mRNA profile has been shown in Figure 4.1, 
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hence was omitted from the above figure. Gapdh was used as a loading 
control. Positive controls used are listed in Table 1.2, and negative 
controls came from omitted cDNA template from the reaction (data not 
shown). All RNA samples have been checked for DNA contamination by 
Gapdh PCR. 
 
 
 
Figure 4.11 Comparison of Fgfr1b expression in the GI tract of 
Fgfr2b
wt/wt
, Fgfr2b
flox/flox
 and A33CrePR
+
/Fgfr2b
flox/flox
 following 
RU486 administration. 
RNA was extracted from jejunum and distal colon, and subjected to RT-
PCR. The A33CrePR
+
/Fgfr2b
flox/flox
 mice show largely normal Fgfr1b 
expression. All data was normalised to the mean of Gapdh expression, 
and error bars (±SEM) came from three experiments; n = 4 mice/group. 
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4.4 Discussion 
 
The adult mouse GI tract expresses Fgfr2b mRNA more strongly in the 
distal region of the GI tract, especially in the ileum, than in the stomach 
and proximal small intestine. The results are in contrast to the mRNA 
profile shown in adult rats where Fgfr2b is expressed highest in the 
forestomach and glandular stomach (Housley et al., 1994), suggesting that 
the difference in Fgfr2b mRNA level can be accounted by the difference 
in animal species.  
 
This study utilises the A33-CrePR mouse line that expresses Cre 
recombinase preferentially in the distal region of the GI tract (Malaterre et 
al., 2007) where Fgfr2b is expressed highly, and the Cre is activated upon 
RU486 administration. Western blot for Cre protein in the GI tract of 
A33-CrePR mice confirms this preferential expression. Additionally, 
RU486 administration for two or four weeks consecutively results in 
significant downregulation of Fgfr2b mRNA across the GI tract of A33-
CrePR
+
/Fgfr2b
flox/flox
, with the strongest downregulation observed in the 
distal colon, further providing evidence that the A33-CrePR line gives 
better Cre-mediated excision efficiency in the distal intestine than in the 
proximal small intestine. There is no significant difference in excision 
efficiency between two-week and four-week induction periods, although 
the four-week induction period displays a trend of stronger Fgfr2b 
downregulation. ISH with DIG-labelled Fgfr2 probe show that 
downregulation of Fgfr2b is accounted by the global reduction of Fgfr2b 
transcript across the intestine rather than mosaic deletion of Fgfr2b 
alleles.  
 
For this study, RU486 was administered for four weeks to ensure a higher 
extent of Fgfr2b downregulation while at the same time allowing the mice 
to develop any intestinal phenotypic abnormality. Body weight 
measurement was used as a preliminary parameter to determine whether 
downregulation of Fgfr2b affects the nutrient absorption function of small 
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and large intestines. A33-CrePR
+
/Fgfr2b
flox/flox
 mice show a consistent 
trend of, but insignificant, lower body weight compared to the control 
mice, suggesting that downregulation of Fgfr2b has minor effects on the 
overall absorption function of the intestines.  
 
This study, however, does not preclude changes in other factors, such as 
the absorption capacity of the villi, and level of plasma hormones that 
regulate appetite. Cholecystokinin (CCK), for example, is produced by 
endocrine cells of the duodenum and jejunum, and increased CCK 
expression is associated with decreased appetite (Naslund and Hellstrom, 
2007). Glucagon-like peptide-1 (GLP-1) and GLP-2 are secreted by the 
enteroendocrine cells in the ileum and colon, and function similarly as 
CCK (Naslund and Hellstrom, 2007). Therefore, it will be informative to 
investigate whether the A33-CrePR
+
/Fgfr2b
flox/flox
 mice have a higher 
level of plasma CCK, GLP-1 and GLP-2 that could have contributed to 
the trend of lower body weight observed in these mice compared to the 
controls. 
 
BrdU labelling and active CSP-3 immunostaining on cross sections along 
the different intestinal segments show normal level of proliferation and 
apoptosis in the A33-CrePR
+
/Fgfr2b
flox/flox
 mice. An alternative method of 
measuring proliferation using crypt microdissection also demonstrates 
normal crypt proliferation in the A33-CrePR
+
/Fgfr2b
flox/flox
 mice. In 
contrast to BrdU that labels cells in the S-phase (DNA replication phase) 
of a cell cycle, the vincristine sulphate used in the crypt microdissection 
technique causes mitotic cells to be arrested at metaphase, hence allowing 
accurate quantification on the number of mitotic cells in a full crypt 
volume (Alferez and Goodlad, 2007). However, one disadvantage 
associated with this technique is that the crypts in the duodenum are much 
smaller and have numerous mitotic figures compared to the crypts in the 
distal colon, resulting in frequent overlapping of one crypt with another 
and can result in inaccurate quantification. To overcome this, crypt 
microdissection was only performed on tissues from ileum and colon. 
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The intestinal epithelium of the A33-CrePR
+
/Fgfr2b
flox/flox
 mice also show 
largely normal differentiation markers, including MUC2-producing goblet 
cells, the chromogranin A/B-expressing enteroendocrine cells, and the 
lysozyme-expressing Paneth cells, suggesting that downregulation of 
Fgfr2b does not affect normal intestinal differentiation. Previous chapter 
has shown that loss of Fgfr2b during intestinal development leads to 
significant reduction of intestinal transcription factors, such as Tcf1 and 
Tcf4 (Chapter 3). In this study, Tcf4 mRNA expression is largely 
unperturbed in the A33-CrePR
+
/Fgfr2b
flox/flox
 mice, suggesting that total 
Fgfr2b ablation may be required to see an affect on Tcf4 mRNA 
expression, or an alternative signalling pathway may be regulating Tcf4 
mRNA expression in the adult gut.  
 
So far, our data show that downregulation of Fgfr2b does not affect 
intestinal proliferation, survival and differentiation, which is not an 
expected observation when a growth factor receptor is significantly 
downregulated. It is possible that total Fgfr2b ablation in the intestine 
may be needed to observe a phenotypic abnormality, and there is currently 
no inducible intestinal-specific Cre recombinase line that has 100% 
excision efficiency. Alternatively, Fgfr2b may not be essential in 
maintaining intestinal homeostasis due to possible functional redundancy. 
Expression analysis of the entire Fgfs and Fgfrs, except Fgf19 and Fgf23, 
show presence of numerous Fgfs and Fgfrs along the adult GI tract, 
suggesting that other Fgfs and Fgfrs may be required for maintaining 
intestinal homeostasis.  
 
Fgf18, for example, is expressed in the duodenum, jejunum and ileum as 
shown from our data. Interestingly, administration of recombinant mouse 
FGF18 into normal mice resulted in significant increased of duodenal, 
jejunal and ileal wet weights due to intestinal hypertrophy (Hu et al., 
1998), suggesting a role for Fgf18 in the small intestine. To date, no study 
has reported any intestinal defect in Fgf18
-/-
 mice, however absence of 
Fgf18 leads to perinatal lethality, and proliferation and differentiation 
defects during osteogenesis, chondrogenesis and lung development (Usui 
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et al., 2004, Ohbayashi et al., 2002). In addition, the requirement of Fgfr3, 
the receptor for Fgf18, has been demonstrated to play a role in intestinal 
homeostasis.  
 
Fgfr3
-/-
 mice, in which both isoforms of this receptor were ablated, when 
analysed between postnatal day 1 and 28 showed 50% reduction in the 
number of intestinal crypts and reduced !-catenin/Tcf4 signalling (Vidrich 
et al., 2009). However, when analysed at ten weeks of age, loss of Fgfr3
-/-
 
led to a modest increase in the number of replicating TA cells and the size 
of crypts (Arnaud-Dabernat et al., 2008). The difference in results 
suggests that Fgfr3 plays different functions during postnatal day 1 to 28, 
a period that still requires active stem cell proliferation and crypt 
morphogenesis, and ten weeks of age, a period where the number of 
crypts is static and crypt stem cells are relatively quiescent compared with 
the suckling mouse intestine. While we have shown that Fgfr2b is not 
required in the intestine of six-week-old mice, a recent study expressing 
ubiquitous soluble dominant negative FGFR2b from birth to six weeks 
postnatally reported no overt gut defect in the GI tract (Parsa et al., 2008), 
providing further evidence that Fgfr2b is not essential for postnatal 
intestinal development and in the unperturbed adult intestine.   
 
In both murine and human prostate carcinoma, decreased expression of 
FGFR2 resulted in overexpression of FGFR1 (Jin et al., 2003, Yasumoto 
et al., 2004). However, our data showed that Fgfr1b does not compensate 
for the significant downregulation of Fgfr2b, suggesting that the 
compensatory mechanism of FGFR1-FGFR2 may be context-dependent. 
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4.5 Conclusion 
 
In conclusion, we have shown that Fgfr2b and Fgf10 are expressed 
throughout the adult mouse GI tract from forestomach to distal colon, 
with a higher expression towards the distal region of the intestine. The 
A33-CrePR/Fgfr2b
flox/flox
 model is ideal for this study due to its higher 
efficiency of excising the Fgfr2b alleles in the distal region of the 
intestine than in the proximal intestine. 
 
We have also shown that Fgfr2b is not required for maintaining intestinal 
homeostasis, as severe downregulation of Fgfr2b across the adult intestine 
gives little or no effect in intestinal epithelial proliferation, survival and 
differentiation. This can be accounted by functional redundancy of Fgfr2b 
since the adult GI tract also expresses a wide variety of other Fgfs and 
Fgfrs. Fgfr2b may also be essential in other contexts, such as intestinal 
injury and wound healing, which are explored in the next chapter. 
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Chapter 5: Fgfr2b in intestinal injury 
 
5.1 Introduction 
 
Fgfs and Fgfrs have been implicated in tissue injury and wound healing. 
In the GI tract specifically, Fgfr2b and Fgf10 mRNA expression was 
massively upregulated at the base of the intestinal crypts following small 
bowel resection, accompanied by significant increase in epithelial 
proliferation, suggesting a role for Fgfr2b and Fgf10 in enhancing the 
process of gut adaptation (Tai et al., 2009). Fgfr2b and Fgf7 mRNA was 
overexpressed in intestinal tissues obtained from patients with IBD, 
implying a role for Fgfr2b and Fgf7 in intestinal injury (Finch et al., 1996, 
Brauchle et al., 1996). Similar overexpression was also observed in 
inflamed and adapting mucosa of patients with UC and familial 
adenomatous polyposis (FAP), further suggesting an involvement of 
Fgfr2b and Fgf7 in intestinal repair and adaptive changes (Otte et al., 
2005). Administration of either recombinant human (rh) FGF10 or 
rhFGF7 to DSS-induced colitis models of IBD reduced the severity of 
colitis injury, promoted intestinal healing, and increased epithelial 
proliferation (Byrne et al., 2002, Egger et al., 1999, Miceli et al., 1999, 
Zeeh et al., 1996). Similar observations were also reported in a small 
intestinal ulceration model in rat following administration of either 
rhFGF7 or rhFGF10, further suggesting that Fgfr2b and its ligands 
promote wound healing by stimulating epithelial proliferation (Han et al., 
2000, Playford et al., 1998). 
 
While these studies demonstrated the therapeutic roles of Fgf7, Fgf10 and 
Fgfr2b in intestinal injury and wound healing, the requirement for these 
growth factors and receptor in these models has not been established. This 
study therefore utilises the A33-CrePR
+
/Fgfr2b
flox/flox
 line to study the 
requirement of Fgfr2b in DSS-induced UC. The A33-
CrePR
+
/Fgfr2b
flox/flox
 line provides an excellent model for this study due to 
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the high excision efficiency of the conditional Fgfr2b alleles in the adult 
colon. We hypothesise that substantial downregulation of Fgfr2b in 
colonic epithelium leads to increased severity of colitis, and delayed 
wound healing. 
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5.2 Materials and methods 
 
5.2.1 RT-PCR 
 
Eighteen six-week old male Fgfr2b
flox/flox
 mice were administered 4% 
(w/v) DSS (31403; Sigma-Aldrich) in their drinking water for five days 
consecutively, followed by normal drinking water. Mice were culled in 
batches of three at the following time-points; prior to DSS administration 
(Day 0), followed by one day (Day 1), three days (Day 3), five days (Day 
5), seven days (Day 7), and thirteen days (Day 13) after DSS 
administration. RNA was extracted from proximal and distal colon 
respectively, and cDNA synthesis was performed as previously described 
(Section 2.4). Taqman RT-PCR was performed for Fgf1, Fgf3, Fgf7, 
Fgf10, Fgf22, Fgfr1b, and Fgfr2b as previously described (Section 2.4.6).  
 
5.2.2 In situ hybridisation 
 
Similar setup of experiment as Section 5.2.2 was performed, except 
twelve mice were used and culled in batches of two at each time-point. 
Gut tissues were dissected, fixed, processed and embedded as previously 
described (Section 2.5.2). ISH for Fgfr2b was performed as previously 
described (Section 2.3.3). 
 
5.2.3 RU486 and DSS administration 
 
RU486 mix was prepared as previously described (Section 2.2.1). Forty 
six-week-old male A33-CrePR
+
/Fgfr2b
flox/flox
 and Fgfr2b
flox/flox
 mice were 
given 250 µl of RU486 mix until the mice were culled. After the initial 
fourteen days of RU486 administration, mice were given 4% (w/v) DSS 
in drinking water for five days consecutively, followed by normal 
drinking water. Mice were culled in batches of six (three Fgfr2b
flox/flox
 and 
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three A33-CrePR
+
/Fgfr2b
flox/flox
 mice) on one day (Day 1), three days 
(Day 3), five days (Day 5), seven days (Day 7), and thirteen days (Day 
13) after DSS administration. 
 
5.2.4 Histology scoring 
 
Mice were injected with BrdU solution (550891; BD Biosciences) at 50 
mg/kg 1 hr before culling. Gut tissues were dissected in cold PBS, fixed, 
processed and embedded as previously described (Section 2.5.2). Tissue 
sections were stained with H&E as previously described (Section 2.5.5). 
Histology scoring was performed in a blinded fashion by a pathologist 
according to the parameters shown in Table 5.1. The scores ranged from 0 
(normal), 1 (mild), 2 (moderate) to 3 (severe).  
 
5.2.5 Immunohistochemistry 
 
Immunohistochemistry was performed with anti-BrdU and anti-CSP-3 
antibodies as previously described (Section 2.5). Morphometry was 
performed as previously described (Section 2.7). 
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Table 5.1 Histologic scoring colitis method. 
 
 
 
 
 
 
 
 
 
 
 
 
Feature scored Score Description
Mononuclear infiltration 0 None
1 Mucosa
2 Mucosa and submucosa
3 Transmural
Neutrophil infiltration 0 None
1 Mucosa
2 Mucosa and submucosa
3 Transmural
Loss of crypts 0 None
1 1-2 crypts
2 3-5 crypts
3 >5 crypts
Ulceration 0 None
1 0-10 crypts
2 >10 crypts
3 >10 crypts and lamina propria
Hyperplasia 0 None
1 up to 3-fold increase 
2 3- to 6-fold increase
3 >6-fold increase 
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5.3 Results 
 
5.3.1 Fgf7 is the main ligand for Fgfr2b during intestinal 
injury and wound healing 
 
RT-PCR was used to determine the expression levels of Fgfr2b, Fgfr1b 
and their ligands during intestinal injury and wound healing. Proximal and 
distal colon was assessed separately to determine any differential 
expression level between them. While some time points show differential 
expression of Fgfs and Fgfrs between proximal and distal colon, most 
time points show closely correlated expression levels (Figure 5.1). 
Expression data show a substantial 80-fold upregulation of Fgf7 
expression one day following DSS administration, and this level decreases 
over the duration of the experiment to 50-fold, thirteen days after DSS 
administration (Figure 5.1). Fgf10 mRNA levels, in contrast, is initially 
upregulated by 5-fold, and this level gradually peaks to 12-fold after one 
week, then subsequently decreases to 9-fold after three days. Fgf1 mRNA 
level is also initially upregulated by 5-fold, and gradually decreases to 
3.5-fold thirteen days after DSS administration. Fgfr2b mRNA is initially 
upregulated by 40-fold, and this level gradually increases to 50-fold over 
the thirteen days duration of the DSS treatment. Fgf3, Fgf22 and Fgfr1b 
mRNA levels, in contrast, are upregulated less than 3-fold initially, and 
the level stays relatively unchanged throughout the thirteen days duration. 
ISH on colonic gut rolls at all time points using DIG-labelled Fgfr2 probe 
show increased expression of Fgfr2b mRNA in injured crypts, epithelial 
cells undergoing re-epithelialisation, restituting crypts, and basal crypts of 
hyperplastic epithelium (Figure 5.2). 
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Figure 5.1 Continue on next page 
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Figure 5.1 Continue on next page 
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Figure 5.1 Expression levels of Fgfr2b, Fgfr1b and their ligands in 
proximal and distal colon of Fgfr2b
flox/flox
 mice with colitis. 
RNA was extracted from proximal and distal colon at various time points, 
and subjected to Taqman RT-PCR. D0: Day 0, D1: Day 1, D3: Day 3, D5: 
Day 5, D7: Day 7, D13: Day 13. ‘D0’ represents the time-point prior to 
DSS administration. All data was normalised to the mean of Gapdh 
expression, and expression level was relative to that of ‘D0’. Black 
asterisks indicate significance calculated between the ‘overall proximal 
and distal value’ and the value at ‘D0’, whereas red asterisks indicate 
significance calculated between the proximal and distal intestine values. 
Error bars (±SEM) came from three experiments; n = 3 mice/group. 
*P<0.05, **P<0.01, ***P<0.001 by Student’s t-test. 
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Figure 5.2 Continue on next page 
 
 
 155 
 
Figure 5.2 Representative images of H&E-stained (left panel) and 
Fgfr2 ISH (right panel) distal colon with ulcerative colitis.  
These images are a representation of the progression of colitis shown by 
two Fgfr2b
flox/flox
 mice at each time point. Images came from Day 0 (no 
DSS treatment), Day 1 and 3 (representative image from two time points), 
Day 5, Day 7 and Day 13. Hyperplasia is seen throughout all the time 
points with various degrees of severity. Negative control came from DIG-
labelled sense Fgfr2 probe on Day 0 tissue sections.  
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5.3.2 Characterisation of DSS-induced colitis  
 
Microscopic examination on the GI tract of Fgfr2b
flox/flox
 mice, following 
DSS administration for five days consecutively, shows reproducible 
ulcerations of the large intestine (Fig. 5.2). At Day 1 and 3 following DSS 
administration, the colon shows signs of mucosal erosion including 
epithelial loss, crypt shortening, and inflammation. Lesions to the 
intestinal mucosa occurs as discrete areas surrounded by normal 
epithelium, consistent with a previous study in this model system (Wirtz 
et al., 2007). Epithelial cell damage is confined to the colon and does not 
involve other regions of the GI tract, such as the small intestine (data not 
shown). Crypt loss and oedema are evident by Day 5. Clear signs of 
mucosal healing, including surface re-epithelialisation and hyperplastic 
crypts, are evident as early as three days after DSS administration. 
 
5.3.3 Downregulation of Fgfr2b increases severity of 
colitis and delays wound healing 
 
The requirement of Fgfr2b in intestinal injury and wound repair in DSS-
induced colitis was assessed using the A33-CrePR
+
/Fgfr2b
flox/flox
 mice. 
Following a combination of RU486 and DSS administration regime, the  
A33-CrePR
+
/Fgfr2b
flox/flox
 mice show several major differences in disease 
severity compared to the control Fgfr2b
flox/flox
 mice. The A33-
CrePR
+
/Fgfr2b
flox/flox
 mice show a higher degree of crypt loss and 
ulceration three days after DSS administration (Figure 5.3). The lesions 
are more widespread, and often include the caecum (data not shown). 
Mononuclear and neutrophil infiltrations appear to be largely similar 
between the two groups at all time points. Cryptitis, crypt abscesses, 
goblet cell depletion and fibrosis are rarely observed in both groups at all 
time points.  
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Interestingly, repair of damaged epithelium is also dramatically impaired 
in the A33-CrePR
+
/Fgfr2b
flox/flox
 mice with minimal surface re-
epithelialisation observed three days after DSS administration. The A33-
CrePR
+
/Fgfr2b
flox/flox
 mice also maintain higher hyperplasia, loss of crypts 
and ulceration scores at Day 7 and Day 13 after DSS administration, while 
at these time points, the control mice have significantly lower 
corresponding scores. The overall score, which only takes account of 
mononuclear and neutrophil infiltrations, loss of crypts, ulceration, and 
hyperplasia, shows a consistently high severity of injury and delayed 
wound healing in the A33-CrePR
+
/Fgfr2b
flox/flox
 mice compared to the 
Fgfr2b
flox/flox
 mice (Figure 5.3). 
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Figure 5.3 Continue on next page 
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 160 
Figure 5.3 Continue on next page 
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Figure 5.3 Histological scoring of the large intestine of Fgfr2b
flox/flox
 
and A33CrePR
+
/Fgfr2b
flox/flox
 mice following combination of RU486 
and DSS administration. 
Scoring was based on overall assessment of the proximal and distal colon. 
D1: Day 1, D3: Day 3, D5: Day 5, D7: Day 7, D13: Day 13. The 
A33CrePR
+
/Fgfr2b
flox/flox
 mice have more severe injury with delayed 
wound healing. Error bars (±SEM) came from 8 mice/group. The overall 
data only took account of mononuclear and neutrophil infiltrations, loss of 
crypts, ulceration and hyperplasia. *P<0.05; **P<0.01 by Student’s t-test. 
 
 
5.3.4 Downregulation of Fgfr2b significantly reduces 
epithelial proliferation 
 
To determine whether the A33-CrePR
+
/Fgfr2b
flox/flox
 mice have an 
imbalance epithelial proliferation and apoptosis, tissues were 
immunostained for BrdU and CSP-3, and the positive staining was 
quantified. A33-CrePR
+
/Fgfr2b
flox/flox
 mice consistently show significant 
reduction of epithelial proliferation at all time points, except Day 13, in 
the colonic crypts, compared to the Fgfr2b
flox/flox
 mice (Figure 5.4). In 
contrast, both mice groups rarely show apoptosis, and quantification of 
apoptotic cells show no significant difference between them (Figure 5.4). 
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Figure 5.4 Comparison of proliferation and apoptosis in colon of 
Fgfr2b
flox/flox
 and A33CrePR
+
/Fgfr2b
flox/flox
 following combination of 
RU486 and DSS administration. 
(A) Representation of BrdU immunostaining in proximal colon epithelium 
between both mice groups. 
A 
B 
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(B) Quantification of the mean percentage of cells positively stained cells 
in 20 longitudinally sectioned colonic crypts. D1: Day 1, D3: Day 3, D5: 
Day 5, D7: Day 7, D13: Day 13. The A33CrePR
+
/Fgfr2b
flox/flox
 mice show 
reduced epithelial proliferation compared to the Fgfr2b
flox/flox
 mice. All 
data was presented as mean (±SEM). * P<0.05; ** P<0.01; *** P<0.001 
by Student’s t-test; n = 8 animals/group. 
 
 
5.3.5 Fgfr1b can compensate for the significant 
downregulation of Fgfr2b during injury and wound 
repair 
 
Fgfr1b expression level was compared between A33-CrePR
+
/Fgfr2b
flox/flox
 
and Fgfr2b
flox/flox
 mice to determine whether Fgfr1b may compensate for 
the downregulation of Fgfr2b during tissue injury and wound healing. RT-
PCR data shows a trend of upregulation of Fgfr1b mRNA expression at 
all time points, with significance noted at Day 3 and Day 7 in the A33-
CrePR
+
/Fgfr2b
flox/flox
 mice compared to the Fgfr2b
flox/flox
 mice (Figure 
5.6). 
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Figure 5.5 Relative expression of Fgfr1b in the distal colon of 
Fgfr2b
flox/flox
 and A33CrePR
+
/Fgfr2b
flox/flox
 following combination of 
RU486 and DSS administration. 
Fgfr1b can compensate for the downregulation of Fgfr2b with 
significance observed at Day 3 and Day 7. All data was normalised to the 
means of Gapdh expression, and error bars (±SEM) came from three 
experiments; n = 3 animals/group. *P<0.05 by Student’s t-test. 
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5.4 Discussion 
 
There is currently no study that compares expression of multiple Fgfs and 
Fgfrs in a colitis model, and this study not only provides such comparison 
but also the progression of the gene expression across a set of time points. 
In our colitis model, Fgfr2b, Fgf7 and Fgf10 are the top three genes that 
are significantly upregulated at all time points. Interestingly, Fgf7 shows 
the highest mRNA expression (approximately 90-fold) starting from one 
day after DSS administration compared to all other Fgfs, suggesting that 
Fgf7 is the main ligand for Fgfr2b during injury. Such high expression 
level correlates with previous studies showing upregulation of Fgf7 
mRNA by 50 to 150-fold higher in patients with IBD (Brauchle et al., 
1996), and by 160-fold within 24 hours in skin injury in rats (Werner et 
al., 1992).  
 
While Fgf7 expression decreases over time, Fgf10 expression is 
upregulated at later time points even though the level of expression is 
nowhere near the level of Fgf7, indicating that Fgf10 may play a more 
important role in the wound healing process. Administration of rhFGF10 
has been shown to stimulate epithelial proliferation in small intestinal 
ulceration models, and induce in vitro migration in human epithelial 
colorectal adenocarcinoma Caco-2 cell line (Han et al., 2000), suggesting 
that Fgf10 acts as a wound-healing agent to stimulate epithelial cell 
proliferation and hastens wound closure. 
 
The higher Fgfr2b expression level than Fgfr1b throughout the time 
points suggests that Fgfr2b is the more important receptor during 
intestinal injury and wound healing. While the requirement of Fgfr1b in 
intestinal injury and wound healing has not been investigated, Fgfr1b
-/-
 
mice have no obvious phenotype, but Fgfr1c
-/- 
embryos died at E9.5 
during gastrulation due to defect in cell migration through the primitive 
streak (Partanen et al., 1998). Mice deficient in both Fgfr1 isoforms 
displayed phenotypes similar to that of Fgfr1c
-/-
 embryos (Deng et al., 
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1994, Yamaguchi et al., 1994), demonstrating the possible functional 
redundancy of Fgfr1b. 
 
The expression level of Fgfr2b, however, dos not match the expression 
level of Fgf7. In normal human intestine, Fgf7 expression has been 
demonstrated in stromal fibroblasts underlying the mature enterocytes in 
the colon, but in human IBD cases, Fgf7 expression can also contributed 
by activated (but not resting) intestinal !" intraepithelial T lymphocytes 
(IELs) (Finch et al., 1996, Rubin et al., 1989, Aaronson et al., 1991, 
Boismenu and Havran, 1994). This suggests that the high Fgf7 expression 
observed earlier is contributed by the additional source of Fgf7 
expression, and the activation of T-lymphocytes may be independent of 
the level of Fgfr2b. Mice deficient of !" (TCR"-/-) have increased 
susceptibility to DSS-induced mucosal injury and delayed wound repair, 
suggesting that !" IEL cells help preserved the integrity of damaged 
epithelium by providing localised delivery of KGF (Chen et al., 2002). 
 
ISH with DIG-labelled antisense Fgfr2 probe show an upregulation of 
Fgfr2b mRNA in epithelial crypts at all time points, including damaged 
crypts, basal hyperplastic crypts, and restituting crypts, demonstrating that 
Fgfr2b is expressed by cells that require a strong proliferation impulse. 
Our data is in agreement with a previous study demonstrating 
overexpression of Fgfr2b in the mucosal epithelial cells lining the colonic 
crypts of IBD patients (Finch et al., 1996, Brauchle et al., 1996).  
 
To better understand the requirement of Fgfr2b in intestinal injury and 
wound healing, both Fgfr2b
flox/flox
 and A33-CrePR
+
/Fgfr2b
flox/flox
 mice 
were given a combination of RU486 and DSS to ensure constant 
downregulation of Fgfr2b during colitis. The colon of these mice was 
monitored over a period of thirteen days. Histological scoring data show a 
more severe loss of crypts and ulceration in the A33-CrePR
+
/Fgfr2b
flox/flox
 
mice than in the control Fgfr2b
flox/flox
 mice, suggesting that 
downregulation of Fgfr2b increases the susceptibility to intestinal injury. 
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Surprisingly, the mononuclear and neutrophil infiltration scores are 
largely similar between both mice groups, indicating that downregulation 
of Fgfr2b does not affect the infiltration ability of mononuclear and 
neutrophils at the site of injury. A previous study on Fgfr2b-null skin 
showed a significant increase of !" IELs in Fgfr2b-null skin (Grose et al., 
2007), however we were not able to assess the level of !" IELs in our 
models as the antibody failed to recognise the antigen in both formalin-
fixed paraffin-embedded and fresh frozen tissue sections by IHC in our 
hands. There is little evidence of cryptitis, crypt abscesses, goblet cell 
depletion and fibrosis, which are phenotypes associated with more 
advanced stages of colitis, indicating that the level of Fgfr2b 
downregulation in our models may not be sufficient to observe these 
advanced stages.  
 
Our data also shows that regeneration of the intestinal mucosa is 
significantly delayed but not abrogated in the A33-CrePR
+
/Fgfr2b
flox/flox
 
mice. While the control A33-CrePR
+
/Fgfr2b
flox/flox
 mice show high extent 
of hyperplasia at Day 3 that gradually decreases over time, the A33-
CrePR
+
/Fgfr2b
flox/flox
 mice show a peak hyperplasia score at Day 7. 
Additionally, A33-CrePR
+
/Fgfr2b
flox/flox
 mice have significantly higher 
severity score of loss of crypts and ulceration at Day 7 and Day 13, 
implying that downregulation of Fgfr2b leads to delayed wound healing.  
 
Assessment of epithelial proliferation and apoptosis on the colonic crypts 
shows a significant reduction of proliferation in the A33-
CrePR
+
/Fgfr2b
flox/flox
 mice, suggesting that this observation contributes to 
the increased susceptibility to injury and delayed wound healing observed 
in these mice. Our findings are consistent with a previous study in a skin 
injury model showing that mice expressing dominant-negative Fgfr2b 
transgene displayed substantially delayed re-epithelialisation in wounded 
skin due to reduced proliferation rate of epidermal keratinocytes at the 
wound edge (Werner et al., 1994). Interestingly, while epithelial 
proliferation in the controls decreases over the thirteen days period, the 
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epithelial proliferation in the A33-CrePR
+
/Fgfr2b
flox/flox
 mice increases 
slowly and gradually with a peak proliferation rate achieved at Day 13, 
even though the peak rate is nowhere near to that of the controls, 
indicating that the epithelial cells in the A33-CrePR
+
/Fgfr2b
flox/flox
 mice 
are attempting to proliferate as much as possible even at Day 13. It will be 
interesting to extend the duration of the experiment beyond thirteen days 
to determine whether the A33-CrePR
+
/Fgfr2b
flox/flox
 mice will achieve 
similar peak proliferation rate as the controls, and the length of time 
needed for these mice to complete the wound healing process. 
Additionally, the level of apoptosis is unchanged in the A33-
CrePR
+
/Fgfr2b
flox/flox
 mice compared to the controls, suggesting that 
downregulation of Fgfr2b does not affect cell survival during injury and 
wound healing.  
 
The existence of parallel or compensatory mechanisms operating to 
maintain intestinal homeostasis may account for the ability of the A33-
CrePR
+
/Fgfr2b
flox/flox
 mice to eventually repair intestinal lesions. In both 
murine and human prostate carcinoma, decreased expression of FGFR2 
resulted in overexpression of FGFR1 (Jin et al., 2003, Yasumoto et al., 
2004). Indeed, our data show an upregulation trend of Fgfr1b expression 
in the colitis model of A33-CrePR
+
/Fgfr2b
flox/flox
 mice, with significance 
observed at Day 3 and 7 after DSS administration, suggesting that Fgfr1b 
can, to some extent, compensate for the downregulation of Fgfr2b. 
Despite this, the A33-CrePR
+
/Fgfr2b
flox/flox
 mice continue to have more 
severe injury and delayed wound healing than the controls, suggesting that 
Fgfr1b compensation is insufficient to induce the protective effect and 
tissue repair in the absence of Fgfr2b, and other cytokines including other 
Fgfs and Fgfrs may contribute to the wound repair process. 
 
Fgf2, for example, has been shown to be upregulated within 12 hours 
following radiation of the small intestine, and administration of rhFGF2 
prior to irradiation significantly enhanced crypt stem cell survival 
(Houchen et al., 1999). Administration of rhFGF20 to DSS-colitis mice 
significantly reduced the severity and extent of mucosal damage, and 
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enhanced wound repair (Jeffers et al., 2002). This was an interesting 
finding, given that Fgf20 is not expressed in the normal mouse GI tract as 
shown by our data (Chapter 4, Figure 4.10). This is also confirmed by 
another study showing Fgf20 mRNA being absent in the normal intestinal 
mucosa but present in adenomas of Apc
Min/+ 
mice (Chamorro et al., 2005), 
indicating a complex mechanism by which Fgfs and Fgfrs act during 
tissue injury and wound healing, including for members that are not 
expressed in normal GI tissue. 
 
Numerous studies have so far shown the therapeutic roles of Fgf7 and 
Fgf10 in intestinal injury and wound healing, but no study to date has 
investigated the specific roles/requirement of Fgf7 or Fgf10 in this 
scenario. Fgf7
-/-
 mice have no overt phenotype, and Fgf7 is not required 
for skin injury and healing, suggesting a possible functional redundancy 
of Fgf7 (Guo et al., 1996). However, the Fgf7
-/-
 mice will need to be 
challenged with DSS to ascertain its requirement in intestinal injury and 
wound healing. Due to perinatal lethality associated with Fgf10
-/-
, 
investigation on the requirement of this growth factor in intestinal injury 
and wound healing will require a conditional Fgf10 line, and this line has 
recently been generated (Abler et al., 2009). Subsequent crossing of 
conditional Fgf10 line with the A33-CrePR generating the A33-
CrePR/Fgf10
flox/flox
 line will enable the investigation on the requirement of 
Fgf10 in DSS-induced colitis. 
 
 
 
 
 
 
 
 
 
 
 170 
5.5 Conclusion 
 
In conclusion, we have shown that Fgf7 is the main ligand for Fgfr2b 
during colonic injury and wound healing. Fgf10 may play a role in the 
wound healing process, but its requirement in colonic injury and wound 
healing will need the use of a conditional Fgf10 line crossed to an 
inducible intestinal-specific Cre line. Epithelial cells that require strong 
proliferation impulse, such as injured and regenerating crypts, heavily 
express Fgfr2b. 
 
We have also shown that Fgfr2b is required for reducing colonic 
susceptibility to injury, and promoting wound repair. Downregulation of 
Fgfr2b leads to a greater extent of injury and delays wound healing in 
DSS-induced colitis, contributed by reduced epithelial proliferation. This 
knowledge will contribute to our understanding of the roles played by 
Fgfs and Fgfrs in human IBD. 
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Chapter 6: Characterisation of stomach-
specific promoters 
 
6.1 Introduction 
 
Normal gastric development in the mouse requires Fgfr2b and Fgf10, as a 
previous study examining Fgfr2b
-/-
 or Fgf10
-/-
 embryos showed 
disproportionately reduced glandular stomach with absence of early 
differentiation markers, including the GATA family of transcription 
factors and H
+
/K
+
-adenosine triphosphate (ATP4b), and abnormal 
expression of the hedgehog family of signalling molecules (Spencer-Dene 
et al., 2006). In the adult rat stomach, Fgfr2b mRNA is expressed at a 
level of two to three times higher than that in the liver and intestine 
(Housley et al., 1994). FGFR2b is also expressed in the normal human 
gastric tissue by parietal cells and surface mucous cells, and is 
upregulated in gastric carcinoma tissues (Matsunobu et al., 2006, Shin et 
al., 2000), suggesting a role for Fgfr2b in normal gastric homeostasis and 
carcinogenesis. However, the requirement of Fgfr2b in gastric 
homeostasis and injury has not been demonstrated, and therefore, this 
study broadly aims to understand how targeted ablation of Fgfr2b in adult 
stomach can affect epithelial proliferation, survival, differentiation, and 
response to injury.  
 
A previous study has shown that parietal cell ablation leads to 
accumulation of pre-parietal, pre-neck cells and depletion of zymogenic 
chief cells, suggesting that parietal cells are required for normal 
coordination of migration-associated terminal differentiation of pit, neck 
and chief cells (Li et al., 1996). Therefore, using an animal model to study 
Fgfr2b ablation in the parietal cells will allow us to understand the 
requirement of Fgfr2b in gastric homeostasis. Additionally, the first line 
of defence against injury and Helicobacter species infiltration is the 
mucus produced by the gastric surface cells, and targeted ablation of 
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Fgfr2b in the gastric surface mucosa will allow us to understand the 
requirement of Fgfr2b during injury. We hypothesise that ablation of 
Fgfr2b in the gastric parietal and surface mucous cells leads to disrupted 
epithelial proliferation and apoptosis, aberrant differentiation, and 
increased susceptibility to injury. 
 
As loss of Fgfr2b is perinatal lethal, this study will require the use of a 
stomach-specific inducible Cre-expressing line crossed with our 
conditional Fgfr2b line. Since there is currently no inducible stomach-
specific Cre line, the initial aim of this study is to generate two novel 
inducible stomach-specific Cre lines that target Cre expression into the 
two sites of Fgfr2b expression independently: parietal cells and surface 
mucous cells. The minimal promoters used were from Atp4b and trefoil 
factor 1 (Tff1) respectively. The Atp4b minimal promoter has been well 
characterised and used successfully by several studies to direct transgene 
expression into the parietal cells (Syder et al., 2004, Oh et al., 2005). In 
contrast, the Tff1 minimal promoter has been partially characterised 
(Terada et al., 2001), and has not been used in any study to date to drive 
transgene expression, therefore the Tff1 promoter region will require 
further characterisation to find the optimal region to drive stomach-
specific Cre expression. Generation of these inducible stomach-specific 
Cre-expressing lines would represent important new tools for the future to 
study loss-of-function of Fgfr2b and other conditional alleles in normal 
development and disease models, such as the Helicobacter felis infection 
model of gastric adenocarcinoma (Wang et al., 1998). 
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6.2 Materials and Methods 
 
6.2.1 In situ hybridisation 
 
Adult stomach tissue from three six-week-old male C57BL/6 mice 
weighing approximately 23 g to 26 g was dissected, fixed, and embedded 
as previously described (Section 2.5.2). To visualise the localisation and 
expression of Fgfr2b mRNA, ISH was performed on tissue sections using 
DIG-labelled antisense Fgfr2 probe as previously described (Section 
2.3.3). 
 
6.2.2 DNA cloning 
 
Genomic DNA was extracted from 0.5 cm
3
 of liver tissue from a six-
week-old male C57BL/6 mouse according to Section 2.10.1. Atp4b 
minimal promoter and two Tff1 promoter fragments (Tff1_Fragment 3 and 
Tff1_Fragment 5) were amplified by PCR from the genomic DNA using 
PfuUltra High-Fidelity Taq polymerase (600382; Stratagene) to obtain 
minimal nucleotide errors. Only two Tff1 promoter fragments were 
generated by PCR because the remaining Tff1_Fragment 1, 2 and 4 could 
be easily generated by restriction digest from Tff1_Fragment 5. Atp4b and 
Tff1 promoter fragments were generated with additional restriction sites 
on either end to facilitate cloning into a vector (Figure 6.1 and Table 6.1). 
The 20 µl PCR reaction contained 1X PfuUltra HF reaction buffer, 0.2 
mM of each dNTP, 2.0 or 2.5 mM of MgCl2, 0.3 µM of each primer, 1 U 
of PfuUltra HF DNA polymerase, and 50 ng of genomic DNA. The PCR 
cycling parameters were similar to Section 2.4.4, except the annealing 
temperature of the primers was according to Table 6.1. PCR products 
were analysed by agarose gel electrophoresis to confirm correct amplicon 
size (Section 2.4.5), and gel-purified to obtain a pure amplicon (Section 
2.10.2). 
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PCR products were digested with the appropriate restriction enzymes 
corresponding to their additional restriction sites, and column-purified as 
previously described (Section 2.10.2). An appropriate amount (see 
formulae below) of luciferase cloning vector pGL3-Basic (E1751, 
Promega) was digested and column-purified as previously. The amount of 
luciferase cloning vector required was calculated according to the 
following formulae: 
 
amount of vector (ng) x size of insert (kb) x 3 = amount of insert (ng) 
 
The purified PCR fragments were ligated into the purified cloning vectors, 
and the recombinant plasmids were transformed into E. coli DH5! cells 
(Section 2.10.4 and 2.10.6). Twelve transformed colonies for each 
recombinant plasmid were grown in 5 ml mini LB cultures supplemented 
with 50 µg/ml ampicillin, and recombinant plasmids were purified from 
these cultures (Section 2.10.7). DNA sequencing was performed on 150 
ng of the recombinant plasmids to validate the nucleotide sequence 
accuracy of the PCR fragments (Section 2.10.8). Tff1_Fragment 5 was 
sequenced with primers SEQ1 to SEQ10, Tff1_Fragment 3 was 
sequenced with a combination of SEQ1, and SEQ6 to SEQ10, and Atp4b 
minimal promoter was sequenced with a combination of SEQ1, SEQ11 
and SEQ12 (Table 6.2). Once the nucleotide sequences were verified to be 
100% accurate, the mini-cultures were used to inoculate 250 ml maxi LB 
cultures supplemented with 50 µg/ml ampicillin, and recombinant 
plasmids were purified from these cultures (Section 2.10.7). 
 
The recombinant plasmid of Tff1_Fragment 5 was separately double 
digested with appropriate restriction enzymes corresponding to 
Tff1_Fragment 1, Tff1_Fragment 2 and Tff1_Fragment 4, and column-
purified (Section 2.10.2, 2.10.3 and Table 6.1). An appropriate amount of 
the pGL3-Basic vector was digested and column-purified similarly. The 
purified PCR fragments were ligated into the purified cloning vectors, and 
the recombinant plasmids were transformed into E. coli DH5! cells as 
size of vector (kb)                        1 
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previously. Five transformed colonies for each recombinant plasmid were 
grown in 5 ml mini LB cultures supplemented with 50 µg/ml ampicillin, 
and recombinant plasmids were purified from these cultures (Section 
2.10.7). Following a test restriction digest on a small amount of the 
recombinant plasmids and subsequent verification of DNA fragment size 
by agarose gel electrophoresis, one mini culture from each recombinant 
plasmid was used to inoculate 250 ml maxi LB cultures supplemented 
with 50 µg/ml ampicillin, and recombinant plasmids were purified from 
these cultures (Section 2.10.7). 
 
6.2.3 Promoter analyses 
 
All five Tff1 luciferase constructs were transiently transfected into three 
cell lines: GSM10 (a mouse gastric surface mucous cell line), AGS and 
HGT101 (two human gastric cancer lines), whereas the Atp4b luciferase 
construct was transiently transfected into MGE507 (a mouse parietal cell 
line) (Section 2.11.1). Transient transfection and luciferase assay were 
performed according to Section 2.11.4 and 2.11.5. Following verification 
that Tff1_Fragment 1 (thereafter known as ‘Tff1 minimal promoter’) and 
Atp4b minimal promoter gave the best luciferase activity, both luciferase 
constructs were transiently transfected into 3T3 (mouse fibroblast), HC11 
(mouse mammary epithelium) and nTERT (human keratinocyte) cell lines 
to determine the specificity of these minimal promoters. Transient 
transfection and luciferase assay were performed as previously. 
 
To determine the positive regulatory elements on the Tff1 minimal 
promoter, the minimal promoter was transiently transfected into two 
separate GSM10 cell lines that were previously grown for 24 hrs in either 
serum-free media or serum-free media supplemented with 10 ng/ml 
epidermal growth factor (EGF). Transient transfection and luciferase 
assay were performed as previously. 
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6.2.4 Generation of transgenic constructs 
 
Both luciferase constructs carrying the Tff1 and Atp4b minimal promoters 
were double digested with their respective restriction enzymes to obtain 
the minimal promoters, made blunt-ended by Klenow polymerase 
(M0210L; NEB), and gel-purified (Section 2.10.2, 2.10.2 and Fig. 6.1). A 
CreER
T2
 plasmid (a kind gift from Prof. Chambon, Strasbourg, France) 
was double digested with Nde1 and BspEI, made blund-ended and gel-
purified as previously. Both minimal promoters were ligated into the 
CreER
T2
 plasmid, and the recombinant plasmids were transformed into E. 
coli DH5! cells (Section 2.10.4 and 2.10.6). Twelve transformed colonies 
for each recombinant plasmid were grown in 5 ml mini LB cultures 
supplemented with 50 µg/ml ampicillin, and recombinant plasmids were 
purified from these cultures (Section 2.10.7). DNA sequencing was 
performed on 150 ng of the recombinant plasmids to verify the orientation 
of the cloned minimal promoters (Section 2.10.8 and Table 6.2). Once the 
correct colony was identified, the mini-cultures were used to inoculate 
250 ml maxi LB cultures supplemented with 50 µg/ml ampicillin, and 
recombinant plasmids were purified from these cultures (Section 2.10.7). 
40 µg of Tff1-CreERT2 and Atp4b-CreERT2 were double digested with 
SalI/AatII and SalI/BssSI and gel-purified (Section 2.10.2 and 2.10.3). 
DNA sequencing was performed on these purified constructs to confirm 
their nucleotide sequences (Section 2.10.8 and Table 6.2). Final transgenic 
constructs were then submitted to the Transgenic Service (Cancer 
Research UK) for pronuclear microinjection into fertilised CBA/B6 
zygotes.  
 
6.2.5 Validation of transgenic founders 
 
CBA/B6 founders were crossed with ROSA26 reporter strain (R2R). The 
R2R line originated from Dr. Philippe Soriano, Fred Hutchinson Cancer 
Research Center, USA, and has been previously characterised (Soriano, 
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1999). F1 progenies were assessed by PCR genotyping for Cre (Section 
2.1.3). Founders that had ten or more consecutive littermates that were 
negative for Cre genotype were culled. From founders that had progenies 
with positive a Cre genotype, two CreER
T2+
/R2R and CreER
T2wt
/R2R 
mice were culled, and reverse transcription PCR was performed on RNA 
extracted from their glandular stomachs to verify presence of Cre mRNA 
(Section 2.4.4). Following the confirmation of Cre mRNA, another two 
CreER
T2+
/R2R and CreER
T2wt
/R2R were given tamoxifen (1 mg per day) 
for five days consecutively and culled on the following day (Section 
2.2.2). Glandular stomach tissues from these mice were dissected for 
wholemount X-gal staining (Section 2.6.3). 
 
 
 
Figure 6.1 List of promoter fragments generated by PCR. 
Each promoter fragment has restriction sites added on either end, which 
are denoted by the restriction enzyme names. The number below each 
enzyme denotes the position of the nucleotide relative to the 
transcriptional start site of the gene denoted as ‘0’ in red. Nucleotide 
direction is shown as 5’ to 3’. 
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Table 6.1 Primer sequences for amplifying Tff1 promoter fragments 
and Atp4b minimal promoter.  
 
 
Table 6.2 Primer sequences for DNA sequencing. 
 
 
 
 
 
 
 
Promoter 
fragment
Sequence (5' to 3')
Annealing 
temp (x°C)
Amplicon        
size
Extension 
time
Forward CCGACGCGTCTGAGTCC
TTTCATGGAGCACGA
Reverse CCGAAGCTTAGCTTCAC
GGGAAGACCACGA
Forward AAGGTGTGCGGAAATGG
ATTCAG
Reverse CCGAAGCTTAGCTTCAC
GGGAAGACCACGA
Forward ATTGGTACCTCTAGAGC
TCTTTCCTCTGG
Reverse ATTAAGCTTGTCCTCTCC
TGCTTGCCTGGA
1 min 30 s
5 min
3 min
Atp4b minimal 
promoter
59.0 1071 bp
Tff1_Fragment 3 69.0 2827 bp
Tff1_Fragment 5 62.4 4934 bp
Primer 
label
Sequence (5' to 3')
Annealing 
temp (°C)
SEQ1 ACTAACATACGCTCTCCATC 53.0
SEQ2 GCATCACCTGTAGTCAGC 52.0
SEQ3 TGTGCACAGCTAGACCTG 55.0
SEQ4 GTTATTAACTACACCTATTCCCCG 55.0
SEQ5 ACAGATATGCGAGGTGGT 55.0
SEQ6 AAGTAGGAAAACTCAACCC 52.0
SEQ7 TTCCCATCTGTGTTTGCATGC 60.0
SEQ8 TTTCCATGTTAGCACTGTG 52.0
SEQ9 CTCAGAGACTATGACCCAG 52.0
SEQ10 CCAAGTCGATGACATTATAC 52.0
SEQ11 GCCCTGAATACCTAGATCC 54.0
SEQ12 TCCAGGTAGTTGTAGGCAC 54.0
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6.3 Results 
 
6.3.1 Fgfr2b mRNA is expressed in stomach epithelium 
 
ISH was used to determine the localisation on Fgfr2b mRNA in an adult 
mouse stomach. Results show abundance of Fgfr2b mRNA in the 
forestomach squamous epithelium, pepsinogen-secreting chief cells, 
mucous-producing pit and neck cells, a minor portion of parietal cells, and 
basal and surface of antral glands (Figure 6.2). 
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Figure 6.2 Expression sites of Fgfr2b mRNA in an adult C57/BL6 
mouse gastric epithelium. 
Images on the left panel were from H&E staining, and images on the right 
panel were from Fgfr2b ISH. Red arrows mark the expression site of 
Fgfr2b mRNA. Positive control from adult duodenum of C57/BL6 show 
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positive Fgfr2b staining in the crypts and villi, whereas negative control 
using DIG-labelled sense Fgfr2 probe show no staining in the gastric 
epithelium (data not shown).  
 
6.3.2 Stomach-specific promoters were successfully 
cloned and validated 
 
All five Tff1 promoter fragments and Atp4b minimal promoter were 
successfully generated and cloned into the pGL-3 Basic luciferase vector 
(Figure 6.3). Following the confirmation of nucleotide sequences by DNA 
sequencing, all five Tff1 promoter fragments were subjected to luciferase 
assay in gastric-specific cell lines to determine the optimal minimal 
promoter. Tff1_Fragment 1 (-641 bp to +27 bp) gives the highest 
luciferase readout in GSM10 (approximately nine times more than the 
promoter-less luciferase vector), AGS and HGT101 cell lines compared to 
the other four promoter fragments (Figure 6.4). The Atp4b minimal 
promoter (-1,025 bp to +24 bp) also gives approximately four times more 
luciferase readout than the promoter-less luciferase vector in MGE507 
cell line (Figure 6.4). Evaluation of minimal promoter specificity by 
luciferase assay in non-gastric cell lines (3T3, HC11, nTERT) show no 
significant difference in luciferase readout between the Tff1, Atp4b and 
promoter-less luciferase vector (Figure 6.4). Additionally, the Tff1 
minimal promoter yields three times more luciferase activity in the 
GSM10 cell line grown in serum-free media supplemented with EGF        
10 ng/ml than in a plain serum-free media (Figure 6.5). 
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Figure 6.3 PCR amplification of all five Tff1 promoter fragments and 
Atp4b minimal promoter. 
Tff1_F3, Tff1_F5 and Atp4b fragments were generated by PCR, whereas 
Tff1_F1, Tff1_F2 and Tff1_F4 fragments were generated from restriction 
digest of Tff1_F5 fragment. 
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Figure 6.4 Promoter analyses by luciferase assays. 
All Tff1 promoter fragments and Atp4b minimal promoter were cloned 
upstream of the luciferase gene (Luc) of pGL-3 Basic vector. Luciferase 
vector bearing the promoter fragments were transfected into various cell 
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lines together with a constant amount of phRL-CMV (Renilla). Luciferase 
activity was measured and normalised to Renilla luciferase activity. 
Tff1_F1 gives the most optimal luciferase expression in GSM10 cells, and 
the cloned Atp4b minimal promoter activates luciferase expression in 
MGE507 cells. These minimal promoters do not activate luciferase 
expression in non-gastric cell lines. The values (relative to the promoter-
less pGL-3 Basic vector) (±SEM) indicated were the average of three 
independent experiments. *P<0.05, **P<0.01, ***P<0.001; n = 3 
samples/group. 
 
 
 
Figure 6.5 Effects of EGF on Tff1 minimal promoter activity. 
Luciferase vector bearing the Tff1 minimal promoter was transfected into 
GSM10 cells together with a constant amount of phRL-CMV (Renilla) in 
media with or without EGF 10 ng/ml. Luciferase activity was measured 
and normalised to Renilla luciferase activity. The Tff1_F1 minimal 
promoter contains EGF response element, which upregulates luciferase 
expression in the presence of recombinant EGF. The values (relative to 
the promoter-less pGL-3 Basic vector) (±SEM) indicated were the 
average of three independent experiments. ***P<0.001; n = 3 
samples/group. 
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6.3.3 Identification of Tff1-CreERT2 and Atp4b-CreERT2 
founders 
 
Of the total number of zygotes injected with the Tff1-CreER
T2
 (175 
zygotes) and Atp4b-CreER
T2
 (182 zygotes), approximately 23% of these 
were born as founders, and approximately 35% of these founders were 
positive for the Cre allele. These positive founders were crossed with R2R 
mice, and approximately 58% of these founders transmitted the Cre allele. 
A further 30% of these founders expressed Cre mRNA in the glandular 
stomach, and further X-gal staining showed that none of these founders 
produced active Cre protein (Table 6.3 and Figure 6.6). 
 
 
Table 6.3 Identification of transgenic founders. 
 
 
 
 
 Born
 +ve Cre 
genotype
Transmitted 
Cre  genotype
 +ve Cre 
mRNA
 +ve for X-
gal staining
Tff1-CreER
T2
175 45 13 7 2 0
Atp4b-CreER
T2
182 39 15 9 3 0
Construct
Number of founders
No. of 
zygotes 
injected
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Figure 6.6 Validation of transgenic founders by wholemount X-gal 
staining. 
Stomach tissues were isolated from the Tff1-CreER
T2+
/R2R and Atp4b-
CreER
T2+
/R2R mice induced with tamoxifen and stained wholemount 
with X-Gal. ‘F’ and ‘G’ mark the forestomach and glandular regions 
respectively. Positive and negative controls came from duodenal tissue of 
adult Villin-CreER
T2+
/R2R and Villin-CreER
T2wt
/R2R mice respectively 
that were subjected to similar induction and X-gal staining protocols. Both 
stomach tissues, including negative control, showed absence of X-Gal 
staining, while positive control showed presence of staining, validating 
the induction and X-Gal staining protocols. 
 
 
 
 
 
 
 
 
 
 
 
 
G G 
F 
 
F 
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6.4 Discussion 
 
In order to determine the requirement of Fgfr2b in gastric homeostasis 
and injury, this study initially aims to look at the expression site of Fgfr2b 
mRNA in a normal adult mouse. Our novel data using ISH shows that 
Fgfr2b mRNA is expressed by most gastric lineages, including the 
forestomach squamous epithelium, fundus chief cells, parietal cells, 
surface mucous cells, mucous neck cells, and antral surface and bottom 
glands. There are surprisingly few parietal cells that express Fgfr2b 
mRNA, which contrasts with a previous study reporting the restricted 
expression of Fgfr2b in parietal and surface mucous cells in the normal 
human gastric epithelium (Matsunobu et al., 2006), suggesting that 
expression site of Fgfr2b mRNA differs between human and murine. 
Additionally, these rare-stained parietal cells could be the immature pre-
parietal cells that give rise to mature parietal cells during terminal 
differentiation (Karam et al., 2003), or represent a particular subtype of 
mature parietal cells. To date, no study has reported a marker for 
differentiating pre-parietal and parietal cell population, or reported 
different subtypes of mature parietal cells. 
 
To generate two inducible Cre lines under the stomach-specific Atp4b and 
Tff1 minimal promoters respectively, Atp4b minimal promoter (-1,035 bp 
to +24 bp) was initially cloned into the pGL-3 luciferase vector and 
successfully validated in a mouse gastric pre-parietal (MGE507) cell line. 
In order to thoroughly characterise the Tff1 promoter, five Tff1 promoter 
fragments with staggered lengths were cloned and compared by luciferase 
assays in three gastric cell lines (GSM10, AGS and HGT101), and 
promoter nucleotide -641 bp to +28 bp is determined to be the best Tff1 
minimal promoter. Preliminary testing on the specificity of these minimal 
promoters by luciferase assays in non-gastric cell lines suggests that both 
minimal promoters are specific for directing transgene expression in the 
gastric epithelium.  
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The efficiency of the Tff1 minimal promoter can be attributed to the 
presence of an AP-1 site (-ATGAATCA-) (Terada et al., 2001), which is 
involved in the signalling pathway Src-homology tyrosine phosphatase 2 
(SHP2)/Ras/ERK/AP-1 originating from gp130, a common interleukin 
(IL)-6 co-receptor (Taga and Kishimoto, 1997). IL-6 family cytokines are 
required for maintaining gastric homeostasis by regulating TFF1 via co-
receptor gp130 (Giraud et al., 2007), and gp130 mutants with abrogated 
SHP2 signalling pathway develop gastric adenomas by three months of 
age, accompanied by significant downregulation of TFF1 expression 
(Tebbutt et al., 2002).  
 
Another possible positive regulatory element on the Tff1 minimal 
promoter is the EGF response element. TFF1 expression in human gastric 
epithelium has been closely associated with EGF secretion by the 
subjacent mucous neck cells (Wright et al., 1990). The -428 bp to -332 bp 
flanking region of the human Tff1 gene contains a 10-fold enhancer 
element that responds to EGF (Nunez et al., 1989), even though the exact 
sequence of this enhancer element is still under investigation. Our 
investigation on the mouse Tff1 minimal promoter by luciferase assays 
using media with and without EGF 10 ng/ml shows a 2.5-fold increase in 
promoter activity, confirming the presence of an EGF response element in 
our Tff1 minimal promoter. 
 
Comparison of the promoter activity between GSM10 and HC11 cell lines 
suggests the presence of a stomach-specific regulatory element in the Tff1 
minimal promoter. Both GSM10 and HC11 are epithelial cell lines, and 
have been maintained in growth medium containing EGF 10 ng/ml. Even 
though HC11 cells have been shown to express EGFRs (Taverna et al., 
1991), the Tff1 minimal promoter is only active in the GSM10 cell line 
and not in the HC11 cells, confirming the presence of stomach-specific 
element in this minimal promoter, and activation of this stomach-specific 
element is a pre-requisite for transgene expression under the Tff1 minimal 
promoter. However, the exact sequence of this stomach-specific element 
is still under investigation. 
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After screening 175 founders of Tff1-CreER
T2
 and 182 founders of 
Atp4b-CreER
T2
, none of the founders was positive for Cre protein activity 
in the mouse stomach. This observation is in common with a previous 
study generating a transgenic line expressing human growth hormone 
(hGH) under the similar Atp4b minimal promoter which showed an 
approximately 4% success rate (from the number of liveborn mice 
screened) of finding a transgenic founder that expressed hGH, suggesting 
an extremely low success rate of using this minimal promoter to create a 
transgenic line (Lorenz and Gordon, 1993). Observations from in vitro 
validation experiments do not always correspond to that in in vivo studies 
due to differences between both biological systems. An alternative 
explanation is that the transgene may have been integrated into 
transcriptionally inactive/repressive sites, thus reducing the transcription 
efficiency of the transgene. One possible solution is to inject the 
transgenic constructs into twice the number of zygotes that was originally 
used in this study, thereby increasing the number of live-born mice for 
screening and giving a higher success rate of identifying the transgenic 
founders. Alternatively, the stomach-specific Cre inducible constructs can 
be targeted more specifically into the X-linked hypoxanthine guanine 
phosphoribosyl transferase (Hprt) locus as this region has a high 
consistency for expression, consistent location of transgene integration, 
and provides the ability to control the copy number of transgene (Hatada 
et al., 1999, Guillot et al., 2000, Evans et al., 2000, Cvetkovic et al., 2000, 
Bronson et al., 1996).  
 
 
 
 
 
 
 
 
 190 
6.5 Conclusion 
 
In conclusion, we have shown that Fgfr2b is expressed in various cell 
lineages of the adult mouse stomach epithelium, including mucus-
producing pit and neck cells, acid-producing parietal cells and 
pepsinogen-secreting zymogenic chief cells. We have also generated two 
tamoxifen-inducible Cre constructs under the stomach specific promoters: 
Tff1 (-641 bp to +28 bp) and Atp4b (-1,035 bp to +24 bp) minimal 
promoters.  
 
From our in vitro experiments, we have validated that these minimal 
promoters are efficient and specific for driving transgene expression in 
mouse stomach. Further characterisation on the Tff1 minimal promoter 
reveals the presence of EGF response element and a stomach-specific 
element. While random integration of these transgenic constructs gave no 
reliable founder, this study has nevertheless increased our understanding 
of the regulatory elements of the Tff1 promoter.  
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Chapter 7: Final conclusions 
 
Fgfs and Fgfrs mediate epithelial-mesenchymal crosstalk that is essential 
in tissue proliferation, survival, differentiation and motility across 
multiple organs, including skin and the GI tract. We have used several 
established mouse models, complemented by in vitro studies, to 
investigate loss-of-function of Fgf10 and Fgfr2b in GI development, 
homeostasis and injury. In brief, our experiments have shown that: 
 
1. Fgf10 and Fgfr2b are required for normal duodenal development, as 
loss of either Fgfr2b or Fgf10 results in disproportionately short small 
intestine (due to reduced epithelial proliferation), duodenal atresia 
(due to increased tissue apoptosis at a focal point on the duodenum), 
and gastric heterotopia in the rostral duodenum (due to defective 
anterior-posterior patterning at the stomach-duodenum boundary prior 
to intestinal differentiation). Aberrant expression of Wnt is associated 
with anterior-posterior patterning defect, with Fgf10-Fgfr2b signalling 
regulating Tcf4 expression via the Grb2/Sos/Ras/MAPK pathway. 
 
2.  Fgfr2b is not required for maintaining adult intestinal homeostasis, as 
substantial downregulation of Fgfr2b does not significantly affect 
body weight, and intestinal proliferation, survival and differentiation. 
Possible functional redundancy of Fgfr2b in adult GI tract could have 
contributed to these observations. 
 
3. Fgfr2b is required to fully protect against intestinal injury and to 
promote wound healing. Downregulation of Fgfr2b in our DSS-
induced ulcerative colitis model shows an increase in severity and 
delays wound healing, a consequence of reduced epithelial 
proliferation. 
 
4. Fgfr2b is expressed by various lineages of the adult gastric epithelium, 
including the mucus-secreting pit and neck cells, acid-secreting 
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parietal cells, and pepsinogen-secreting chief cells. The Tff1 (-641 bp 
to +28 bp) and Atp4b (-1,035 bp to +24 bp) minimal promoters are 
optimal for constructing inducible stomach-specific Cre lines to ablate 
Fgfr2b in the adult stomach epithelium. 
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Appendix 
 
Buffers and solutions 
 
Unless otherwise stated, distilled water refers to ‘Mili-Q Plus’ water 
produced by the reverse osmosis ultra pure water system (Milipore). 
 
Carnoy’s fixative 
Absolute ethanol (101077Y; VWR)   60 ml 
Chloroform (22711.324; VWR)   30 ml 
Glacial acetic acid (100015N; VWR)   10 ml 
 
10% neutral buffered formalin pH 7.8 (NBF) 
Formalin, full strength (37-40% formaldehyde) 100 ml 
(361387P, VWR) 
Na2HPO4 (S7907; Sigma-Alrich)   6.5 g 
NaH2PO4 (S8282; Sigma-Aldrich)   4 g 
Distilled water     900 ml 
 
4% paraformaldehyde (PFA) 
Paraformaldehyde (16005; Sigma-Aldrich)  16 g 
Phosphate buffered saline (PBS)   400 ml 
Paraformaldehyde was dissolved in PBS at 70°C, and cooled to RT before 
use.  
 
Phosphate buffered saline (PBS) 
NaCl (S7653; Sigma-Aldrich)   8 g 
KCl (P9333; Sigma-Aldrich)    0.35 g 
Na2HPO4 (Sigma-Aldrich)    1.43 g 
NaH2PO4 (Sigma-Aldrich)    0.25 g 
Distilled water     1 L 
pH adjusted to 7.2, and solution was autoclaved before use. 
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PBST solution was made by adding 1 ml of Tween-20 (63158; Sigma-
Aldrich) into 1 L of PBS. 
 
Base solution for RU486 mix 
Carboxymethylcellulose (21901; Sigma-Aldrich) 25 mg 
Tween-80 (P1754; Sigma-Aldrich)   50 µl 
Distilled water     10 ml 
Solution was autoclaved before use. 
 
20X SSC 
NaCl (Sigma-Aldrich)    17.53 g 
Sodium citrate (S1804; Sigma-Aldrich)  8.82 g 
Distilled water     100 ml 
pH adjusted to 5.0, and solution was autoclaved before use. 
 
Tris buffered saline (TBS) 
NaCl (Sigma-Aldrich)    8.76 g 
Tris (t1378; Sigma-Aldrich)    6.05 g 
Distilled water     1 L 
pH adjusted to 7.5. 
PBST solution was made by adding 1 ml of Tween-20 (63158; Sigma-
Aldrich) into 1 L of PBS. 
 
10X maleic buffer 
Maleic acid (63180; Sigma-Aldrich)   116 g 
NaCl (Sigma-Aldrich)    88 g 
Distilled water     1 L 
pH adjusted to 7.5. 
 
0.01 M sodium citrate buffer 
Tri-sodium citrate  (25114; Sigma-Aldrich)  2.94 g 
0.2 M HCl      22 ml 
Distilled water     1 L 
pH adjusted to 8.0. 
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Luria-Bertani broth (LB) 
Tryptone (T7293; Sigma-Aldrich)   10 g 
Yeast (51475; Sigma-Aldrich)   5 g 
NaCl (Sigma-Aldrich)    5 g 
Distilled water     1 L 
Solution is autoclaved before used. 
LB agar was made by dissolving 15 g of agarose (A4718; Sigma-Aldrich) 
into 1 L of LB broth. 
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Suppliers and distributors 
 
 
Supplier Address
Ambion Austin, TX, USA
Applied Biosystems Foster City, CA, USA
BD Biosciences New Jersey, USA
BDH Laboratory Supplies Inc. Hertfordshire, UK
BioGenex Laboratories Inc. San Ramon, CA, USA
Calbiochem Nottingham, UK
DAKOCytomation A/S Cambridge, UK
Fisher Scientific Leicestershire, UK
GE Healthcare Buckinghamshire, UK
Gibco BRL Ltd. Renfrewshire, UK
Graphpad Software San Diego, CA, USA
Hollingsworth & Vose Co. Ltd. Gloucestershire, UK
Invitrogen Ltd. Paisley, UK
Launch Diagnostics Ltd. Kent, UK
Mayne Pharma Plc Leamington Spa, Warwickshire
Microzone Ltd. West Sussex, UK
Milipore Watford, UK
Nalgene Rochester, NY, USA
NanoDrop Technologies Wilmington, DE, USA
New England Biolabs (NEB) New York, USA
Nunc Rochester, NY, USA
Pierce Biotechnology Cramlington, Northumberland
Promega Hampshire, UK
Qiagen West Sussex, UK
R&D Systems Europe Ltd. Abingdon, UK
Roche Diagnostics Ltd. Burgess Hill, UK
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Supplier Address
Sigma-Aldrich Co. Ltd. Gillingham, UK
Stratagene La Jolla, Ca, USA
Tesco London, UK
The Binding Site San Diego, CA, USA
Thermo Scientific Rochester, NY, USA
Vector Laboratories Burlngame, SA, USA
VWR International Ltd. Leicestershire, UK
